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Chapter 1: General introduction
 
 
The molecular complexity of the synapse
The brain consists of an intricate network formed by billions of interconnected neurons and 
glial cells (1). The fast information transfer between neuronal cells is at the foundation of 
brain function, enabling our interpretation of the environment, emotions, memories and most 
of the physiological activities of our body. In particular, the communication between neurons, 
as well as between neurons and peripheral tissues (e.g. muscle cells), occurs through a 
specialized cellular structure, the synapse (Fig. 1A). Under physiological conditions, trillions 
of synapses mediate neurotransmission in the brain and undergo activity-dependent plasticity 
allowing the modulation of synaptic strength. Dysregulation of the synaptic molecular 
composition, structure and/or function may cause psychiatric and neurodegenerative 
disorders.
Synaptic transmission involves the transfer of signals from the presynaptic sender to 
the postsynaptic signal-receiving neuron through neurotransmitters (Fig. 1B). In the 
presynaptic terminal, neurotransmitters are packed and stored in synaptic vesicles. Neuronal 
electrical activity (axon membrane depolarization) leads to Ca2+ influx and vesicles fusion 
with the cell membrane by which neurotransmitters are released into the extracellular space. 
At the postsynaptic side, the neurotransmitters activate their corresponding receptors 
initiating the transduction and propagation of the signal in the receiving neuron.
From a mechanistic perspective, the synapse can be considered a complex 
machine composed of a large number of pieces (Fig. 1C). Over 2,000 different proteins 
represent the molecular building blocks of the biological processes involved in synaptic 
transmission (2). From pre- to postsynaptic signaling, multiple different molecular machines 
come into play (Fig. 1A). For instance, the conversion of an electrical signal in the 
presynapse into a chemical signal involves a protein release machinery that responds to 
calcium ions (3, 4). Voltage gated calcium channels (CaV) transform the electrical signal into 
a flow of Ca2+ ions that activates synaptotagmin, located at the synaptic vesicles. This 
triggers a cascade of events, involving a series of highly conserved proteins (SNARE 
complex (5)), to mediate the vesicle fusion with the membrane and neurotransmitter release. 
The synaptic expression of several of these proteins is crucial since their complete absence 
has been shown to be highly detrimental to neurotransmitter release and lethal for the 
organism (6, 7). Moreover, mutations in these and other synaptic proteins may cause 
neurological disorders (3), so-called synaptopathies (8, 9). To bring pre- and postsynapse in 
close proximity and to align the neurotransmitter release site with the postsynaptic receptors, 
the role of transsynaptic proteins complexes is essential. For instance, neurexin and 





the synapse (10). Again, these proteins are vital for the organism and complete absence of 
neuroligin has been shown to be lethal (11), whereas mutations in neurexins and neuroligins 
are linked to psychiatric disorders, such as autism spectrum disorder and schizophrenia (10).
Finally, postsynaptic receptors, such as the α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid receptor (AMPAR) and γ-aminobutyric acid receptor (GABAR), receive the 
signal from the neurotransmitters and initiate the signal transduction in concert with many 
proteins, both in the membrane and in the postsynaptic density. Lack of AMPARs in the 
postsynaptic membrane leads to silent synapses without functional excitatory synaptic 
transmission (12).
Figure 1. Typical architecture of the chemical excitatory synapse. A) The excitatory synapse as 
observed at 100,000 fold magnification using transmission electron microscopy. B) Simplified model of 
excitatory synaptic transmission. During the presynaptic SV cycle, the neurotransmitter glutamate 
packed in small vesicles is released to the extracellular space at the active zone. The glutamate binds to 
postsynaptic receptors activating signal transduction mechanism. Lastly, neurotransmitters are retrieved 
from the extracellular space, SVs are recycled by endocytosis and reused for synaptic transmission. C) 
Three-dimensional model of the presynapse containing 60 proteins (depicted in different colors) based 
on their molecular structure and estimated organization. SVs, synaptic vesicles; Mit, mitochondria; PSD, 
postsynaptic density. Panel C was adapted with permission from Wilhelm et al,2014 (13).
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Each synaptic protein has its particular amount and location in the synapse. 
Previous studies have shown that proteins tend to be ubiquitously expressed in cells from 
different tissues (14), with significant differences in expression levels. The balance in 
expression levels between proteins is fundamental for the adequate functioning of biological 
processes, including synaptic transmission. For instance, the level of the presynaptic protein 
Stxbp1 (munc18) controls the number of fusion-ready synaptic vesicles, with lower and 
higher Stxbp1 expression causing a reduced and increased number of docked vesicles in the 
presynaptic terminal respectively (15). Moreover, a mutation in Stxbp1 causing infantile early 
epileptic encephalopathy was found to reduce the protein level to 30%, and decreasing the 
neurotransmitter release by nearly 50% in human neurons (16). Whereas the copy numbers 
are important, also the precise localization of proteins matters. Illustrating the relevance of
protein location, the strength of the synaptic transmission depends on the position of the
receptors in the postsynapse. Surface diffusion followed by trapping of the AMPAR in 
nanodomains (17) at the postsynaptic density was shown to mediate the synaptic 
potentiation involved in learning and memory (18).
Beyond the individual function of the proteins, synaptic transmission requires 
specialized molecular machineries assembled by the interaction of multiple proteins (19).
These molecular machines exponentially increase the complexity of the synaptic architecture, 
as exemplified by the AMPAR. More than 20 protein interactors are involved in all steps of 
the AMPAR life cycle as a postsynaptic receptor (20). For instance, the interaction of AMPAR 
with Frss1l and Cpt1c involves the maturation, trafficking and surface expression of the 
receptor (21–23), whereas the interaction with Cacng2, Shisa6 and Olfm1 regulates the 
receptor properties, mobility and location (24–26). The interplay of these protein interactors is 
probably tightly regulated and together ensures proper subcellular location and functioning of 
the AMPAR at the synapse (22, 24–26). Dysregulation of synaptic proteins expression (27),
mutations in these proteins and their disturbed interactions (28) have been linked to impaired 
synaptic activity and plasticity in several brain disorders, such as autism, epilepsy, intellectual 
disability and schizophrenia (reviewed in (8, 9)).
Synapse formation
Building a synapse requires the assembly of hundreds of proteins into specific functional 
structures.  Glutamate receptors and scaffolding proteins are present in dendrites even 
before synapses are formed (29), as well as the crucial presynaptic elements for vesicle 
fusion (30). When pre- and postsynaptic cells come into physical contact, trans-synaptic 
adhesion molecules initiate the synapse formation. Proteins such as cadherins and integrins 





triggering the recruitment of proteins to the pre- and postsynapse (31). Thus, expression and 
functional incorporation of proteins to each synaptic compartment are timely coordinated. At 
the presynaptic terminal, the canonical release machinery and active zone proteins quickly 
accumulate by the trafficking of specialized transport vesicles. At the excitatory postsynapse, 
the NMDAR is incorporated to the nascent synapse, shortly followed by the recruitment of the 
AMPAR (32). The synaptic proteome keeps gradually developing during the progression of 
the synapse formation and maturation. Perturbing these processes has implications for 
synaptic and circuitry development and may underlie psychiatric and neurodevelopmental 
disorders (33). Further characterization of the molecular assembly during synapse formation 
may contribute to understanding the mechanisms of synaptic transmission and likewise their 
dysfunction in brain disorders. In this thesis, I used a proteomics analysis to describe the 
development of the molecular composition of synapses (Chapter 2).
Synaptic modulation
Once a mature synapse is formed, its composition, shape and strength can be adapted in 
response to neuronal activity. Structural plasticity involves the modulation in size of the 
postsynaptic density and spine head by the reorganization of cytoskeletal and scaffold 
proteins (34). Synaptic strength can be regulated by the trafficking, incorporation and 
stabilization of postsynaptic receptors, such as NMDAR and AMPAR (35). Local protein 
synthesis and signaling to the nucleus are also involved in synaptic plasticity in a later phase. 
These coordinated molecular events result in the modulation and stabilization of synaptic 
efficacy and represent the foundation of learning, memory formation and consolidation (36).
Metabotropic glutamate receptors (mGluR) are also part of the multiple forms and 
mechanisms of synaptic plasticity (35, 37). For instance, mGluR5 is a broad modulator of 
synaptic function at multiple levels, including synapse maturation, long-term depression, and 
at the neuronal systems level, learning and memory (reviewed in (38, 39)). mGluR5 regulates 
the synapse via a complex signal transduction mechanism that involves the crosstalk 
between several signaling pathways. These cascades ultimately lead to the activity-
dependent reorganization of the synapse architecture, regulation of protein synthesis and 
modulation of other receptors, in particular NMDAR and AMPAR. The extensive role of 
mGluR5 in synaptic modulation make this receptor an interesting pharmacological target with 
therapeutic potential in multiple neurodevelopmental and neurodegenerative disorders. The 
molecular synaptic modulation mediated by this impactful receptor is the focus of chapter 3.
Towards revealing the architecture of the synapse
Traditionally, synaptic proteins were first identified and characterized individually (e.g. (40)). 
In the past decade, the synaptic proteome parts list has been described in a high-throughput 
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manner for identity and protein levels (41–44). This comprises over 2,000 different proteins 
(41, 43), which corresponds to approximately 10% of protein-coding genes in mammalian 
genomes. Moreover, a recent worldwide effort allowed the expert-curated annotation of 
synaptic proteins (45). As a result, a reference synaptic proteome was generated comprising 
1,112 high-confidence synaptic proteins. Since proteomics studies of synaptic preparations 
implicate a few thousand proteins in synapses, there are additional synaptic candidates for 
which experimental evidence is currently lacking. In addition, close to 30% of SynGO genes 
(309 proteins) did not present enough evidence to determine their biological process, 
implying a lack of knowledge for a significant part of the known synaptic proteome.
From the synapse parts list it is not possible to directly infer the interactions that 
organize proteins into nano-machineries important to synaptic function. Targeted approaches 
have been applied to determine the interaction partners of a discrete number of selected 
synaptic proteins, such as AMPAR, Dmxl2 and Cntn2 among others (20, 46, 47). Large-scale 
approaches have been applied to unravel protein interactomes, mainly using non-neuronal 
systems in which synaptic proteins are underrepresented. The most recent and largest 
collection of experimental protein interactions comprises close to 53,000 protein-protein 
interactions from over 8,000 different proteins across the whole human proteome (48).
However, protein interactions from only 464 high confident synaptic proteins were identified, 
illustrating that a comprehensive synaptic interactome is still largely lacking. Despite the 
insights provided by these efforts, untangling the complex synaptic proteome architecture 
and its interaction network is still a major challenge in neurobiology. In chapter 4, we 
advanced the field by investigating the interaction within and between synaptic proteins in a 
proteome-wide scale using innovative proteomic analysis.
Enabling the molecular characterization of the synapse
To investigate the synaptic protein components and how proteins within the synapse interact 
and organize, we need powerful tools. It would be ideal to describe the molecular 
mechanisms of the synapse by the direct visualization of the synaptic proteome. However, 
the extremely high density of proteins packed in the reduced synaptic space and the common 
molecular composition of all proteins are enormous challenges (Fig.1C). To explore the 
complexity of the synaptic proteome, unambiguous identification of each protein is required in 
an unbiased and high-throughput manner. The development of mass spectrometry (MS), 
including instruments, methods and data analysis tools, have hugely contributed to the 
current understanding of the synapse proteome and interactome. Quantitative proteomics 
that interrogates thousands of proteins has been applied to examine specific cells and 





53) and neuron cultures (54). In addition to MS, the recent advances in synapse composition 
also rely on the biochemical preparation of synapses. Over decades of synapse research, 
protocols have been developed to purify the synapse and sub-organelles derived from it (41).
These biochemical procedures form the basis for the molecular dissection of the synapse 
using mass spectrometry.
Mass-spectrometry based proteomics
MS-based proteomics is a powerful and versatile tool for molecular profiling in a broad 
spectrum of applications. Bottom-up quantitative proteomics based on LC-MS/MS is the 
preferential method to identify and measure protein expression levels in biological samples, 
such as the synapse (55). Proteins extracted from a biochemically purified source, e.g. an 
organelle or molecular complex, are enzymatically digested into peptides, which are then 
separated by liquid chromatography and analyzed by mass spectrometry. Traditionally, data-
dependent acquisition (DDA) has been most widely used as approach for discovery 
proteomics (41). Using this strategy, a full mass MS1 scan is followed by the sequential 
selection of the top 5 to 40 most intense precursor ions (depending on the type of mass 
spectrometer) for a subsequent MS/MS scan. The fragment ion spectra from MS/MS scans 
are matched to their corresponding sequences allowing the identification of (tens of) 
thousands of peptides in an experiment. However, the stochastic nature of precursor ion 
selection can compromise reproducibility, especially for complex samples and low abundant 
peptides. The missing peptide identifications among replicates (up to 30% (56)) strongly 
reduce the number of identified proteins.
Recently, SWATH mass spectrometry (a type of Data Independent Acquisition, DIA) 
emerged as an alternative to overcome the previous limitations (57). Using SWATH, all 
peptides within a predefined mass window ranging from 3 to 25 Da are fragmented and 
analyzed by MS/MS. The mass windows are sequentially stepped through in ranges usually 
between 400 to 1200 Da, which should cover the majority of peptides (58). However, the 
MS/MS spectrum of each window is highly complex because it includes fragment ions from 
multiple peptides. Data analysis with a traditional DDA database search strategy, originally 
designed for the identification of a single peptide per MS/MS scan, is not optimal. A way to 
bypass this obstacle is the generation of a reference spectral library, made beforehand by 
DDA (58, 59). The information of the elution time and fragment ions of the peptides can be 
used to link back each fragmentation pattern in the DIA set to the corresponding precursor. 
Recently, new strategies have been developed to enable the analysis without the need of 
extra information from a reference library (60, 61), at an expense of a lower number of 
identified peptides (58). In addition, raw data can be re-interrogated in silico afterwards to test 
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a new hypothesis (using another dedicated spectral library in accordance with the 
hypothesis) without repeating the experiments (62).
Regarding protein-protein interactions, affinity purification approaches have been 
traditionally employed to systematically study individual synaptic protein complexes. Targeted 
affinity capture of tagged proteins and immunoprecipitation in combination with mass 
spectrometry investigate first (direct) and higher order (indirect) protein interactions (20, 63).
For the latter method, antibodies are used to capture the binding partners of a specific target 
protein, which are subsequently identified by mass spectrometry. The success of the 
experiments critically depends on multiple factors, including the solubilization efficiency of the 
proteins, the interactions strength, and the availability of high-affinity and high-specificity 
antibodies.
In recent years, proteome-wide chemical cross-linking combined with mass 
spectrometry (XL-MS) has emerged as a powerful approach for unbiased large-scale 
interactomics (64). In XL-MS, native protein structures and interactions are captured by 
cross-linking reagents, which covalently conjugate amino acid residues in close proximity, i.e. 
two lysine residues in case of disuccinimidyl sulfoxide (DSSO). The length of the cross-linker 
spacer arm imposes a maximal distance restraint onto the linked residues, which are 
subsequently identified by mass spectrometry. Close proximity capturing by cross-linking can 
therefore be used to reveal potential protein-binding interfaces and novel partnerships (by 
inter-protein cross-links) as well as elucidate protein conformations (by intra-protein cross-
links). Moreover, DSSO allows direct cross-linking of proteins in their subcellular 
compartments thereby capturing protein interactions in a physiologically relevant subcellular 
context (65).
Figure 2. Diagram of DDA (A) and DIA (B) mass spectrometry analysis. In both methods, all the co-
eluting precursor peptides (colored spheres) are detected in MS1. A) In DDA, a single precursor is 
selected for fragmentation and subsequent detection in the second stage MS/MS. This process is 
repeated sequentially for each of the most abundant precursor peptides. B) In DIA, all peptides within a 
pre-defined m/z window are selected simultaneously for fragmentation and MS/MS. Next, the selection 






The synapse is the most characteristic feature of the brain that allows the flow of information 
encoding our cognitive functions, behavior and memory. Slight perturbations in synaptic 
function can derive in wide range of psychiatric, neurodevelopmental and neurodegenerative 
disorders (8). The aim of this thesis was to investigate the synaptic proteome and 
interactome in order to gain insights in the molecular mechanisms underlying synaptic 
function. To this end, we exploited the potential of multiple advanced mass spectrometry 
methodologies for protein identification, quantification, and protein interaction determination.
In chapter 2, I investigated the molecular development of the synapse. This process 
requires prominent changes of the synaptic proteome and potentially involves thousands of 
different proteins at every synapse. Although synaptic proteins have been studied in depth 
during critical periods of development, the adaptation of the synaptic proteome throughout 
various stages of postnatal development has not been described. We analyzed the cortical 
synaptic membrane proteome of juvenile, adolescent and adult mice brains using iTRAQ-
based DDA quantitative proteomics. In several cases, proteins from a single functional 
molecular entity, e.g., subunits of the NMDA receptor, showed differences in their temporal 
regulation, which may reflect specific synaptic development features of connectivity, strength 
and plasticity. We also evaluated the function of Cxadr, a protein with high expression level at 
early stages and a fast decline in expression during neuronal development. Knockdown of 
the expression of Cxadr in cultured primary mouse neurons revealed a significant decrease 
in synapse density. Altogether, these results reveal the expression profile of synaptic 
proteome during development and provide new insights into the molecular processes 
underlying synaptogenesis and synapse maturation.
In chapter 3, I explored the mechanism behind the synaptic modulation mediated by 
the metabotropic glutamate receptor 5. mGluR5 plays a major role in the modulation of 
synaptic function and plasticity, as well as in several brain disorders. Despite robust pre-
clinical data, mGluR5 antagonists failed in several clinical trials, highlighting the need for a 
better understanding of the mechanisms underlying mGluR5 function. Using a proteomic 
approach, we determined the molecular response of the synapse to a reduction of mGluR5 
activity by pharmacological inhibition and gene deletion. In both cases, the most prominent 
response of the synaptic proteome was the change in protein expression of key mitochondrial 
pathways. Together with this, we observed morphological and functional alterations of 
mitochondria in mGluR5 KO synapses. Our findings provide new insight into a functional 
connection of mGluR5 and specific mitochondrial function. Based on the results, we postulate 
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a novel role of mGluR5 as a mediator of the intercommunication between synaptic activity 
and mitochondrial function.
In chapter 4, I applied XL-MS as entry into the synapse interactome, in particular to 
reveal the architecture and assembly of synaptic protein complexes. Subcellular preparations 
from mouse hippocampus and cerebellum were cross-linked, preserving the proteins close to 
their native conditions, and analyzed using state-of-the-art mass spectrometry. As a result, 
we generated to the first large-scale cross-linking repository in the brain. The reliability of the 
data was validated by several approaches as we deemed necessary for a recent 
methodology. In addition, a large part of the crosslink data contains novel information which 
allowed us to identify novel protein partners, to model protein conformational dynamics, and 
to delineate within and between protein interactions of main synaptic constituents, such as 
Camk2, the AMPA-type glutamate receptor, and associated proteins. Given the molecular 
complexity of the synapse and the large amount and depth of the data generated, we 
provided the complete dataset as an interactive web-based platform for further investigations 
(http://xlink.cncr.nl). Together, we generated one of the largest cross-linking collections that 
provided new entries into exploration of protein structures and interactions.
In chapter 5, I discussed the impact of the present results into a broader 
perspective, highlighting the challenges and future directions for the molecular 
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Abstract
Development of the brain involves the formation and maturation of numerous synapses. This 
process requires prominent changes of the synaptic proteome and potentially involves
thousands of different proteins at every synapse. To date the proteome analysis of synapse 
development has been studied sparsely. Here, we analyzed the cortical synaptic membrane 
proteome of juvenile postnatal days 9 (P9), P15, P21, P27, adolescent (P35) and different 
adult ages P70, P140 and P280 of C57Bl6/J mice. Using a quantitative proteomics workflow 
we quantified 1560 proteins of which 696 showed statistically significant differences over 
time. Synaptic proteins generally showed increased levels during maturation, whereas 
proteins involved in protein synthesis generally decreased in abundance. In several cases, 
proteins from a single functional molecular entity, e.g., subunits of the NMDA receptor, 
showed differences in their temporal regulation, which may reflect specific synaptic 
development features of connectivity, strength and plasticity. SNARE proteins, Snap 29/47 
and Stx 7/8/12, showed higher expression in immature animals. Finally, we evaluated the 
function of Cxadr that showed high expression levels at P9 and a fast decline in expression
during neuronal development. Knock down of the expression of Cxadr in cultured primary 
mouse neurons revealed a significant decrease in synapse density. 
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Introduction
Chemical synaptic transmission constitutes the major mode of communication in the brain. 
Mature synapses are composed of a transmitter-releasing presynaptic element and a signal-
receiving and -processing postsynaptic compartment (2), that are estimated to contain over 
2000 different proteins (19). In mammals, synaptogenesis starts prenatally and proceeds well 
beyond birth, with rapid and specific changes of synapse numbers, synapse morphology and 
protein expression at early juvenile stage through adolescence (66, 67). In particular, 
synapse number in rodents rapidly increases in the first three weeks after birth (67), and the 
typical synaptic structure with normal sized synaptic vesicles and postsynaptic thickening, 
can be observed at the end of the first postnatal week (68). These developmental changes 
allow neurons to establish connections with appropriate partners, to prune the initial wiring of 
extensive synaptic connections into a more refined and restricted number of relatively stable 
synaptic contacts, and to tune the functional properties of synapses to prepare them for adult 
function and plasticity (69, 70).
Synaptogenesis also involves the timed expression and functional incorporation of 
proteins. Both excitatory and inhibitory synapse formation are initiated by contacting 
transsynaptic adhesion molecules, as exemplified by the presynaptic neurexin - postsynaptic 
neuroligin interaction (71, 72). This contact leads, in the case of excitatory synapse 
formation, to postsynaptic NMDA receptor recruitment to the nascent synapse (73).
Subsequent AMPA receptor recruitment makes the synapse functional and allows rapid
synaptic transmission (74). Finally, receptor subunit switching, for instance replacing NMDA 
receptor subunit Grin2b with Grin2a (75, 76), renders a physiological mature synapse (77). It 
is generally accepted that in addition to these examples the synaptic proteome undergoes 
extensive developmental changes that underlie the progression of synaptogenesis and 
synapse maturation (44). Conversely, dysregulated synaptic protein expression and 
subsequent disturbance of timely interactions of proteins during development have been 
linked to impaired synaptic function in several disorders, such as autism, schizophrenia and 
several forms of mental retardation (8, 78).
To establish insight into synaptic protein expression profiles that cover the diversity 
of the synaptic proteome during the entire span of development, a comprehensive 
proteomics approach is required. In the present study, an iTRAQ reagent-based proteomics 
workflow was employed for the relative quantitation of synaptic membrane proteins across 8 
time points of juvenile, adolescent and adult mouse brain cortex development in a single 8-
plex set of experiments. iTRAQ reagent-based proteomics is particular suitable for time 
series experiments due to the possibility of multiple sample labeling and analysis in one 
2
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experiment. Quantification depends on the measurement of the iTRAQ signature ions 
generated from the tandem mass spectrometry (MS/MS) of the precursor ion. In such a 
complex sample, i.e., the synaptic membrane preparation of the mouse cortex, the number of 
quantified peptides and the accuracy of quantification critically depend on the capacity of the 
peptide separation system, we employed the OFFGEL isoelectric focusing system as first 
dimension separation (79).
In total, 3 independent biological replicates were analyzed, identifying 1978 proteins, 
of which 1560 proteins were present in all three replicates and 696 showed statistical 
differences over time. These data provides a new insight for generating novel hypotheses of 
molecular processes underlying synaptogenesis and synapse maturation.
24




Using the 8-plex iTRAQ reagents, we performed a time-series relative quantification of the 
brain cortical synaptic membrane proteome of juvenile postnatal days 9 (P9), P15, P21 and 
P27, adolescent P35 and adult P70, P140 and P280 mice. As the postsynaptic density is 
crucial for the biochemical enrichment of synaptic membranes, the main target of this study, 
the juvenile age P9 was chosen as the earliest time point.
First, cortical synaptic membrane fractions were isolated, and peptides derived from
trypsin protein digestion were fractionated by Strong Cation Exchange (SCX) 
chromatography, to remove the bulk of free iTRAQ label and other reagents that might 
interfere in subsequent analysis. These fractions were pooled, desalted and separated by 
OFFGEL electrophoresis, in which each OFFGEL fraction was analyzed by Liquid 
chromatography-Mass spectrometry (LC-MS). 
The standard OFFGEL protocol (provided by Agilent Technologies) resulted in 70% 
of the distinct peptides found in single fractions (Experiment 1). Previous studies suggested 
that better separation can be achieved (79). Therefore, the total focusing duration was 
increased to 80 kVh instead of the standard 50 kVh. Thereby separation was improved to 
80% of distinct peptides contained in single fractions (Experiment 2 and 3).
In total, three independent biological samples of synaptic membranes per time point 
were analyzed using OFFGEL methodology (Table 1). A total of 1978 proteins were identified 
with a high confidence protein score (≥unused ProtScore 3) from the combined search of all 
data in the three individual replicates (Supplementary sTable 1). The unused ProtScore is a 
sum of the scores from all peptides matched to the protein. As the maximum score that can 
be assigned to a single peptide is 2, the ProtScore of 3 was derived from ≥ 2 peptides. The 
complete list of proteins and peptides identified in the combined search of all three 
experiments together (‘Total’ column in Table 1) can be found in Supplementary sTable 2, 
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Table 1. List of three independent experiments and the corresponding numbers of identified 
peptides and proteins.
Experiment 1 Experiment 2 Experiment 3 Total
Distinct peptides 22025 21508 17821 40775
High confidence proteins 1769 1877 1822 1978
For adequate statistical analysis, we only considered identified proteins with high 
confidence and were present in all three replicates with no missing values at any time point. 
In total 1560 proteins were shared between the three OFFGEL experiments (Figure 1).
Unbiased interpretation of functional protein groups with significant temporal differences
To reveal the developmental changes in protein expression, the protein abundances of the 
adult mouse sample at P280 were taken as reference to compare with and to visualize the 
levels of proteins of the other 7 age groups. Firstly, hierarchical clustering was performed to 
examine the relative similarities of different developmental stages. This analysis was 
performed on the mean expression levels (log2-transformed) of the three biological 
replicates. Samples taken from adolescent and adult animals clustered into separate groups 
(Figure 2), and were both distant from animals of the youngest developmental stages 
(Figure 2a). Secondly, whereas more than 350 proteins are differentially expressed between 
P280 and the juvenile stages (P15, P21 and P27), only around 150 differentially expressed 
proteins were observed between P280 and the adult stages (Figure 2b). Thus, as expected, 
major changes in protein levels take place in juvenile stages and these differences in 
abundance get smaller towards the fully matured state, as was previously reported (80).
Figure 1. Venn diagram showing the 
distribution of the number of quantified 
proteins over the experiments.
Represented are all 1978 proteins quantified 
with a high confidence protein score 
(ProteinPilot unused ProtScore ≥3, see main 
text) across all three experiments. In total 
1560 proteins are common between the data 
sets.
26
2      Chapter 2
 
To reveal proteins that showed significant change in abundance over time, Bayesian 
Estimation of Temporal Regulation (BETR) statistical testing was employed, which takes 
correcting for multiple testing into account that is obligatory with samples of large size (81).
This resulted in 696 proteins showing a significant increase or decrease in levels over time 
(BETR ≤ 0.001; Supplementary sTable 1). As example, proteins with significantly high fold 
differences at P9 versus P280 are listed in Table 2. Importantly, there is a strong overlap 
between the most differentially expressed proteins reported herein with previous studies (44).
For instance Fabp7, which showed the highest ratio between P9 and P280 animals, is a 
protein expressed in neural stem and progenitor cells, reaches a maximum on E14 and 
gradually decreases after birth (82, 83). Also, the strong decrease in expression of Dcakd 
was previously reported (44), as holds for proteins having a role in neurite outgrowth (e.g., 
Marcks and Gap-43; Figure 3A). To confirm the results obtained by iTRAQ based proteomics 
we performed immunoblotting analysis for several well-known synaptic proteins with different 
patterns of expression, showing good agreement between both methods (Figure 3B, 
Supplementary sFigure1).
Figure 2. Protein expression relationship between samples of different developmental stages. (A) 
The average values of the protein levels of the different age groups were hierarchically clustered. The 
vertical distance connecting two samples within the dendrogram reflects similarity between the samples.  
(B) Number of proteins that were significantly different in abundance between P280 and other 
developmental stages (one-sample student’s t-test, p-≤0.05). P280 was taken as reference for the 
relative quantification of the other 7 age groups.
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Table 2. Proteins with high fold differences at P9 compared with P280.
Gene name Protein name P9/P280 (log2)
Fold
difference BETR
Fabp7 Fatty acid-binding protein, brain 3.33 10.09 0.000
Dcakd Dephospho-CoA kinase domain-containing protein 2.50 5.67 0.000
Mbp Myelin basic protein -2.47 5.54 0.000
Marcksl1 MARCKS-related protein 2.45 5.45 0.000
Cxadr Coxsackievirus and adenovirus receptor homolog 2.21 4.64 0.000
Plp1 Myelin proteolipid protein -2.17 4.50 0.000
Gjc2 Gap junction gamma-2 protein -2.16 4.45 0.001
Sdc3 Syndecan-3 2.06 4.18 0.000
Stmn2 Stathmin-2 2.06 4.16 0.000
Slc1a2 Excitatory amino acid transporter 2 -1.90 3.74 0.000
Camk2a
Calcium/calmodulin-dependent 
protein kinase type II subunit 
alpha 
-1.80 3.47 0.000
Tppp Tubulin polymerization-promoting protein -1.79 3.45 0.000
Tesc Calcineurin B homologous protein 3 1.79 3.45 0.001
Dcx Neuronal migration protein doublecortin 1.75 3.36 0.000
Tubb5 Tubulin beta-5 chain 1.73 3.31 0.000
Dpysl3 Dihydropyrimidinase-related protein 3 1.69 3.23 0.000
Stxbp5l Syntaxin-binding protein 5-like -1.69 3.22 0.000
Map1b Microtubule-associated protein 1B 1.68 3.20 0.000
Hrsp12 Ribonuclease UK114 -1.60 3.03 0.000
Dhcr7 7-dehydrocholesterol reductase 1.60 3.02 0.000
Plgrkt Plasminogen receptor (KT) 1.59 3.02 0.000
Eef1a1 Elongation factor 1-alpha 1 1.56 2.95 0.000
Tuba1a Tubulin alpha-1A chain 1.54 2.91 0.000
Pdxk Pyridoxal kinase -1.53 2.88 0.000
Lmnb1 Lamin-B1 1.51 2.85 0.000
Eno2 Gamma-enolase -1.47 2.77 0.000
Tuba4a Tubulin alpha-4A chain -1.47 2.77 0.000
Dpysl5 Dihydropyrimidinase-related protein 5 1.45 2.73 0.000
Atat1 Alpha-tubulin N-acetyltransferase 1 1.43 2.70 0.000
Pacsin1
Protein kinase C and casein 
kinase substrate in neurons 
protein 1 
-1.43 2.70 0.000
Hapln4 Hyaluronan and proteoglycan link protein 4 -1.42 2.68 0.000
Nav1 Neuron navigator 1 1.42 2.68 0.000
Gap43 Neuromodulin 1.42 2.67 0.000
Sncb Beta-synuclein -1.41 2.66 0.000
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Syn1 Synapsin-1 -1.41 2.66 0.000
Atp1a1
Sodium/potassium-
transporting ATPase subunit 
alpha-1
-1.41 2.66 0.000
Nrn1 Neuritin -1.40 2.64 0.000
Kcna1 Potassium voltage-gated channel subfamily A member 1 -1.37 2.59 0.000
Bdh1 D-beta-hydroxybutyrate dehydrogenase, mitochondrial 1.37 2.58 0.000
Tubb3 Tubulin beta-3 chain 1.37 2.58 0.000
Slc17a7 Vesicular glutamate transporter 1 -1.34 2.54 0.000
Cat Catalase 1.34 2.53 0.000
Hapln1 Hyaluronan and proteoglycan link protein 1 -1.34 2.53 0.000
Thy1 Thy-1 membrane glycoprotein -1.32 2.50 0.000
Sv2b Synaptic vesicle glycoprotein 2B -1.31 2.48 0.000
Stx1b Syntaxin-1B -1.31 2.48 0.000
To capture the functional significance of protein regulation in an unbiased manner, we 
interrogated the data with Ingenuity Pathway Analysis (IPA). Data from P9 to P280, the time 
range that generally gives the largest fold differences, was compared for different categories: 
(1) disease and disorders, (2) molecular and cellular functions, and (3) physiological system 
development and function (Supplementary sTable 6A). The low p-values for neurological and 
psychological disorders, nervous system development, and function and behavior, reflect the 
nature of the synapse preparation (84). To probe the alteration of underlying biological 
processes, we interrogated specifically the diseases and function annotation in IPA. The top 
5 for functional annotation and for diseases and disorders annotations are shown in Table 3. 
All the information generated from the IPA analysis, including protein identities for each 
process, are shown in supplementary sTable 6B. As expected, the main biological processes 
differentially regulated during neuronal development were neurotransmission and 
neuroplasticity (LTP), the latter may underlie the synaptic features of learning and cognition, 
not yet fully developed in immature synapses. Interestingly, abnormal processes of 
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Figure 3. Relative iTRAQ levels and SDS-PAGE immunoblot analysis of selected synaptic 
proteins. (A) The abundance profile of each protein depicted is presented as the ratio of signal intensity 
(fold difference on log2 scale) of the mean of three biological independent iTRAQ sets compared to the 
reference sample (P280). (B) SDS-PAGE immunoblot analysis of the selected proteins with an 
increasing (left) or decreasing (right) expression pattern across time points.              
Biological processes are often driven by specific multi-protein machineries. It is 
expected that proteins contained in such interaction are co-regulated. Examples are for 
instance the ribosome, of which the residing proteins are all co-regulated during development 
in this study (data not shown). In addition, synaptic proteins may assemble into larger 
networks, in which residing proteins together may regulate function. To reveal how protein 
networks are altered during development, we examined the regulation of the main pre-and 
postsynaptic networks as predicted by IPA. The biological process neurotransmission is 
found to be the main process with proteins still at low levels at P9 (Table 3). In accordance, a 
lower level of the canonical NMDA receptor protein complex and other postsynaptic proteins 
are revealed at P9 (Figure 4A), reflecting a feature of the immature nature of the synaptic 
preparation. Members of GST known to be involved in detoxification process were also down 
regulated, and this pathway is indicated as having an indirect interaction with the 
postsynaptic proteins. Similar to these postsynaptic proteins, core presynaptic proteins at P9 
were also present at lower levels. For instance, low levels of proteins that control or regulate 
membrane fusion and membrane retrieval, involving the t- and v-SNARE proteins and the 
proteins of endocytosis can be observed (Figure 4B). 
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Interestingly several non-canonical SNARE proteins, namely Snap 29/47, Stx 7/8/12 and Syn 
3, were oppositely regulated at P9 with higher expression levels. Syn 3 has been reported to 
show a high level of expression in growth cones of immature neurons (85), however, the 
functions and localization of the non-canonical SNARE proteins are less clear. IPA reveals an 
extensive connection of Snap29 to other canonical presynaptic proteins. It was reported to 
have broad tissue expression and appears to participate in many fusion events including 
Golgi, endosome and lysosome membranes in many cell types. It is suggested as a negative 
regulator of SNARE complex disassembly after fusion (86, 87). Snap47 on the other hand 
seems to have function similar to Snap 25 (i.e., having a role in synaptic vesicle fusion), and 
in addition plays role in axon branching (88, 89). The roles of various Stx isoforms in 
neurotransmission have been poorly documented, but are believed to have functions specific 
to synaptic vesicle fusion and recycling (90).
Table 3. Diseases and functional annotations from proteins that show significant differences 
between P9 and P280.
Functional annotation p-value Predicted activation Molecules
neurotransmission 3.06E-51 decreased 103
long-term potentiation 3.87E-39 decreased 69
learn 6.42E-31 decreased 81
cognition 3.20E-30 decreased 84
transport of synaptic vesicle 6.99E-25 decreased 29




movement disorder 5.37E-61 increased 186
neurological signs 9.31E-38 decreased 113
seizure disorder 1.84E-30 increased 87
tremor 8.27E-20 increased 36
ataxia 3.40E-15 increased 43
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Figure 4. Unbiased construction of 
protein sub-networks by IPA from 
proteins showing significant 
developmental changes. (A) and (B) 
show mainly the networks of post- and 
pre-synaptic proteins, respectively. 
Green color intensity indicates the level 
of down-regulation and red for up-
regulation in P9/P280 comparison. 
Continuous and discontinuous 
connections indicate direct or indirect 
interaction, respectively. 
The connection of Snap29 to other canonical presynaptic exocytosis proteins 
suggests that it is a presynaptic protein as well. In order to test this possibility, we compared 
the relative abundance of Snap29 to several canonical synaptic proteins across biochemical 
fractionated synaptic organelles as an initial characterization of their spatial distribution in 
mature synapses (Figure 5). Presynaptic (Syp) and postsynaptic (Dlg4 and Grin2b) proteins 
showed their typical enrichment in synaptosome and PSD fraction (47, 91–93), respectively. 
Snap29 spatial distribution generally followed the same pattern as Syp, in accordance to the 
vesicle/SNARE-related functions mentioned above. This distribution pattern supports the 
notion that, in mature neurons, Snap29 is a presynaptic protein. The functional role of these 
preferentially early expressed SNARE proteins remains to be determined.
32
2      Chapter 2
 
Figure 5. SDS-PAGE immunoblot and stain-
free gel images of different biochemical 
fractions of adult mouse cortex. Samples of 
different enriched subfractions were resolved 
on SDS-PAGE, and then immunoblotted for 
specific synaptic markers. NMDA receptor 2b 
(Grin2b) and Dlg4 proteins are markers of 
postsynaptic density fraction; synaptophysin 
(Syp) is a marker of the presynaptic terminal. 
Hom: homogenate; P2: pellet 2; Syn: 
synaptosome; Sym, synaptic membrane; PSD: 
Triton X-100 insoluble postsynaptic density 
fraction. Normalization of the protein input was 
performed using the stain-free gel.
Presynaptic proteins
In addition to IPA analysis, several major functional classes of presynaptic proteins members 
were identified (Figure 6). Interestingly, synaptic vesicle proteins showed increasing levels 
with slight differences in the order of extent of regulation (Figure 6A), with some exceptions, 
namely synapsin 3 (Syn3), as previously described (85), and Scamp2. All vesicle-type proton 
ATPase subunits showed an increase in level throughout brain development with only small 
variation between the subunits (Figure 6B). The tight co-expression of the subunits reflects 
the fact that together these proteins form a functional proton-pump in the synaptic vesicle
membrane (94). Interestingly, glutamate and GABA vesicular transporters (Figure 6C) show 
different expression from P9 to P27, to converge in adolescence (P35), the critical period of 
regulation of the excitatory-inhibitory balance (95, 96). Bassoon (Bsn), piccolo (Pclo) and 
Erc2 form a complex that binds synaptic vesicles and plays a role in their transport to the 
docking site (97), and also showed a similar increase in levels (Figure 6D). Cask showed no 
change, whereas Lin7A and Munc13 (Unc13a) were increased. On the other hand, levels of 
proteins involved in priming and exocytosis, e.g., syntaxin 1 (Stx1) and Stxbp1 were more 
variable (Figure 6E). Snap 29/47 and Stx 7/8/12 follow a decrease in expression levels along 
all time points. Voltage-dependent calcium channel subunits (e.g. Cacnb3 and Cacnb4) 
followed same patterns of increasing expression or did not change (e.g. Cacnb1 and 
Cacna2d1), except for some subunits, such Cacna1c, that shows a diminished level around 
P35 (Figure 6F). Proteins important for endocytosis and recycling of synaptic vesicles (98,
2
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99), such as clathrins (Clta, Cltb, Cltc), dynamin 1 (Dnm1) and amphiphysin 1 (Amph), 
increase in levels over time in a similar fashion (Figure 6G). Taken together, proteins of the 
presynaptic machinery show an overall increase in levels during development, reflecting the 
increase in numbers and/ or maturation of the presynaptic terminal and the onset of synaptic 
vesicle release cycle. Increase in numbers of synaptic vesicles during development, has 
been shown previously (68, 100), and might explain the observed increase of synaptic 
vesicle proteins that is shown here. 
Postsynaptic proteins
The postsynaptic element of a glutamatergic synapse contains a densely packed protein 
structure containing various types of glutamate receptors, scaffolding proteins, signaling 
proteins, adhesion molecules and cytoskeletal proteins (92). The tetrameric ionotropic 
AMPA- and NMDA-type glutamate receptors in most cases are comprised of two different 
subunit types (101). The NMDA receptor is composed of subunit GluN1 (Grin1) and either 
Figure 6. Relative levels of typical presynaptic proteins. The abundance profile of each protein 
depicted is presented as the ratio of signal intensity (fold difference on log2 scale) of the mean of three 
biological independent iTRAQ sets compared to the reference sample (P280). Synaptic proteins were 
assigned to specific functional groups, such as synaptic vesicle proteins (A), proteins important for 
docking (D), proteins involved in priming and exocytosis (E), and proteins implicated in clathrin-mediated 
endocytosis and recycling (G). In addition, the expression profile of the different subunits of the vacuolar 
ATPase is shown (B), vesicular transporters (C) and calcium channels (F). The asterisks at the protein 
names indicate significant difference in level over at least two time points (BETR ≤ 0.001; Supplemental 
Table 4).
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the GluN2A (Grin2a) or GluN2B (Grin2b) subunit. Grin1 and Grin2b abundance levels 
increase slightly over time, whereas Grin2a has clearly a lower expression level in young 
animals, which increases over time (Figure 7A), suggesting that the NMDA receptor subunit 
composition shifts from predominating Grin1-Grin2b in young animals, to Grin1-Grin2a in 
adult animals, with a described corresponding change in NMDA receptor channel properties 
(76). For AMPA receptors, the subunit GluA1 (Gria1) has constant expression pattern, 
whereas GluA2 (Gria2) and 3 (Gria3) have a lower expression level at early developmental 
stages, which increases over time (Figure 7B). Other glutamate receptors, such as the 
kainate-type glutamate receptor and the metabotropic glutamate receptors, mostly showed 
constant levels throughout all stages (Figure 7C). Important contributors to the architecture of 
the postsynapse are scaffolding proteins, including members of the PSD-95 family (Dlg), 
together with associated proteins (SAPAPs or Dlgap) and SH3 domain and ankyrin repeat 
proteins (Shanks). These are involved in clustering of glutamate receptors and cell adhesion 
molecules, as well as the recruitment of signaling molecules and the anchoring of these to 
the cytoskeleton (102). Also these proteins showed differential developmental expression 
patterns (Figure 7D-E) and generally increased in levels over time. 
Figure 7. Relative levels of typical postsynaptic proteins. The abundance profile of each protein 
depicted is presented as the ratio of signal intensity (fold difference on log2 scale) of the mean of three 
biological independent iTRAQ sets compared to the reference sample (P280). Synaptic proteins were 
assigned to specific functional groups, such as ionotropic glutamate receptors; NMDA- (A), AMPA- (B), 
kainate-type and metabotropic glutamate receptors (C), scaffolding proteins of the PSD (D-E), inhibitory 
GABAB and GABAA receptor subunits and gephyrin (F-G). The asterisks indicate proteins significantly 
regulated over at least two time points (BETR ≤ 0.001; Supplemental Table 4).
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There is a remarkable similarity in the general expression pattern of AMPA, NMDA receptor 
subunits and family members of PSD-95 (such as Dlg1, 2, 4 and all Dlgap), all following a 
gradual increment with a maximum at P35, and then leveling off at P70. This event seems to 
be correlated with the maturation and synapse formation that occurs until adolescence, and 
the synaptic refinement that takes place until that particular period (96).
The inhibitory metabotropic GABAB receptors, present in excitatory synapses, and 
ionotropic GABAA receptors, in inhibitory synapses (103), showed variable expression profiles 
throughout the developmental stages (Figure 7F-G). The increase in expression levels of 
GABAA receptor α1 (Gabra1), β2 (Gabrb2) and γ2 (Gabrg2) subunits, whereas others such 
as α3 decrease (Gabra3), indicates a subunit composition shift towards the major adult 
isoform (α1, β2 and γ2) (104). Gephyrin (Gphn), which is considered a major scaffolding 
protein at inhibitory synapses, did not show a significant regulation. In addition, the 
extrasynaptic GABAA receptor α4 subunit (Gabra4) level was higher when neuronal 
maturation neared completion, as has been described previously (105).
GABAB receptors remained unchanged, or were increased slightly over time, such 
as in case of the GABAB receptor 2 (Gabbr2, Figure 7G). Moreover, potassium channel 
tetramerization domain (KCTD) 12 and 16, part of GABAB receptor complex, were found 
decreasing and increasing in levels, respectively, until stabilization around P35 in accordance 
with the high expression of KCTD12 in fetal brain (106).
Adhesion molecules
The pre- and postsynaptic elements are held together by interactions of cell adhesion 
molecules present in the opposite synaptic membranes. During synaptogenesis, these 
proteins are involved in target recognition, induction of pre- and post-synaptic differentiation, 
and in the alignment of pre- and postsynaptic neurotransmitter release and reception 
machineries (71). The best-characterized cell adhesion molecules include neuroligins-
neurexins, ephrins-ephrin receptors, the Ig superfamily, cadherins, and the neurofascin 
family. The expression patterns of adhesion molecules (Figure 8) reveal high diversity in the 
immature synapses at P9 even between members of the same family. Whereas, most 
proteins belonging to the cadherin superfamily maintained a fairly constant level over the 
whole developmental period, Ig superfamily members show highly diverse protein expression 
patterns. For example, Ncam1 was found highly abundant at P9 and decreased towards 
maturation, whereas Ncam2, SynCAMs (Cadm) and Icam5 were slightly increased in 
expression (Figure 8A-B). 
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Figure 8. Relative levels of cell adhesion molecules. The abundance profile of each protein depicted 
is presented as the ratio of signal intensity (fold change on log2 scale) of the mean of three biological 
independent iTRAQ sets compared to the reference sample (P280). Major classes of cell adhesion 
molecules were grouped based on their expression patterns into (A) overall decreasing levels (ephrin 
receptors, NCAM), (B) increase in levels (SynCAM, Contactin, ICAM), or (C) not changed (cadherins, 
neuroligins, neurexins and contactins). The asterisks indicate proteins significantly regulated over at least 
two time points (BETR ≤ 0.001; Supplemental Table 4).
Functional validation of a highly regulated protein: Cxadr
Among all quantified proteins, Coxsackie virus and adenovirus receptor (Cxadr) showed one 
of the highest ratios between the P9 and P280 animals (Table 2). Cxadr acts as a cell 
adhesion molecule interacting through its PDZ-domain binding motif with intracellular scaffold 
proteins including PSD-95, and it has been implicated in the regulation of neurite extension 
(107). The relatively high expression levels of Cxadr at P9 and its fast decline in expression 
soon thereafter suggest that it may play a role in synapse formation or maturation. To test 
this, we knocked down the expression of Cxadr in cultured primary mouse neurons. Neurons 
were obtained from E18 mouse embryos and transduced at DIV2 with lentiviruses expressing 
either one of three different shRNAs against Cxadr or a scrambled negative control shRNA. 
At DIV14, cells were fixed, stained for dendritic and synaptic markers, and analyzed using 
high-content microscopy. Neuron numbers, dendrite length and synapse numbers were 
quantified unsupervised and fully automated using Columbus software (PerkinElmer) (Figure 
9A). None of the shRNAs significantly reduced neuron numbers, indicating normal cell 
viability (Figure 9B). All three shRNAs against Cxadr however significantly reduced synapse 
densities, i.e., the number of synapses per dendrite length, compared with either control 
shRNA-transduced cells or with untreated cells (Figure 9C). This reduction was on average 
8.4% ± 4% (shRNA #1, p<0.05; shRNAs #2 and #3, p<0.01).
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Figure 9. Cxadr knockdown affects synapse formation in vitro. (A) Images of primary mouse 
hippocampal neurons transduced with a negative control shRNA or with one of three shRNAs against 
Cxadr. Top panels show image selections with MAP2 staining (red) to identify dendrites and VAMP 
staining (green) to identify presynaptic spots. The MAP2 channel (row 2) was used to create a dendritic 
mask, and the VAMP channel (row 3) was used to identify synaptic spots within the dendritic mask 
region. Examples of the dendritic masks and identified synaptic spots are shown in row 4 on top of the 
VAMP staining. Scale bars: 10 µm. (B) Transduction with shRNAs did not affect neuron numbers. (C) All 
three shRNAs against Cxadr reduced synapse densities. Cxadr shRNAs, n=5; control shRNA, n=8; 
untreated cells, n=15. *p<0.05; **p<0.01.
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Discussion
To investigate the molecular development of the synapse, we have used OFFGEL separation 
of proteins and an iTRAQ-based mass spectrometry analysis of the synaptic membrane 
fraction of the mouse cerebral cortex. iTRAQ technology enabled comparing eight different 
developmental stages in a proteome-wide manner in a single experiment. Although synaptic 
proteins have been studied in depth during critical periods of development (44, 108), the 
adaptation of the synaptic proteome throughout various stages of postnatal development has 
not been described. This is the first study of the relative quantification of synaptic proteins at
eight distinct time points of postnatal brain development, including juvenile, adolescent and 
adult stages. 
This study was performed with three independent biological replicates per 
developmental stage divided over three iTRAQ experiments. Among 1978 identified proteins, 
1560 were common to the three iTRAQ experiments, and 696 showed statistically significant 
change in abundance in two or more developmental stages. The analysis with IPA reveals 
that neurotransmission and tissue development are the main regulated processes during 
neuronal maturation. A higher number of regulated proteins is observed in juvenile and 
adolescent animals (P9 - P27), which stabilized in adults (P70, P140, P280), which seems to 
be a general pattern observed in different studies (80, 100). In the still developing brain (at 
P9 or P15) the machinery for protein synthesis was more abundant, consistent with the 
notion that a development puts a higher demand on the supply of new (synaptic) proteins 
(109, 110).
The majority of presynaptic proteins showed gradual increase in levels, which is in 
line with previous studies (100, 108). The synaptic vesicle integral membrane proteins such 
as V-ATPases, SV2, Syn and Syp have a low expression levels at P9, and together these 
increased to a constant level at P27. This was accompanied with similar changes in levels of 
bassoon (Bsn), piccolo (Pclo) and Erc2, organizers the active zone. Proteins involved in 
endocytosis, such as clathrin (Clt), dynamin (Dnm1) and synaptojanin (Synj1), also increased 
and stayed at a constant level at around P27. As immature synapses at P9 grow in size, they 
become filled with larger numbers of synaptic vesicles and generate a wider active zone 
present at P27 (68, 100). Accordingly, many proteins of the vesicle release machinery, e.g., 
synapsin (Syn) and synaptophysin (Syp), increased in abundance during development. 
Proteins involved in docking of synaptic vesicles to the active zone, however, did not show 
such a clear pattern of abundance change. For instance, Cask showed constant levels 
throughout all time points, whereas Lin7A and Stxbp1 abundance increased from P9 
onwards. On the other hand, the non-canonical SNARE protein Snap29, with a presynaptic 
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enrichment, has a higher expression level at P9 that decreases over time. Preferential early 
expression patterns were also observed for Snap47and Stx 7,8,12. The functional 
significance of differential expression patterns in developmental changes of distinct vesicle 
release machinery proteins is of interest and remains to be investigated.
Developmental changes of pre- and postsynaptic elements likely show coordinated 
expression to match full synapse maturation. Indeed, the typical postsynaptic scaffolding 
proteins SAP-97 (Dlg1), PSD-93 (Dlg2) and PSD-95 (Dlg4) showed expression patterns that 
are similar to those of the presynaptic synaptic vesicle proteins, synaptic vesicle glycoprotein 
and secretory carrier-associated membrane protein. SAP-102 (Dlg3) showed a different 
expression pattern as described previously (111) with high expression in young animals (P9) 
and lower levels in adult animals (P280). This protein mediates synaptic trafficking of AMPA-
and NMDA-type receptors during synaptogenesis (112), a process that is also linked to the 
developmental shifts of NMDA and AMPA receptor subunits. In later stages, PSD-95 takes 
over the functions of SAP-102 (Dlg3), mediating the developmental increase of AMPA 
receptor transmission and the replacement of Grin2b with Grin2a-containing NMDARs (113,
114).
Co-regulation or distinct expression patterns of proteins over time might give clues 
to shared roles either during synapse formation, maturation or in synaptic plasticity. Proteins 
with highest P9 to P280 ratio are listed in Table 2. Signaling proteins with known involvement 
in neurite extension and axon growth of cortical neurons, such as the Calcium-calmodulin 
binding PKC substrate proteins Marcksl1 and Gap-43 (115, 116), were relatively abundant 
early in development. In the adult brain, these proteins regulate synapse morphology through 
remodeling of the actin cytoskeleton. Levels of several isoforms of the microtubule-
associated protein family strongly decreased over time (e.g. Map1b), whereas other specific 
tubulin-cytoskeleton associated proteins (e.g. Tppp) increased as previously demonstrated in
the visual cortex during adolescence (108). These findings suggest discrete functions of 
Tubulin-associated proteins during brain development, which needs further investigation.
In addition to the proteins previously reported involved in neurite outgrowth and 
synaptogenesis, there are a number of proteins currently not known to be associated with 
synapse formation and/or maturation. One of the most regulated proteins identified was the 
cell adhesion molecule Coxsackie virus and adenovirus receptor (Cxadr). The low expression 
and restricted distribution of Cxadr in mature brain indicates that this protein might play a 
prominent role in immature synapses. In general, the functionality of cell adhesion molecules 
is diverse; they stabilize synaptic contacts, promote neurite outgrowth and act in path-finding, 
control of synaptic formation and are involved in regulation of synaptic transmission and 
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plasticity. In order to test the functional implication of Cxadr in synapse development, we 
knocked down the expression of Cxadr in cultured primary mouse neurons. All three shRNAs 
against Cxadr significantly reduced synapse densities, suggesting that Cxadr play a role in 
synapse formation or maturation, which goes in parallel with the expression profile of the
protein.
Fatty acids are critical structural components of the brain and essential for normal 
brain development, including the generation of neuronal membranes, differentiation and 
migration (117), and axon outgrowth mechanism are controlled by phospholipid-mediated 
signaling (118). In line with this, we found Lipid phosphate phosphatase-related protein type 
3 (Lppr3), Low-density lipoprotein receptor-related protein 1 (Lrp1) and Fatty acid synthase 
(Fasn), all involved in lipid homeostasis, highly expressed in juvenile synapses at P9. 
Remarkably, Fatty acid-binding protein 7 (Fbp7) has the largest ratio between P9 and P280 
animals. Specifically localized in neural cells, this protein has been described to play an
essential role in neurogenesis (82), and has been associated with psychiatric illnesses, such 
as schizophrenia and autism (83, 119).
In particular during adolescence, important changes in cortical architecture and 
function occur, such as regulation of the neuronal excitatory-inhibitory balance (96, 120). Our 
data enable to follow specific protein expression changes that are taking place during this 
period. For instance, different expression of vesicle transporters (e.g. vesicular glutamate 
transporter 1 (Slc17a7) and 2 (Slc17a6)) and regulation of excitatory and inhibitory receptors 
(e.g. GluA2/3 of AMPA receptor, KCTD12/16) occurs at P35 (adolescence). Adolescence is 
generally regarded as a vulnerable period in the development of mental illnesses, such as 
anxiety, mood disorders or schizophrenia (120). Expression profiles of disease-associated 
proteins in this critical period may help to better understand that synaptic molecular basis of 
disease development. Of interest is Cacna1c (Cav1.2 alpha subunit 1c), which is associated 
with schizophrenia (121). This protein shows an increasing abundance during early 
development, but in contrast with the other calcium channels subunits, has a lower 
expression at P35, after which it is then stabilized. The functional implication of this particular 
regulation is still unknown and might be considered for further analysis. Conversely, proteins 
with similar critical period patterns may be considered as potential risk proteins and studied 
further in that context.
Finally, it has to be considered that this study does not distinguish between the 
large diversity of neuronal cell types, including the vast majority of excitatory neurons (122)
and the different types inhibitory cells. These different cortical cell types possess particular 
developmental properties. The results shown here represent the average protein changes 
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occurring in all cortical synapses during development. Consequently, neuron type-specific 
expression or developmental regulation of proteins in sparse neuron types might become too 
diluted to be detected.
In conclusion, proteome analysis of synapses in the developing brain as described 
here might aid in understanding the underlying molecular mechanisms of synapse formation 
and maturation. Developmental changes in protein levels are likely indicative for a functional 
role at a specific stage in synaptogenesis. The synaptic membrane fraction used here 
consists in principle of pre- and postsynaptic plasma membrane proteins and proteins that 
adhere to those. The development of a specific synapse ontology would be instrumental in 
generating hypotheses on the roles of distinct synaptic proteins. Besides this, various 
proteins discussed may be likely candidates for further functional and/or synaptic 
developmental studies.
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C57Bl/6J mice were bred in our facility. Animals were decapitated on postnatal days P9, P15, 
P21, P27, P35, P70, P140 or P280. Following decapitation, the brains were removed and the 
cortex was dissected. The tissue was rapidly frozen and stored at -80 °C until further use. 
These experiments were approved by the animal ethics committee of the VU University. The 
methods were carried out in accordance with the approved guidelines.
Sample Preparation
Synaptic membranes were isolated from a single mouse cortex as described previously (47,
91), except for mice of postnatal day 9, of which cortices of two animals were pooled to 
obtain sufficient tissue for subsequent analysis. In short, brain tissue was homogenized in 
ice-cold 0.32 M sucrose and centrifuged at 1,000 x g for 10 min. The supernatant was loaded 
on top of a sucrose gradient consisting of 0.85 M and 1.2 M sucrose. After ultracentrifugation 
at 100,000 x g for 2 h, the synaptosome fraction was collected at the interface of 0.85/1.2 M
sucrose and then lysed in hypotonic solution. The resulting synaptic membrane fraction was 
recovered by ultracentrifugation using the sucrose step gradient as stated above. Synaptic 
membranes were harvested at the 0.85/1.2 M interface. Protein concentration was 
determined by a Bradford-based assay (Bio-Rad Protein Assay). 75 µg protein of synaptic 
membrane sample was dried in a SpeedVac and used for quantitative proteomics. 
Quantitative Proteomics
iTRAQ labeling: A single set of iTRAQ experiments contained 8 samples corresponding to 
the cortical synaptic membranes prepared from mice of different ages at postnatal days, P9, 
P15, P21, P27, P35, P70, P140 and P280. In total 3 sets of iTRAQ experiments were carried 
out on biologically independent samples. The previously described protocol for iTRAQ 
labeling of peptides was followed (123). The dried synaptic membranes were resuspended in 
28 µl of 0.5 M Triethylammonium bicarbonate buffer pH 8.5, containing 0.85 % RapiGest 
(Waters associates). A 2 µl cleavage reagent (50 mM Tris[2-carboxyethyl] phosphine) was 
added and incubated at 55 °C for 1 h. A 1 µl Cys blocking reagent (50 mM S-methyl 
methanethiosulfonate) was added and incubated at room temperature for 10 min. Next, 5 µg
of trypsin (Promega) dissolved in water was added and incubated overnight at 37 °C. 
Trypsinized peptides were tagged with one unit iTRAQ reagent (Sciex) dissolved in 80 µl 
isopropanol. After incubation at room temperature for 2 h the 8 samples were pooled and 
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acidified with 5 % TFA to pH 2.5 - 3.0. After 45 min, the sample was centrifuged and the 
supernatant was dried in a SpeedVac overnight.
Strong Cation Exchange (SCX) liquid chromatography: The dried iTRAQ sample was 
dissolved in loading buffer (20 % acetonitrile, 10 mM KH2PO4, pH 2.9) and injected into a 
SCX column (polysulfoethyl A column from PolyLC). Peptides were eluted with a linear 
gradient of 0-500 mM KCl in 20 % acetonitrile, 10 mM KH2PO4, pH 2.9, over 25 min at a flow 
rate of 200 µl/min. Fractions were collected at 1 min intervals. SCX fractions were pooled, 
desalted by solid phase extraction, dried, redissolved in water and subjected to OFFGEL 
separation.
OFFGEL peptide separation: Peptides were fractionated according to their pI using the 
Agilent OFFGEL 3100 fractionator (Agilent Technologies). Urea 1M was added to the IEF 
buffer instead of 5 % glycerol mentioned in the manual. Commercially available IPG dry strips 
24 cm, with a linear pH gradient ranging from 3-10 (GE-Healthcare) were used. The strips 
were rehydrated with 40 µl/well rehydration solution in the assembled device for 30 min. 
150 µl of the pooled SCX fractions redissolved in water were loaded on each well. The cover 
fluid (mineral oil, Agilent Technologies) was added to both ends of the gel strip. The focusing 
method OG24PE01, as supplied by the manufacturer was used in the first OFFGEL 
experiment (Experiment 1). Typical voltage ranging from 500 to 4500 V was applied until 
50 kVh was reached. The maximum current was set to 50 mA and the maximum power to 
200 mW. In the subsequent two biological independent samples a longer focusing was 
applied till 80 kVh (Experiments 2 and 3). The higher volt-hour improved separation. In total 
24 fractions were collected per OFFGEL experiment. Each OFFGEL fraction was pre-
cleaned using the HLB µElution plates (Waters). The eluates were dried in a SpeedVac, 
redissolved in 20 µl 0.1 % TFA, and subjected to LC-MS/MS analysis. 
Reverse Phase liquid chromatography: Peptides were delivered with a FAMOS autosampler 
at 30 µl/min to a C18 trap column (1 mm x 300 µM i.d. column) and separated on a nano-C18 
column (150 mm x 100 µm i.d. column) at 400 nl/ min using the LC-Packing Ultimate system. 
Peptides were separated using linearly increasing concentration of acetonitrile from 5-40 % in 
50 min and to 90 % in 1 min. The eluent was mixed with matrix (7 mg α-cyano-
hydroxycinnaminic acid in 1 ml 50 % acetonitrile, 0.1 % TFA, 10 mM dicitrate ammonium) 
delivered at a flow rate of 1.5 µl/min and deposited off-line to the Applied Biosystems metal 
target every 15 s for a total of 192 spots using the probot (Dionex). 
Mass spectrometry (MS/MS): Samples were analyzed on a 4800 or 5800 proteomics 
analyzer (AB-Sciex). Collision-induced dissociation of peptides was performed at 1 kV with 
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air as collision gas. Peptides with signal to noise ratio above 50 at the MS mode were 
selected for MS/MS, at a maximum of 20 MS/MS per spot. The precursor mass window was 
set at 200 relative resolution (FWHM). The MS/MS spectrum for each peptide was averaged 
from 2000 laser shots. The MS run time per OFFGEL fraction of 192 spots were about half to 
two days for 5800 and 4800 proteomics analyzer, respectively. Thus, the total 5800 
proteomics analyzer measurement time for a single OFFGEL experiment was about 12 days. 
All the original machine generated data was deposited in PRIDES for public access 
(PXD004129).
Protein identification and quantification: Data obtained by mass spectrometry for each 
experiment and all three combined were analyzed with ProteinPilot software (version 4.5; 
Applied Biosystems; MDS Sciex) using the Paragon algorithm (version 4.5.0.0; (124)) as the 
search engine. MS/MS spectra were searched against a mouse database without isoforms 
(Uniprot-Swissprot_2014/03). The parameters were set to iTRAQ 8-plex (peptide labeled), 
cysteine modification by MMTS, and trypsin digest. The detected protein threshold was set to 
0.05 (10% confidence), bias correction was executed, and iTRAQ isotope correction factors 
were included. The fold change between labeled peptides (denominator: iTRAQ label 121, 
age P280) was calculated during the search (Supplementary sTable 2-5). The total number 
of proteins and peptides were obtained by performing a combined search with ProteinPilot 
including all three replicates (Supplementary sTable 2).
The resulting data for each biological replicate were combined, and reverse sequences and 
proteins with no quantitative values were removed. Furthermore, only proteins with a 
ProteinPilot unused value larger than 3 (peptide contribution values not claimed by another 
protein) across all three experiments were considered for posterior analysis (Supplementary 
sTable1).
Clustering and statistical analysis of protein expression profiles
Hierarchical clustering was used to visualize the similarity between the developmental 
stages. Time point clustering using Euclidean distance was performed on the log2-
transformed means of the three replicates. To determine the number of statistically significant 
changed proteins between the reference (P280) and the other time points, a one-sample 
student’s t-test was executed in Perseus (MaxQuant, v1.5.2.6). The Bayesian Estimation of 
Temporal Regulation (BETR), which was initially developed for microarray data analysis (81),
was used to reveal statistical significant differences of the proteins in 3 replicates across the 
8 developmental stages. Proteins were considered as significantly changed with a BETR 
≤ 0.001.  Finally, proteins with significant differences were imported into IPA for core analysis 
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without user intervention. IPA identifies genes associated with a list of relevant functions and 
diseases, and the list is ranked according to the significance of the biological functions. We 
used direct and indirect interactions, and all the types of relationship for the analysis.
SDS-PAGE Immunoblot Analysis
Synaptic membrane fractions from individual animals were mixed with 5x SDS sample buffer 
and heated to 98 °C for 5 min. Proteins were separated on a 8 % SDS-polyacyrlamide gel 
containing 0.5 % TCE in a Mini-Protean Electrophoresis System (Bio-Rad). After 
electrophoresis, proteins in the gel were modified and scanned in the Gel Doc EZ imager 
(Bio-Rad) (125). Proteins were electroblotted onto a PVDF membrane overnight at 40 V, and 
scanned in the Gel Doc EZ imager. Membranes were blocked with LI-COR blocking solution, 
incubated with primary antibodies at 4 °C overnight, and then incubated with a matched 
secondary antibody conjugated to either IRDye 680 (goat-anti-mouse) or IRDye 800 (goat-
anti-rabbit) for 1 h. After washing, the blot was scanned with the Odyssey Fc imaging system 
(LI-COR Bioscience) and analyzed with Image Studio software (version 2.0.38). Differences 
in loading amount were corrected were corrected to (TCE-activated) total protein on the gel. 
In addition, samples from different subcellular compartments of adult mouse cortex were 
employed for immunoblot with secondary antibodies conjugated to Horseadish peroxidase 
and scanned with Femto ECL Substrate (Thermo Fisher Scientific).
The following antibodies were used for immunoblot analysis; Grin2a (1:1000, Abcam, 
ab14596), Grin2b (1:1000, Neuromab, 75-101), Gria2 (1:1000, Neuromab, 75-002), Gria3 
(1:1000, Abcam, ab87609), Gap43 (1:1000, Sigma, G9264), Marcks (1:250, GenScript, 
A00511), Nptn (1:500, Gift from K. H. Smalla), Cxadr (1:500, obtained from GenScript, raised 
against the synthetic peptide PDLKGRVHFTSNDVC), PSD95 (1:10000, Neuromab, 75-028), 
Syp (1:2000, GeneScript, A01307) and Snap29 (1:1000, Synaptic Systems, 111303).
Primary neuron culture, Cxadr knockdown and high-content microscopy
Hippocampi were dissected from E18 wildtype C57Bl/6 mouse embryos. Neurons were 
plated in 96-well glass bottom plates (Cellstar, Greiner Bio-One, Frickenhausen, Germany) 
that were coated with poly-D-lysine (Sigma-Aldrich) and 5% heat-inactivated horse serum 
(Invitrogen). Cells were plated at a seeding density of 15k/well and cultured in Neurobasal 
medium supplemented with 2% B-27, 1.8% HEPES, 1% glutamax and 1% Pen Strep (all 
from Invitrogen) at 37°C/5% CO2 for 14 days. Two days after plating, cells were transduced 










or a non-targeting negative control shRNA (Sigma; SHC204:
CCGGCGTGATCTTCACCGACAAGATCTCGAGATCTTGTCGGTGAAGATCTTTTT) at 
MOI=2.1*107 TU/ml. After 14 days, cells were fixed for 12 minutes using 4% 
paraformaldehyde and 1% saccharose in PBS (pH 7.4), washed with PBS, permeabilized 
with 0.25% Triton X-100 in PBS for 10 minutes and blocked for 1 h in 1% BSA in 0.25% 
Triton X-100 in PBS. Neurons were stained with chicken anti-MAP2 (Bio Connect, 
Cambridge, UK; 1:5,000), and VAMP (Synaptic Systems, Billerica, MA, USA; 1:1,000) 
overnight at 4 °C. Antigens were visualized using DyeLight 549 (Jackson; 1:400) and Alexa 
488 (Invitrogen 1:400) incubated for 2 h at room temperature. Cultures were imaged at 40x 
using an Opera LX HCS instrument (PerkinElmer, Waltham, MA). Columbus software 
(PerkinElmer) was used to quantify neuron numbers and synapse densities (i.e., total VAMP-
positive puncta on MAP2-positive dendrites divided by the total dendrite length measured). 
Statistical significance was determined by Student t-tests.
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Supplementary figures
Supplementary Fig. 1. Quantitative immunoblotting analysis of selected synaptic proteins. The 
abundance profile of each protein depicted is presented as the ratio of signal intensity (fold difference on 
log2 scale) of the iTRAQ sets (blue) or immunoblotting (red) compared to the reference sample (P280). 
The y-axis indicates fold change on a log2 scale and changes in protein abundance with increasing age 
are shown from left to right (x-axis).
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Abstract
The metabotropic glutamate receptor 5 (mGluR5) is an essential modulator of synaptic 
plasticity, learning and memory; whereas in pathological conditions, it is an acknowledged 
therapeutic target that has been implicated in multiple brain disorders. Despite robust pre-
clinical data, mGluR5 antagonists failed in several clinical trials, highlighting the need for a 
better understanding of the mechanisms underlying mGluR5 function. In this study, we 
dissected the molecular synaptic modulation mediated by mGluR5 using genetic and 
pharmacological mouse models to chronically and acutely reduce mGluR5 activity. We found 
that next to dysregulation of synaptic proteins, the major regulation in protein expression in 
both models concerned specific processes in mitochondria, such as oxidative 
phosphorylation. Second, we observed morphological alterations in shape and area of 
specifically postsynaptic mitochondria in mGluR5 KO synapses using electron microscopy. 
Third, computational and biochemical assays suggested an increase of mitochondrial 
function in neurons, with increased level of NADP/H and oxidative damage in mGluR5 KO. 
Altogether, our observations provide diverse lines of evidence of the modulation of synaptic 
mitochondrial function by mGluR5. This connection suggests a role for mGluR5 as a 
mediator between synaptic activity and mitochondrial function, a finding which might be a 
relevant for the improvement of the clinical potential of mGluR5.
Graphical abstract
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Introduction
The group 1 metabotropic glutamate receptor 5 (mGluR5) is a G-protein coupled receptor 
expressed widely across the brain, predominantly in hippocampus, striatum and cortex (126).
Pharmacological and genetic animal models have revealed a major role of mGluR5 in 
learning and memory in hippocampus (127–130). mGluR5 is an essential postsynaptic 
modulator of synaptic plasticity (131, 132), facilitating the induction and persistence of long-
term potentiation (LTP) and mediating long-term depression (LTD) (127, 133, 134). This type 
of LTD requires the synthesis of new proteins, a process regulated by mGluR5 at multiple 
levels (135). Moreover, this receptor is also known to participate in synapse formation, 
maintenance and maturation (136, 137).
mGluR5 regulation of the synapse is mediated by an intricate signal transduction 
mechanism, which involves the interplay of several signaling pathways (reviewed in (38, 39)). 
The coordinated action of multiple second messengers [such as inositol triphosphate (IP3), 
Ca2+ and mitochondrial reactive oxygen species (ROS) (138)], protein kinases (e.g. PKC, 
MAPK, mTOR and ERK1/2) and scaffold protein interactions (139) comprises the cascades 
underlying mGluR5 functions. This complicated signaling system ultimately leads to the 
regulation of diverse downstream processes and illustrates the extensive role of mGluR5 in 
synaptic function at different levels. For instance, mGluR5 is preferentially coupled to Gq/G11 
to activate phospholipase C, producing IP3 and releasing Ca2+ from intracellular stores. In 
the canonical signaling, this leads to the activation of kinases, e.g. CaMKII, PKC, that 
modulate the function of ion channels, such as the NMDAR, which subsequently affects 
synaptic plasticity (38). Alternatively, mGluR5-mediated production of IP3 can also lead to the 
generation of mitochondrial ROS, which activate ERK and PKA to increase neuronal 
excitability (138).
mGluR5 has been implicated in multiple brain disorders, including schizophrenia 
(140), Alzheimer’s disease (141, 142), Parkinson’s disease (143), major depressive disorder 
(review (144)) and fragile X syndrome (123, 145, 146). In line with this, the therapeutic 
potential of mGluR5 pharmacological modulation, in particularly allosteric inhibition, has been 
extensively described, e.g. in addiction (reviewed in (147, 148)), Huntington’s disease (149),
chronic stress and depression (150, 151), Alzheimer’s disease (152), fragile X syndrome 
(153) and Parkinson’s disease (154). Despite robust pre-clinical data, mGluR5 antagonists 
failed in clinical trials for depression (reviewed in (155)), Parkinson’s disease (156) and 
fragile X syndrome (157).
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The relevance of mGluR5 in synaptic function, various brain disorders and its 
therapeutic potential have been greatly demonstrated. However, the negative outcome of 
mGluR5 antagonists in clinical trials reveals the need for a better understanding of the 
complex processes underlying mGluR5 function and inhibition at the synapse. Here, we used 
a proteomic approach to investigate the synaptic response to the reduction of mGluR5 
activity. By using pharmacological and genetic mouse models, we found that the most 
prominent effect of mGluR5 inhibition and gene deletion was the change in protein 
expression of specific pathways in the mitochondria. Electron microscopy analysis revealed 
the alteration in shape and area of postsynaptic mitochondria in mGluR5 KO synapses, 
whereas computational and biochemical assays suggested an increase of mitochondrial 
function in neurons. Together, our observations uniquely indicated the modulation of 
mitochondrial function by mGluR5, which may be relevant for improving the clinical potential 
of mGluR5.
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Results
Mitochondrial protein expression is regulated in mGluR5 KO
To investigate the mechanism behind the function of mGluR5 in the synapse, we 
first applied quantitative proteomics to wild type (WT) and mGluR5 knockout (KO) mice. The 
synaptic proteome was enriched by preparing synaptosomal fractions from mouse 
hippocampus. Proteins were digested into peptides and analyzed by mass spectrometry 
using the label-free SWATH acquisition method (Sequential Window Acquisition of all 
THeoretical mass spectra) (42). Data analysis was performed considering only proteins with 
>2 high quality peptides for downstream analysis. After filtering, 11,400 peptides from 1,766 
proteins were identified (Fig. 1A, Data S1A). Proteins were quantified with a median 
coefficient of variation of 9% and 8% for the 6 biological replicates of WT and KO 
synaptosome preparations, respectively (Fig. S1). As a result, the expression of 26 proteins 
was found increased and 38 decreased in mGluR5 KO synaptosomes (eBayes p ≤ 0.01, Fig. 
1A).
To gain insight in the underlying processes regulated, we performed gene ontology 
enrichment analysis (Fig. 1B and Data S1B). The most prominent overrepresentation 
identified was the mitochondria, with general ontology terms such as ‘mitochondrion’, and 
more specifically the mitochondrial inner membrane. In total 73% of all up-regulated proteins 
were mitochondrial. Moreover, several of these proteins also showed high fold-changes, such 
as Me3 (malic enzyme 3), which is the most up-regulated protein with ~2.5 times higher 
protein expression in mGluR5 KO than in WT controls (p = 6.6 x 10-11). Eighteen proteins 
from ‘metabolic pathways’ (KEGG), mainly related to the glucose metabolism, were found 
consistently down-regulated in mGluR5 KOs (0.85 fold of the WT protein expression on 
average). Other metabolic pathways were obtained from other sources, such as ‘small 
molecule biosynthetic process’ (Gene Ontology biological process), ‘metabolism of 
carbohydrates’ (Reactome), ‘glycolysis and gluconeogenesis’ (Wikipathways).
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Figure 1. Quantitative proteomics analysis of mGluR5 KO synaptosomes. (A) Volcano plot showing the 
distribution of fold-change protein expression in mGluR5 KO synaptosomes compared to WT mice 
(N=6). Proteins above the dotted line were considered significantly regulated (eBayes p < 0.01). Proteins 
are labeled and colored based on the 3 non-overlapping annotations with highest protein count in (B). 
Asterisks in the protein name tags indicate synaptic proteins based on SynGO. (B) Gene ontology 
enrichment analysis for the significantly regulated proteins (p < 0.01) depicted in (A). The ontology terms 
with the highest protein count from each database source are indicated. (C) SDS-PAGE immunoblot 
validation of selected proteins found decreased (Grm5, Grm1), increased (Me3), or non-affected (Dlg4) 
in mGluR5 KO (N=3). In agreement with the mass spectrometry data, Grm5, Grm1 and Me3 protein 
expression were found significantly regulated (t-test p = 0.001, 0.014 and 0.002, respectively), but not 
Dlg4 (p = 0.93). Protein loading was visualized and quantified in-gel using 2,2,2-Trichloroethanol to 
correct total protein amount differences. CORUM, the comprehensive recourse of mammalian protein 
complexes; GO:BP, Gene Ontology Biological Processes; GO:CC, Gene Ontology Cellular 
Compartment; KEGG, Kyoto Encyclopedia of Genes and Genomes; REAC, Reactome; WP, 
WikiPathways Ontology. All bar graphs, means ± SD.
Several known synaptic proteins, as annotated in SynGO (45), were found among 
the regulated proteins. As expected, mGluR5 (Grm5) was the protein most significantly 
decreased in expression; compared to the background signal of the KO where Grm5 was not 
identified. Other synaptic proteins with decreased expression level included mGluR1 (Grm1), 
Gad1 and Pacsin1; while the expression of Prkcb (Protein kinase C beta type), Gpc1 and 
Kcnd3 (Potassium voltage-gated channel subfamily D member 3) were found increased, 
which may involve compensatory mechanisms to the lack of mGluR5 activity.
As an independent validation of the results obtained by mass spectrometry, we 
performed immunoblotting analysis of several proteins and with different directions of 
regulation (Fig. 1B). In all cases we found good agreement between approaches, i.e. 
mGluR5 was absent in KO mice, mGluR1 was significantly down-regulated, mitochondrial 
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Me3 was strongly up-regulated, and Dlg4 (PSD95) was not found regulated with either 
method.
Taken together, these data revealed a predominant increase of mitochondrial 
proteins expression in mGluR5 KO synaptosomes and, to lesser extent, the decrease of 
metabolic proteins expression and differential expression of synaptic proteins.
Postsynaptic mitochondrial morphology is altered in mGluR5 KO
We next asked whether the mitochondrial protein differential expression in mGluR5 WT/KO 
may be derived from changes in the structure and/or trafficking of mitochondria to the 
synapse. To answer this, we used transmission electron microscopy (EM) of hippocampal 
CA1 region synapses from WT and mGluR5 KO brains sections (Fig. 2A). First, 209 WT and 
247 KO synapses were analyzed to assess whether there is a preferential mitochondrial 
localization to the synapse in mGluR5 KO. No significant difference was observed in the 
percentage of synapses containing mitochondria (36% of the WT and 42% of the KO 
synapses; Fig. 2B). In addition, the distance of the mitochondria to the synapse (active zone 
or postsynaptic density) was not found significantly altered (Fig. 2C), neither for presynaptic
and postsynaptic mitochondria separately (Fig. S2A). Thus, mitochondrial localization does 
not seem to be altered in mGluR5 KO synapses.
Second, the morphology of the synaptic mitochondria was measured. We analyzed 
the area and perimeter of 59 WT and 86 KO synaptic mitochondrial compartments. Both 
parameters were found significantly decreased in mGluR5 KO synapses (Fig. 2D), while the 
synaptic active zone length did not change (Fig. S2B). Furthermore, we found the 
postsynaptic mitochondrial area and perimeter significantly decreased in mGluR5 KOs (Fig. 
2E), whereas the presynaptic mitochondria were not affected (Fig. 2F). Next, we calculated 
the elongation index, which gives an indication of the shape of the mitochondria. A perfect 
circular shape corresponds to an elongation index of 1, while higher values indicate more 
elongated or complex shapes. The elongation index of postsynaptic mitochondria was found 
reduced in mGluR5 KOs (Fig. 2E), whereas for presynaptic mitochondria this was not 
significantly different from WTs (Fig. 2F). Altogether, the mitochondrial compartment in 
mGluR5 KO exhibited a smaller area, perimeter and elongation index for the postsynapse, 
but not for the presynapse, matching the mainly postsynaptic expression of mGluR5.
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Figure 2. Electron microscopy analysis of mGluR5 KO synaptic mitochondria. (A) Representative 
images of typical asymmetric glutamatergic synapses from WT and mGluR5 KO hippocampus (N=6). 
Synaptic mitochondria are highlighted in green. (B) Percentage of synapses containing mitochondria in 
either the pre- or post-synaptic compartment (N=6, n=209 for WT; N=6, n=247 for KO). No significant 
difference was found between WT and KO (t-test, p = 0.64). (C) Linear distance from the presynaptic and 
postsynaptic mitochondria to the active zone and postsynaptic density, respectively. No significant 
difference was found between WT and KO (nested p = 0.29). (D) Area and perimeter of mitochondria 
located in both the pre- and post-synaptic compartment were significantly reduced in KO mice (nested p 
= 0.028 and 0.003, respectively). (E) Area, perimeter and elongation index of mitochondria located in the 
post-synaptic compartment were significantly reduced in KO mice (nested p = 0.002, 0.001 and 0.019, 
respectively). (F) No significant differences were found between WT and KO in the area, perimeter and 
elongation index of mitochondria located in the presynaptic compartment (nested p = 0.20, 0.09 and 
0.11, respectively). * p < 0.05, ** p < 0.01. All bar graphs, means ± SD.
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Acute pharmacological inhibition of mGluR5 regulates mitochondrial protein expression
 To explore the synaptic mechanisms underlying mGluR5 function in an alternative model of 
diminished mGluR5 activity, we investigated acute pharmacological inhibition of mGluR5 
using quantitative proteomics. Adult WT mice were treated once or twice with CTEP, a 
negative allosteric modulator of mGluR5 with a long half-live in mice (153, 158). Animals 
were sacrificed 2 (CTEP2h), 24 (CTEP1d) and 48 hours (CTEP2d) after the first 
administration (Fig. 3A). Hippocampal synaptosomes were isolated and analyzed by mass 
spectrometry as indicated above, using mice treated with vehicle as control. From the 2072 
proteins quantified across all experimental conditions (Data S2A), in total 52 proteins were 
significantly regulated upon CTEP treatments (eBayes p ≤ 0.01, Fig. 3B-C); 45 were found 
regulated in the CTEP2h group (Fig. 3B), while only 5 proteins were regulated in CTEP1d 
(Fig.3C) and 3 in CTEP2d (Fig. 3D). All three groups were quantified with a low 8% median 
coefficient of variation within replicates (Fig. S3A). 
Figure 3. Quantitative 
proteomics analysis of 
synaptosomes of CTEP-treated 
mice. (A) Experimental design. 
Adult WT mice were treated with 
CTEP or vehicle and sacrificed 
2 (CTEP2h), 24 (CTEP1d) and 
48 hours (CTEP2d) after the 
first administration as indicated 
(N=6). (B-D) Volcano plots 
showing the distribution of fold-
change protein expression in 
CTEP-treated mice 
synaptosomes from the 
CTEP2h (B), CTEP1d (C) and 
CTEP2d (D) groups compared
to vehicle control. Proteins 
above the dotted line were 
considered significantly 
regulated (eBayes p < 0.01). (E)
Heatmap showing the 
differentially abundant 
synaptosome proteins between 
CTEP-treated and control mice. 
Color gradient (blue-red)
indicates the fold changes 
compared to vehicle control. 
Asterisks indicate the 
experimental group in which the 
protein was found significantly 
regulated. Proteins were 
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Next, we performed gene ontology enrichment analysis to functionally annotate the 
regulated proteins upon CTEP treatment (Fig. 3E and Data S2B). Interestingly, 79% of the 
proteins found up-regulated belong to the mitochondrion, which parallels the results obtained 
from mGluR5 KOs. Whereas little overlap was found for the proteins significantly regulated in 
mGluR5 KO and CTEP-treated mice (Fig. S3B), gene ontology enrichment analysis revealed 
the same 8 GO cellular component terms in both models, including mitochondrion, 
mitochondrial envelope and mitochondrial inner membrane. Furthermore, we observed that 
the mitochondrial and metabolic proteins regulated in mGluR5 KOs followed the same 
direction of regulation in CTEP2h with smaller fold-change (Fig. S3C). Among the down-
regulated proteins, we found the synaptic Bin1-Dnm1-Ehbp1 complex, Arhgap44, Map2k1 
and Pak3, as well as Pacsin1 and Got1, of which expression was also significantly decreased 
in the mGluR5 KO. All in all, the expression of multiple mitochondrial proteins was found 
increased 2 hours after the CTEP treatment, partly replicating the effects identified in the KO.
Reduced mGluR5 activity alters specific mitochondrial pathways
To gain insight in the mGluR5-mediated mitochondrial protein regulation, we inspected 
several aspects of the mitochondrial proteome. First, we explored the distribution of 
expression fold-changes in CTEP2h for all mitochondrial proteins, as annotated by MitoMiner 
(Fig. 4A). We found that mitochondrial proteins followed a significant bimodal distribution 
compared to a randomized protein selection (p <2.2x10-16, 100 iterations), i.e. mitochondrial 
proteins tended to form two groups in the CTEP2h treatment, one without expression 
changes and one with higher expression compared to controls. To uncover the specific 
mitochondrial processes implicated, the mitochondrial proteins were grouped based on their 
cellular compartment, protein complex and biological functions, as retrieved from Uniprot, 
CORUM and MitoXplorer, respectively. Regarding the distribution over the sub-organelle 
compartments, proteins located in the mitochondrial inner membrane and intermembrane 
space showed higher fold-changes, compared with the mitochondrial matrix (Fig. S4A). 
Regarding the biological function, the highest fold-changes were found for proteins related to 
the oxidative phosphorylation, mitochondrial carrier and dynamics (Fig. 4B). Accordingly, the 
protein complexes with highest fold-changes correspond to oxidative phosphorylation and 
mitochondrial intermembrane space bridging complexes (Fig. S4B). The visualization of the 
oxidative phosphorylation pathway confirmed a broad coverage of proteins identified, with a 
1.15-fold median increased expression in synaptosomes of CTEP-treated mice (Fig. 4C). In 
contrast, the cytosolic proteins from the pentose phosphate pathway, glycolysis and ROS 
defense showed the lowest fold-changes, in line with the decreased protein expression of 
metabolic pathways observed in the mGluR5 KO. Altogether, the short-term inhibition of 
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mGluR5 appears to affect the protein expression of specific pathways of the mitochondrial 
proteome, in particular the oxidative phosphorylation.
To understand the functional implication of the mitochondrial pathways regulated, 
the levels of NADP/H (a cofactor of several mitochondrial enzymes) and oxidative damage 
(partly derived from the oxidative phosphorylation activity) were analyzed in mGluR5 KO 
hippocampus. Total NADP/H in KO hippocampus was 21% higher in comparison to WT (Fig. 
4D), which matches well with the increased protein expression of NAD(P)H-dependent 
mitochondrial enzymes, such as Me3. To assess oxidative damage, we measured the 
malonaldehyde (MDA) produced via lipid peroxidation as a consequence of oxidative stress. 
Total MDA level in KO hippocampi was significantly increased 38% compared to WTs (Fig. 
4E), which indicates elevated lipid damage resulting from oxidative stress. Taken together, 
the increased level of NADP/H and oxidative damage observed in mGluR5 KO hippocampus 
suggests higher oxidative stress partly derived from the augmented mitochondrial activity, 
including the oxidative phosphorylation.
Neuronal mitochondrial proteins are mostly regulated by the mGluR5 inhibition
In the adult mouse brain, mGluR5 is mostly expressed in neurons (159, 160), however, other 
cell types may also be indirectly implicated in the mGluR5-mediated mitochondrial regulation. 
While the synaptosome preparations analyzed mostly contain neuronal synaptic 
mitochondria, impurities of free mitochondria from other cell-types might also be present in 
this fraction. Interestingly, the expression of mitochondrial proteins differs across tissues and 
cell types to adjust to different tasks and demands (161, 162) and, thus, these expression 
differences can be used to discriminate between cell-types. To determine the cells most 
affected by the manipulation of mGluR5 function, we examined the cell-type distribution of 
the mitochondrial proteome. First, we performed expression weighted cell-type enrichment 
(EWCE) analysis on the mitochondrial proteins significantly regulated by CTEP2h treatment, 
with all identified mitochondrial proteins as background. When using a single-cell 
transcriptomic (scRNA-seq) dataset from mouse cortex (163), the most significant cell-types 
obtained correspond to excitatory neurons, including neuronal types from multiple cortical 
layers (Fig. 4F, Data S3A). To confirm this result using independent single-cell datasets, we 
performed cell-type enrichment analysis using 29 publicly available scRNA-seq datasets from 
mouse and human nervous system tissue as implemented in FUMA (164). Accordingly, the 
vast majority of the most significant cell-types obtained correspond to neurons, including 84% 
of the three most significant cell-types per dataset (Data S3B, Fig. S5).
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Figure 4. Mitochondrial pathway and cell-type enrichment analysis of CTEP-induced protein expression 
regulation. (A) Distribution of protein expression fold-changes induced by the treatment with CTEP 
(CTEP2h group) for all quantified mitochondrial proteins and a randomized control (100 iterations). The 
mitochondrial proteins distribution was significantly different from the control. (B) Boxplot showing the 
distribution of mitochondrial protein expression fold-changes (CTEP2h group) in different functional 
categories based on MitoXplorer. Solid and dotted vertical lines indicate no change and ±0.1 fold-change 
(log2), respectively. (C) Visualization of CTEP-mediated protein expression modulation onto the 
mitochondrial electron transport chain (wikipathways WP111_107324). Color gradient represents the 
protein expression fold-change (CTEP2h group). Proteins in gray were not identified. (D) Total level of 
the cofactor NADP/H was increased in mGluR5 KO hippocampus compared to WT (N=5). (E) Total MDA 
(malonaldehyde) level was increased in mGluR5 KO hippocampus compared to WT (N=7 for WT; N=5 
for KO), as an assessment for oxidative damage. (F) Expression weighted cell-type enrichment analysis 
for the differentially abundant mitochondrial proteins and the 50 mitochondrial proteins with larger fold-
changes upon CTEP2h treatment. The dendogram represents the hierarchical relationship between cell-
types. * p < 0.05, *** p < 0.001. All bar graphs, means ± SD.
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To test whether mitochondrial proteins with stronger CTEP-induced regulations are 
associated with a specific cell-type, we performed EWCE analysis on the 50 mitochondrial 
proteins with higher fold-change upon CTEP2h treatment. Similar to the significantly 
regulated proteins, higher fold-change mitochondrial proteins were enriched in neuronal cell-
types (Fig. 4F, Data S3A). As an independent assessment, we correlated the genetically 
determined expression of all mitochondrial and non-mitochondrial genes with mGluR5 (Fig. 
S6A). mGluR5 mostly exhibited either a positive or negative correlation with mitochondrial 
genes, in contrast with the absence of correlation observed between mGluR5 and all non-
mitochondrial genes. The expression profiles of mitochondrial genes significantly correlated 
with mGluR5 revealed that the positive and negative correlations correspond to genes little 
and highly expressed in non-neuronal cell types, respectively (Fig. S6B). Moreover, positively 
correlated genes showed a higher fold-change in protein expression than the negatively 
correlated genes upon CTEP treatment (Fig. S6C). The same trend was found using single-
cell protein expression (162), where mitochondrial marker proteins for granule cells showed 
higher fold-changes than for astrocytes (Fig. S6D). Taken together, the mitochondrial 
proteins most regulated by the treatment with CTEP appear to be enriched in neuronal cell-
types, matching the mostly neuronal mGluR5 expression, while non-neuronal mitochondrial 
proteins were less affected.
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Discussion
In this study, we investigated synapse adaptation to loss or impaired mGluR5 function from a 
proteomic perspective. By using a mGluR5 KO mouse model, we first assessed the 
adaptation of synaptic proteins to the chronic lack of mGluR5 function throughout 
development and lifespan. Pharmacological inhibition of mGluR5 in vivo allowed us to 
evaluate the acute synaptic modulation derived from the reduction of mGluR5 activity in adult 
mice. Despite fundamental differences between these models, we found that the major 
synaptic protein expression changes in both models concerned mitochondrial functions. This 
mGluR5-dependent mitochondrial modulation was further characterized by electron 
microscopy, biochemical and computational analysis.
Mass spectrometry analysis of mGluR5 KO synaptosomes led to the identification of 
64 significantly regulated proteins from different functional categories. Among the synaptic 
proteins, mGluR1 (Grm1) and PKC beta (Prkcb) expression was found decreased and 
increased, respectively. mGluR1 and mGluR5 interact in a protein complex and constitute the 
group 1 metabotropic glutamate receptors family (165), while PKC is involved in mGluR5 
signaling pathway. The increased PKC beta expression and co-regulation of mGluR1-
mGluR5 suggest the rearrangement of downstream effectors rather than the functional 
compensation between receptor family members for the lack of mGluR5 signaling. 
Additionally, Pacsin1 expression was reduced in both the mGluR5 KO and CTEP-treated 
mouse synaptosomes, a protein known to promote AMPA and NMDA receptor endocytosis 
and trafficking (166–168). Moreover, Arhgap44 (169), Map2k1 (170) and Pak3 (171) were
found down-regulated in CTEP-treated mice, which are involved in AMPA receptor trafficking 
and recycling. Given the role of mGluR5 in the modulation of AMPA receptor and induction of 
NMDA receptor trafficking to the surface (172), the action of Pacsin1, Arhgap44, Map2k1, 
Pak3 and mGluR5 is likely coordinated to regulate the overall synaptic response to 
glutamate. Taken together, mGluR5 KO and CTEP-treated mice showed the expression 
regulation of multiple synaptic proteins known to be functionally related to mGluR5.
Despite the regulation of synaptic proteins, the most prominent effect observed in 
both models was the increased expression of mitochondrial proteins. From all up-regulated 
synaptosome proteins, 73% and 79% were mitochondrial for mGluR5 KO and CTEP-treated 
mice, respectively. Mitochondrial and synaptic function are tightly interconnected (173).
Neuronal activity triggers a rapid burst of mitochondrial fission and elevation of mitochondrial 
calcium (174). Vice versa, mitochondria located in axons and dendrites are essential for 
synaptic transmission and plasticity via different mechanisms, such as the regulation of 
calcium homeostasis, ATP production and protein translation (175, 176). Since mGluR5 is 
critically implicated in protein synthesis and LTD, a functional link between mitochondria and 
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mGluR5 is plausible. Interestingly, mitochondrial ROS have been previously shown to act as 
second messenger in mGluR5 signaling pathway (138, 177). Moreover, several lines of 
evidence suggest the essential role of ROS, partly produced by mitochondria, in physiological 
synaptic plasticity, learning and memory, while the pathological disruption of ROS balance 
impairs these processes (178). Considering the common role of mitochondria and mGlulR5 
as modulators of synaptic plasticity, mGluR5 may represent a key hub for the crosstalk 
between synaptic transmission and mitochondria.
In addition, several proteins involved in glucose metabolism were found down-
regulated in mGluR5 KOs, but not as extensively in CTEP-treated mice. Although a relatively 
low overlap in protein identity of significant proteins was found between both models, the 
metabolic and mitochondrial proteins regulated in mGluR5 KOs showed the same trend upon 
CTEP treatment with smaller effect size. This observation suggests that the acute inhibition 
of mGluR5 can modulate the levels of the same proteins at the synapse, but not as strong as 
the chronic lack of mGluR5 activity in the KOs. Remarkably, the effect of the pharmacological 
inhibition of mGluR5 seems quickly reversible since it was not found 24 hours after CTEP 
administration, regardless of the long CTEP half-life (158). Together, acute and chronic 
mGluR5 function inhibition both induce a substantial increase in mitochondrial protein 
expression.
Observations combined from mGluR5 KO and CTEP-treated mice revealed several 
aspects of the mGluR5-mediated mitochondrial regulation. First, no preferential synaptic 
localization was found for mitochondria in the mGluR5 KO, suggesting that the increased 
protein expression was not simply caused by a higher number of mitochondria included into 
the synaptosome preparation. Accordingly, pharmacological inhibition of mGluR5 seems to 
regulate the protein expression of specific pathways rather than the whole mitochondrial 
proteome. Second, a reduced area, perimeter and elongation index of synaptic mitochondria 
were found in mGluR5 KOs while the synapse length was unaffected, implicating 
mitochondria with smaller size and more circular shape. Since mitochondrial morphology and 
function are closely associated, these morphological changes might indicate a modulation of 
mitochondrial activity. Indeed, pathway analysis from CTEP-induced mice indicated 
regulation of oxidative phosphorylation proteins, which are implicated in the production of 
oxidative stress and ROS. Consistently, an increased oxidative damage and NADP/H, 
cofactor of multiple mitochondrial enzymes, were observed in mGluR5 KO, possibly 
underlying a higher mitochondrial activity. Mitochondrial morphology and activity can be 
adjusted by synaptic activity via fusion/fission events, which are required for synaptic 
plasticity (174). Considering the function of mGluR5 as a glutamate receptor, these 
observations suggest that mGluR5 might be implicated in the connection between synaptic 
3
65
Reduced mGluR5 activity modulates mitochondrial function
 
activity, the release of glutamate and mitochondrial function. Lastly, the morphological 
alteration of mitochondria were found only in the postsynaptic compartment, matching the 
main subcellular localization of mGluR5 (126). In parallel, cell-type enrichment analysis 
showed that the mitochondrial pathways mostly regulated by CTEP-treatment correlated best 
with neuronal cell types, consistently with the primary neuronal mGluR5 expression in adult 
brain (159, 160). Collectively, these results strongly suggest a direct link between mGluR5 
and the mitochondrial function in the synapse.
In previous studies, indications of the association between mGluR5 and 
mitochondrial function have been found. MGluR5 was shown to modulate ATP levels in 
different types of cells (179–181), production of ROS (138, 177, 180, 182), mitochondrial 
mass (180) and mitochondrial biogenesis (183). Our study revealed that mGluR5, in addition 
to these, can also regulate specific mitochondrial proteins, morphology and NADP/H level. 
Our observation of an mGluR5-dependent postsynaptic mitochondrial morphology may partly 
explain the dysfunctional mitochondrial respiration and morphology recently reported in a 
fragile X syndrome mouse model (184), in which mGluR5 plays a predominant role (185).
Moreover, the proteomic data provides a new entry into exploration of the specific 
mitochondrial pathways implicated and the mechanisms by which mitochondrial function 
responds to mGluR5. Among the multiple downstream effectors of mGluR5 signaling, PKC 
beta (Prkcb) level was found increased in mGluR5 KO, and MEK1 (Map2k1) level decreased 
in CTEP-treated mice. These observations suggest the involvement of Gq-IP3-PKC rather 
than MEK-ERK signaling pathway in the mGluR5-mediated mitochondrial regulation, which 
might be considered for further investigation. Accordingly, mitochondrial ROS have been 
found activated by mGluR5 through IP3 (138), and mitochondrial respiration in synaptic 
fractions is known to be altered via PKC and IP3 in ischemia (186–188). Taken together, we 
found new evidence for the connection between mGluR5 and mitochondrial function, and 
provided data to generate hypotheses for future investigation regarding the underlying 
mechanistic link between mGluR5 and mitochondria, as well as the functional and 
therapeutic implication of this relation.
Our proteomic analysis indicated an increase in the level of mitochondrial proteins, 
in contrast with the reduced mitochondrial size shown by EM analysis. Although these results 
appear to mismatch, both observations could be compatible. The increase in levels of 
mitochondrial proteins might reflect a different metabolic state of the mitochondria rather than 
a change in their size. Accordingly, we found only protein levels within specific mitochondrial 
pathways increased, instead of the whole mitochondrial proteome, and increased NADP/H 
levels suggesting changes in mitochondrial physiology. Alternatively, the increased protein 
levels may also be derived from presynaptic mitochondria, for which a morphological 
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alteration was not observed, and/or different types of dendritic spines not easily identified by 
EM analysis.
In conclusion, the most prominent mGluR5-mediated synaptic response identified 
was the regulation of mitochondria. Given the important role of mitochondria in disorders of 
the central nervous system (189) and the broad therapeutic potential of mGluR5, this 
functional relationship represents an interesting connection to consider regarding 
improvement of treatments and the outcome of clinical trials. Moreover, we postulate the role 
of mGluR5 as a regulator of the link between synaptic activity and mitochondrial function.
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Materials and Methods
Animals and drug administration
Grm5 knock-out mice (The Jackson Laboratory; from strain B6.129-Grm5tm1Rod/J; stock 
number 003558) were bred and maintained on a C57Bl/6J background in our facility. Male 
wild type C57Bl/6J mice aged 2-3 months were treated by intraperitoneal (i.p.) injection of 2 
mg/kg 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-
yl)ethynyl)pyridine (CTEP, Axon Medchem, cat. number 1972), as previously described (134,
152, 158), or vehicle (1% DMSO, 5% Tween-80, 30% PEG, 65% saline). Solution was 
passed through a 0.45 μm filter and adjusted to an administration volume of 10 mL/kg. 
Animals were sacrificed 2 hours or 1 day after treatment. After removing the brains, the 
hippocampus was dissected and stored at −80 °C until further use. The experiments were 
performed according to the guidelines approved by the Central Committee for Animal 
Experiments (CCD) and the Animal Welfare Body (IVD) of the VU University Amsterdam.
Synaptosome preparation
Synaptosomes were individually prepared from 6 WT and 6 KO mice, as well as 6 WT mice 
treated with CTEP or vehicle as previously described (190). Hippocampi were homogenized 
in HEPES buffer (5 mM HEPES, pH 7.4, 0.32 M sucrose, with EDTA-free protease inhibitor 
cocktail, Roche) in a dounce homogenizer (12 strokes, 900 rpm). The homogenate was 
centrifuged at 1,000 x g for 10 min and the supernatant was subsequently centrifuged in a 
0.85/1.2M sucrose gradient at 100,000 x g for 2 hours. The synaptosomes collected from the 
0.85/1.2 M sucrose interface were concentrated by centrifugation at 18,000 x g for 20 min. 
Protein concentration was determined by using Bradford colorimetric assay (Bio-Rad, 
5000006EDU).
Sample preparation for mass spectrometry
Synaptosome samples were further processed by filter-aided sample preparation (FASP) 
with some modifications (42). In short, 20 μg of protein mixed and incubated with 75 μL 2% 
SDS, 1 mM Tris(2-carboxyethyl)phosphine for 1 hour at 55°C. Samples were incubated with 
0.5 μL 200 mM methyl methanethiosulfonate for 15 min to block the cysteines. Samples were 
mixed with 200 μL 8 M urea in Tris (pH 8.8) and transferred to Microcon-30 filter tubes 
(Millipore). Next, the samples were centrifuged 15 min at 14,000 x g and sequentially washed 
four times with 200 μL 8 M urea in Tris buffer and 4 times with 50 mM ammonium 
bicarbonate. Protein digestion was performed with 0.7 μg Trypsin/Lys-C Mix (MS grade, 
Promega) in 50 mM ammonium bicarbonate overnight at 37 °C. Peptides were recovered 
with 200 μL 50 mM ammonium bicarbonate, dried in SpeedVac and stored at -20°C until use.
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LC-MS analysis
Peptide samples were analyzed by micro LC-MS/MS as described previously (191). Briefly, 
we used an Ultimate 3000 LC system (Dionex, Thermo Scientific) with a 5 mm Pepmap 100 
C18 column (300μm i.d., 5μm particle size, Dionex) to trap the peptides and a 200 mm 
AlltimaC18 column (300μm i.d., 3μm particle size) for fractionation. A linear gradient of 
acetonitrile was applied in the mobile phase at a flow rate of 5μL/min, from 5 to 18% in 88 
min, to 25% at 98 min, 40% at 108 min and to 90% in 2 min. Peptides were electro-sprayed
with a micro-spray needle (at 5500 V) into a TripleTOF 5600 mass spectrometer (Sciex).The 
data-independent acquisition method consisted of a parent ion scan of 150 ms followed by 
SWATH (Sequential Window Acquisition of all THeoretical mass spectra) windows of 8 Da 
with 80 ms scan time, stepped through 450-770 m/z mass range. The collision energy for 
each window was determined for a 2+ ion centered upon the window with 15 eV spread.
Spectronaut Pulsar (v12.0.20491, (192)) was used for data analysis with a spectral 
library generated from synapse-enriched samples containing spike-in iRT reference peptides 
(Biognosys). Cross-run normalization was enabled and all other parameters were set at 
default. The peptides considered for down-stream analysis were quantified with a Q-value ≤ 
10-3 across all samples in at least half of the groups in each dataset (allowing one outlier 
within each group). Only proteins with at least two peptides were considered. The mass 
spectrometry proteomics datasets generated during the current study are available in the 
PRIDE repository, with the identifier PXD023809.
SDS-PAGE immunoblotting
Synaptosome samples were mixed with 5X Laemmli buffer and incubated at 90 ºC for 5 min. 
Proteins were separated on SDS-polyacyrlamide gels containing 2,2,2-Trichloroethanol for 
total protein amount visualization. After electrophoresis, gels were scanned using a Gel Doc 
EZ imager (Bio-Rad) and electro-transferred onto a PVDF membrane overnight at 40 V. 
Membranes were blocked with 5% non-fat milk (Sigma-Aldrich), incubated with primary 
antibody at 4 ºC for 1 hour and then with matching HRP-conjugated secondary antibodies at 
4 ºC for 1 hour (Agilent Dako). After washing, the membranes were scanned with Femto ECL 
Substrate (Thermo Fisher Scientific) using the Odyssey Fc system (LI-COR Bioscience). 
Images were quantified using Image Studio software (version 2.0.38). Differences in loading 
were corrected using the quantification of the total protein amount and immunoblot signals 
were normalized to the controls. The following primary antibodies were used: anti-ME3 
(Abcam, ab172972), anti-mGluR5 (GenScript, A01493), anti-Rat mGluR1α (BD Biosciences, 
556331) and anti-PSD-95 (NeuroMab, 75-028).
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Electron microscopy (EM)
Wild type and mGluR5 KO mice (6 per group) were perfused with ice-cold phosphate-buffer 
saline (PBS, pH 7.4), followed by 4% paraformaldehyde (PFA) in PBS. Brains were 
immersed overnight in 4% PFA in PBS and then in 30% sucrose, 0.02% NaN3 in PBS. 
Brains were sliced in 40 μm sagittal sections with a cryostat. Sections were sequentially post-
fixed in 1% osmium tetroxide, 1.5% potassium ferricyanide, dehydrated in an ascending 
ethanol series, and embedded in epoxy resin. Hippocampal CA1 region was cut into 80 nm 
sections and contrasted with 0.5% uranyl acetate and lead citrate. Transmission EM analysis 
was performed at 100,000 magnification using a JEOL1010 electron microscope (JEOL) and 
a side-mounted CCD camera (Morada, EMSIS). Digital images were processed with iTEM 
analysis software (EMSIS).
The synapse length (active zone and postsynaptic density), mitochondrial 
compartment area, perimeter and distance to the synapse (shortest distance to the active 
zone or postsynaptic density) were determined in at least 200 synapses per genotype using 
ImageJ software (imagej.nih.gov/ij). Both symmetric and asymmetric synapses were included 
in the analysis. Only mitochondria within 500 nm from the center of the active zone or 
postsynaptic density were considered (193). The elongation index corresponds to 
1/circularity, where circularity was calculated as 4π x Area/Perimeter2 (194). All image 
acquisition and analyses were performed blinded for genotype.
NADP/H and 2-Thiobarbituric Acid Reactive Substances (TBARS) assay
Total NADP/H level was determined with a NADP/NADPH assay kit (Abcam, ab65349) 
following the provided protocol. In brief, 5 WT and 5 mGluR5 KO mouse hippocampi were 
homogenized in 500 μL extraction buffer and centrifuged at 20.000 x g for 5 min at 4 ºC. The 
supernatant was transferred to a 10k Da column (Sartorius Stedim Biotech) and centrifuged 
at 4,000 x g for deproteinization. The unfiltered protein fraction was kept for protein 
quantification using Bradford colorimetric assay (Bio-Rad, 5000006EDU). Cycling reaction 
mix was added to each sample in duplicate and developed for 3 hours. Samples were 
scanned (optical density at 450 nm) in a SpectraMax i3 (Molecular Devices), individual 
sample background was subtracted and protein concentration was used for normalization.
Total malonaldehyde (MDA) level was determined with a TBARS assay kit (Oxford 
Biochemical Research, FR45). Hippocampi dissected from 7 WT and 5 mGluR5 KO mice 
were homogenized, centrifuged and filtered as described above. Samples were mixed in 
duplicate with indicator solution and incubated at 65 ºC for 45 min. Samples were scanned 
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(585 nm emission, 532 nm excitation) in a SpectraMax i3 (Molecular Devices), background 
was subtracted and protein concentration was used for normalization
Gene Ontology (GO) enrichment analysis and databases
GO enrichment analysis was performed using g:Profiler (195), with g:SCS method for 
multiple testing correction and all proteins identified as background. Only proteins labeled as 
“Known mitochondrial” from MitoMinner (196) were considered for down-stream analysis on 
mitochondrial proteins. Mitochondrial proteins were classified based on their subcellular 
localization as retrieved from Uniprot, protein complexes from CORUM (197) and functional 
annotation as curated by MitoXplorer (198). Proteomic data was visualized onto the electron 
transport chain (wikipathways WP111_107324, (199)) using PathVisio (200).
Cell-type enrichment analysis
Expression weighted cell-type enrichment (EWCE) analysis was performed as previously 
described (201). We used a publicly available single-cell RNA sequencing (scRNA-seq) 
dataset generated from mouse primary visual cortex (163), including only the exonic data. 
Uninformative cell-types were excluded. Additionally, cell-type enrichment analysis was 
performed as implemented in FUMA (164), using 29 of the available pre-processed scRNA-
seq datasets generated from nervous system tissue. All mitochondrial proteins identified in 
the CTEP proteomic dataset were used as background.
Gene expression correlation analysis
Grm5 gene expression was correlated with all mitochondrial and non-mitochondrial genes 
expression based on a reference scRNA-seq dataset, generated from mouse primary visual 
cortex (163). The raw exonic count data was converted into counts per million (CPM) and 
log10 transformed with pseudo-count 1. Per gene per cell type (subclass) average was 
calculated for expression values different from 0. Uninformative cell-types were excluded 
(i.e., “Low quality”, “Batch grouping”, “High intronic”, “Doublet”) and expression data was 
median normalized. Spearman correlation was performed between Grm5 expression data 
and the rest of the genome. 
Experimental design and statistical analyses
For proteomic analysis, the experiments were performed in randomized blocks (202). Protein 
abundances were Loess normalized with Limma R package (‘normalizeCyclicLoess’ 
function,10 iterations, ‘fast’ method) (203). Empirical Bayes moderated t-statistics were 
applied (p < 0.01) using the same R package (‘eBayes’ and ‘topTable’ functions), without 
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multiple testing correction to allow more proteins into the pathway analysis. For EM analysis, 
outlier identification was performed using GraphPad Prism 6 (ROUT, 1%). Nested statistics 
were applied by using a linear mixed-effects model as implemented in lme4 R package (204).
Student’s t test was applied to analyze the percentage of synapses with mitochondria. For 
gene expression correlation analysis, the statistical assessment was performed using corrplot 
R package with ‘fdr’ adjustment for multiple testing correction. Correlations with FDR 
corrected p-values < 0.05 were considered significant. For enrichment analyses, the 
statistical tests integrated in each method were used. Shapiro-Wilk test and visual inspection 
were used to test for normality. Other statistical analyses were performed using Student’s t 
test.
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Supplementary Data
Data S1 Complete results table of the mass spectrometry analysis of mGluR5 KO 
synaptosomes. (A) Quantitative and statistical analysis of all proteins identified with at least 
two high quality peptides in WT and mGluR5 KO synaptosomes. Mitochondrial proteins were 
labeled as retrieved from MitoMinner. (B) Gene ontology enrichment analysis for the 
significantly regulated proteins (eBayes p < 0.01) in mGluR5 KO. Proteins with increased 
(unregulated) and decreased (downregulated) expression in mGluR5KO were analyzed 
separately
Data S2 Complete results table of the mass spectrometry analysis of CTEP-treated mice. (A)
Quantitative and statistical analysis of all proteins identified with at least two high quality 
peptides in synaptosomes of CTEP-treated mice scarified 2 (CTEP2h), 24 (CTEP1d) and 48 
hours (CTEP2d) after the first administration. Mitochondrial proteins were labeled as 
retrieved from MitoMinner. (B) Gene ontology enrichment analysis for the significantly 
regulated proteins (eBayes p < 0.01) in CTEP2h group compared to vehicle control. Proteins 
with increased (unregulated) and decreased (downregulated) expression in CTEP-treated 
mice were analyzed separately
Data S3 Cell-type enrichment analysis table of CTEP-induced mitochondrial protein 
expression regulation. (A) Complete results of expression weighted cell-type enrichment 
(EWCE) analysis on the differentially abundant mitochondrial proteins and the 50 
mitochondrial proteins with larger fold-changes upon CTEP2h treatment. (B) Extended cell-
type enrichment analysis (FUMA) of the differentially abundant mitochondrial proteins upon 
CTEP-treatment (CTEP2h group) using 29 different scRNA-seq datasets from mouse and 
human nervous system tissue
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Supplementary Figures
Figure S1 Quality control for the quantitative proteomics analysis of mGluR5 KO synaptosomes. Boxplot 
showing the distribution of coefficients of variation for all quantified proteins in WT and mGluR5 KO 
synaptosomes (N=6)
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Figure S2 Electron microscopy analysis of mGluR5 KO synaptic mitochondria. (A) Linear distance from 
the presynaptic and postsynaptic mitochondria to the active zone and postsynaptic density, respectively.
No significant difference was found between WT and KO. (B) Active zone length for WT and KO 
synapses (N=6, n=209 for WT; N=6, n=247 for KO). All bar graphs, means ± SD
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Figure S3 Quality control for the quantitative proteomics analysis of CTEP-treated mice synaptosomes 
and comparison with mGluR5 KO dataset. (A) Boxplot showing the distribution of coefficients of variation 
for all quantified proteins in synaptosomes from the different CTEP-treatment groups and vehicle control
(N=6). (B) Venn diagram showing the number of significantly regulated proteins identified in both 
CTEP2h and mGluR5 KO proteomic datasets. (C) Expression fold-changes in CTEP2h and mGluR5 KO 
datasets for the significantly regulated proteins in mGluR5 KOs annotated as “mitochondrion” and 
“metabolic pathways” by enrichment analysis (Data S2B). Scatter plot, means ± SD
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Figure S4 Characterization of CTEP-induced mitochondrial protein expression regulation. (A) Boxplot
showing the distribution of mitochondrial protein expression fold-changes (CTEP2h group) in different 
cellular components as retrieved from Uniprot. Solid and dotted vertical lines indicate no change and 
±0.1 fold-change (log2), respectively. (B) Boxplot showing the distribution of mitochondrial protein 
expression fold-changes (CTEP2h group) in different protein complexes based on CORUM database. 
Solid and dotted vertical lines indicate no change and ±0.1 fold-change (log2), respectively
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Figure S5 Cell-type enrichment analysis of CTEP-induced mitochondrial protein expression regulation.
Cell-type enrichment analysis of the differentially abundant mitochondrial proteins upon CTEP-treatment 
(CTEP2h group). The three cell-types with lower p-value are depicted for 29 different scRNA-seq 
datasets from mouse and human nervous system tissue as implemented in FUMA (Data S3B). Colors 
indicate the general cell-type category
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Figure S6 Gene expression correlation analysis between mGluR5 and mitochondrial genes. (A)
Distribution of Spearman correlation coefficients from the gene expression correlation of all mitochondrial 
and non-mitochondrial genes with mGluR5. Positive, negative and cero correlation coefficient values 
indicate gene expression correlation, anti-correlation and no correlation, respectively. (B) Normalized 
gene expression across the different cell-types for the mitochondrial genes significantly correlated with 
mGluR5 (FDR corrected p < 0.05). Red and blue lines indicate genes positively and negatively correlated 
with mGluR5, respectively. Thick lines represent the median expression of the individual genes in each 
category. mGluR5 gene expression is depicted in black as reference. Positive and negative correlations 
correspond mainly to genes little and highly expressed in non-neuronal cell types, respectively. (C)
Boxplot showing the distribution of protein expression fold-changes upon CTEP-treatment (CTEP2h 
group) for the mitochondrial proteins positively and negatively correlated with mGluR5. Colors match the 
gene categories in panel B. (D) Boxplot and distribution of protein expression fold-changes induced by 
the treatment with CTEP (CTEP2h group) for granule cells and astrocytes mitochondrial marker proteins,
as determined by single-cell protein expression (162). Granule cell and astrocyte markers are indicated 
in red and blue, respectively
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Abstract
Synaptic transmission is the predominant form of communication in the brain. It requires 
functionally specialized molecular machineries constituted by thousands of interacting 
synaptic proteins. Here we made use of recent advances in cross-linking mass spectrometry 
(XL-MS) in combination with biochemical and computational approaches to reveal the 
architecture and assembly of synaptic protein complexes from mouse brain hippocampus 
and cerebellum. We obtained 11,999 unique lysine-lysine cross-links, comprising 
connections within and between 2,362 proteins. This extensive collection was the basis to 
identify novel protein partners, to model protein conformational dynamics and to delineate 
within and between protein interactions of main synaptic constituents, such as Camk2, the 
AMPA-type glutamate receptor and associated proteins. Using XL-MS we generated a 
protein interaction resource that we made easily accessible via a web-based platform 
(http://xlink.cncr.nl) to provide new entries into exploration of all protein interactions identified.
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Introduction
Synapses are fundamental signaling units of the brain orchestrating fast information transfer 
between neurons, as well as between neurons and peripheral tissues. Specific synaptic 
protein complexes are crucial to information processing and storage (205), whereas their 
disease-related disruption, known as synaptopathies, are prevalent causes of brain 
disorders, such as autism, epilepsy, intellectual disability and schizophrenia (8). Synapses 
are semi-autonomous organelles with the ability to execute general cellular and metabolic 
processes, e.g., de novo protein synthesis, protein turnover by targeted degradation, and 
energy production independently of the cell soma. Apart from these, synaptic transmission 
and plasticity requires specialized molecular machineries composed of specific proteins 
engaged in transient or stable protein-protein interactions acting at the pre- and/or 
postsynaptic compartments (19). Typically, in the presynapse, neurotransmitter-loaded 
synaptic vesicles are docked at the active zone by scaffold proteins for the subsequent 
membrane fusion driven by calcium-dependent conformational changes of calcium sensors 
and SNARE protein interactions. At the postsynapse, the postsynaptic density (PSD) hosts 
diverse functions in neurotransmission, such as anchoring ionotropic and metabotropic 
glutamate receptors, physically connecting and aligning pre- and postsynaptic elements by 
trans-synaptic cell adhesion molecules, recruiting intracellular signaling effectors, e.g., 
Ca2+/calmodulin-dependent protein kinase II (CaMKII/Camk2) or G-proteins, and linking 
these components to the actin cytoskeleton (2). Proteomic approaches have identified over 
2000 different proteins at the synapse (55, 206), comprising of approximately 10% of protein-
coding genes in mammalian genomes. Due to this complexity, the description of synaptic 
architecture and its extended protein interaction network is still a major challenge. 
The function and organization of synapses critically depend on protein interaction 
and structure, typically resolved by affinity purification-based proteomics and high-resolution 
X-ray crystallography or cryo-EM technologies respectively. Complementary to these 
approaches, chemical cross-linking combined with mass spectrometry (XL-MS) offers the 
advantage of capturing both native protein structures and interactions by cross-linking 
reagents in a physiologically relevant subcellular context (65). The spatial close proximity of 
cross-linked sites can be used to reveal protein binding interfaces, novel partnerships as well 
as protein conformations and dynamics. With recent technical advances, global XL-MS 
analysis of untargeted protein complexes and structures has become feasible (64).
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In this study, we applied XL-MS to probe the complex architecture of the synaptic 
compartment. We identified 11,999 unique lysine-lysine cross-links from 2,362 different 
proteins, representing one of the largest cross-linking datasets (available online at 
http://xlink.cncr.nl). Using various biochemical and computational approaches, we validated 
the fidelity of our procedure and investigated protein interactions and dynamics for key 
synaptic proteins, such as Camk2 and the AMPA receptor. This extensive resource provides 
a novel perspective on protein structures, assemblies and interactions of the synaptic 
proteome.
84
4      Chapter 4
 
Results
Cross-linking mass spectrometry (XL-MS) analysis of the synapse
We applied proteome-wide XL-MS using the MS-cleavable cross-linker DSSO (disuccinimidyl 
sulfoxide) to reveal the architecture and assembly of synaptic protein complexes (Fig. 1A). To 
extensively cover the synaptic proteome, two subcellular fractions, synaptosomes (widely 
synapse enriched) and microsomes (membrane enriched for proteins involved in assembly 
and trafficking), were analyzed from mouse hippocampus and cerebellum. The isolated 
subcellular fractions were immediately cross-linked with DSSO cross-linker to best preserve 
the protein structures and interactions. Cross-linked proteins were digested and analyzed by 
mass spectrometry, as previously described (65, 207). Data analysis was performed using 
XlinkX v2.0 (208), imposing a 2% false discovery rate. This dataset comprised 7,135 unique 
Lys-Lys cross-links (dataset 1 in Table S1A), including 1,552 interprotein cross-links (1,036 
different protein pairs) and 5,583 intraprotein cross-links (within 1,472 proteins). We created 
an interactive web-tool to facilitate the inspection of all the cross-links identified 
(http://xlink.cncr.nl), including the number of samples in which each cross-link was found and 
the associated FDR (also available in Table S1A), which allows the user to evaluate the 
reliability of specific cross-links. We also included filtering options that enable advanced 
visualization of experiment subsets, retrieving the origin of the cross-links, the FDR of the 
identification and overlay with previously reported protein interactions.
To assess whether XL-MS correctly captured the spatial localization of the synaptic 
proteins, we investigated the existence of aberrant cross-links between intra- and extra-
cellular regions of proteins (Fig. 1B). We retrieved all the topological information available in 
UniProt for the cross-linked proteins in the dataset. From the 1156 cross-links mapped to 
known cytoplasmic or extra-cellular regions, only 10 cross-links (0.87%) were found between 
cytoplasmic and extra-cellular regions. This observation suggests the structurally intactness 
of the synaptosomes in the preparations used to generate the cross-linking dataset.
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Fig. 1. Overview of XL-MS workflow and results. (A) Schematic workflow of XL-MS and its 
applications. (B) Pie chart showing the number of cross-links identified between cytoplasmic and extra-
cellular regions of proteins (dataset 1). (C) Sunburst plot showing the annotation in synaptic functions of 
the cross-linked proteins identified (biological processes SynGO terms (45)). Inner rings are parent terms 
of more specific child terms in outer rings, color-coded according to enrichment Q-value. Notably, a wide 
and significant coverage of synapse-specific proteins was found distributed across both pre- and post-
synapse functions. (D) Boxplot showing the distribution of protein abundances in different categories: 
Entire synapse, all proteins identified in standard proteomic analysis; All cross-linked proteins, proteins 
identified in our XL-MS dataset 1; Interprot. only, proteins involved in only interprotein cross-links; 
Intraprot. only, proteins involved in only intraprotein cross-links; Protein with both, proteins involved in 
both intra- and interprotein cross-links. The median abundance for cross-linked proteins is three times 
higher than the synaptic proteome and 10 times higher for proteins involving both intra- and interprotein 
links, showing the influence of protein abundance in the detection of cross-links. Number of proteins and 
the median abundance are indicated in each box. Protein abundance data was obtained from (41). (E)
Distribution of C−C distances of cross-links from 8 selected protein complexes structures (Fig. S2A-
C). 
To reveal the coverage of synapse-specific proteins in the cross-linking repertoire, 
we interrogated the recently established synaptic gene ontology database SynGO (45), which 
includes 1,112 synaptic proteins based on expert-curated literature evidence. From the 
cross-linked proteins identified, 512 mapped to SynGO annotated genes (Table S1B). 57 
Biological Processes terms were significantly enriched across all main synaptic functions 
(such as presynapse, postsynapse, signaling, organization, metabolism and transport, Fig. 
1C) and 32 Cellular Component terms (Fig. S1B), when compared to all brain expressed 
genes as background. This demonstrates the coverage of a wide spectrum of synaptic 
proteins. Moreover, a range of cross-linked proteins identified was found beyond the currently 
annotated SynGO proteins, including general cellular and metabolic proteins known to reside 
in the synapse. 
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The depth and sensitivity of the XL-MS approach was interrogated by comparing the 
abundances of proteins cross-linked over the entire synaptic proteome. Protein abundance 
data was obtained from our previous study using label-free LC-MS quantification on 
equivalent preparations (41). The median abundance of the proteins identified by XL-MS was 
three times higher than the median abundance of the synaptic proteome (Fig.1D). This 
difference was more pronounced (10 times higher) when comparing proteins involving both 
intra- and interprotein links. Only a weak correlation (Pearson R2=0.23) was found for the 
number of cross-linked lysines and the protein abundance corrected for the total number of 
lysine residues (Fig. S1B-C). No correlation was found between the number of cross-linked 
lysines and the total number of lysines of each protein (Fig. S1D), neither for protein 
abundance and the total number of lysines (only a minor effect depending on the sequence 
length, Fig. S1E-G). Altogether, these data indicated that high-abundance proteins were 
preferentially identified, while less abundant proteins were detected more sporadically.
The formation of cross-links is bound to the spatial close proximity between two 
lysine residues embedded in the three-dimensional structure of protein complexes. Thus, the 
confidence of XL-MS datasets can be interrogated by inspecting the spatial distances of the 
cross-linked pairs on previously reported high-resolution structures. We matched the cross-
link data with 8 well-established synaptic, mitochondrial and ribosomal protein complexes 
(Fig. S2A-C). More than 99% of the unique lysine-to-lysine cross-links within the structures 
(363 in total) fell below the distance limit imposed by the DSSO cross-linker (23.4 + 10 Å 
considering in-solution flexibility, Fig. 1E) (209), which supports the fidelity of the cross-linking 
assay. Furthermore, since protein structures are often elucidated in non-physiological 
experimental conditions, cross-linking represents a complementary approach to validate and 
further explore native protein structures in their fractionated subcellular context.
Capturing the structural dynamics and flexibility of Camk2 kinase domains
In combination with structure modeling and dynamic simulation approaches, XL-MS can 
facilitate the investigation of different conformational states and in-solution flexibility of 
unstructured regions in their native fractionated subcellular conditions. Here we focused on 
Ca2+/calmodulin-dependent protein kinase II (CaMKII/Camk2), an essential synaptic protein 
kinase that is crucially involved in the signaling cascade required for synaptic plasticity 
underlying learning and memory. Monomeric Camk2 is comprised of an N-terminal kinase 
domain, a regulatory region, a highly flexible linker region and a C-terminal association (hub) 
domain, which further assembles into a large 12-mer holoenzyme via the C-terminal 
association domains. It undergoes large activity-dependent conformational movements, i.e. 
active or inactive in extended or compact conformation respectively. 
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The observed Camk2a and Camk2b cross-links were mapped onto three different Camk2 
structures (Fig. 2A), including a full-length compact state (PDB 3SOA), a full-length extended 
state (PDB 5U6Y) and a kinase domain-only structure representing the auto-inhibitory 
dimerization of the kinase domain (PDB 2BDW). Furthermore, the kinase domain-only 
structure was combined with the extended structure (PDB 5U6Y) to generate a full-length 
model of the auto-inhibited state (Fig. S2D), allowing the exploration of cross-links between 
the kinase domain dimer and the other regions of the protein. In contrast with the previous 
Camk2 protein structures, our data show that 35% of the cross-links mapped onto the 
extended state of Camk2 exceeded the cross-linker maximum distance restraint (Fig. 2B), 
supporting the existence of large conformational changes. We then focused on K258-
centered cross-links because it is a major cross-linking site at the kinase domain. We 
observed 11 cross-links of K258 that did not comply with any of the three structures 
examined (Fig. 2A), including cross-links between the kinase domain and the rigid central 
hub, as well as in between monomeric kinase domains. This is in agreement with the high 
flexibility of the kinase domain of Camk2 via the linker region. Furthermore, based on a 
number of  cross-links that cannot be explained purely by domain flexibility, we proposed two 
neighboring kinase domains may be arranged as one in compact and the other in extended 
state within the same structure (partial compact state, Fig. 2C). We summarized the 
collection of possible contacts between kinase domains by inferring the movement between 
states using analysis of dynamic regions of Camk2 and an interpolated trajectory between 
states (transient intermediate state, Fig. 2C, Movie S1). Collectively, our cross-linking 
approach captured highly dynamic and extremely large movements between the kinase 
domains and the rigid central hub of Camk2, and suggested multiple contacting possibilities 
between kinase domains upon activation and binding to protein partners.
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Fig. 2. Conformational modeling of Camk2 kinase domains. (A) Cross-link mapping on the extended 
(PDB 5U6Y), the compact (PDB 3SOA) and the auto-inhibited conformation of Camk2 (shown as auto-
inhibited dimer of kinase domains, PDB 2BDW and Fig. S2D). Two highlighted monomers are shown in 
green and orange respectively. For clarity, cross-links are mapped onto the monomer in green only. (B)
Distribution of C−C distances of cross-links from Camk2 mapped onto the extended state (PDB
5U6Y). The hatched pattern indicates cross-links exceeding DSSO maximal distance restraint. (C)
Illustration of domain flexibility and alternative conformational states of Camk2. In all conformational 
states, 6 monomers of Camk2 (half of the complex) are presented. Proposed models of a partial compact 
state (based on PDB 5U6Y and 3SOA) and a transient intermediate state between the extended and 
compact state (snapshot of morph shown in Movie S1) are depicted. Cross-links between K258 (a major 
cross-linking site in the kinase domain, shown as blue sphere) and other lysines (red spheres) are 
highlighted. Cross-links are represented as the Euclidean distance between C atoms of the cross-linked 
residues, indicated in red (if below DSSO maximal distance restraint) or in magenta (if exceeding DSSO 
maximal distance restraint). 
XL-based network for novel protein-protein interaction discovery
The identification of 1,036 protein pairs cross-linked enabled us to construct a XL-based 
protein-protein interaction (PPI) map of the synapse. The PPI network of individual 
subcellular fractions and brain areas are shown in Fig. S3-6, and the combined network in 
Fig. 3A (from dataset 1). The core component of the combined network comprised 577 inter-
connected proteins, with another 218 proteins forming separate modules with at least 3 
proteins connected (Fig. 3A and S7). The number of samples in which each PPI was 
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identified is indicated in Fig. S7. The degree distribution of the combined network follows a 
power law log-log fit (Fig. S8A-B), representing a typical scale-free network topology that 
complies with previously reported characteristics of protein interactomes (210). The core 
component showed a strong modular organization (modularity score 0.89), with a total of 25 
protein clusters defined by unsupervised edge-betweenness clustering (Fig. 3A, Table S2).
The established clusters were significantly enriched for specific GO terms (Fig. 3A), including 
major synaptic sub-compartments and protein assemblies such as ‘intrinsic component of 
postsynaptic density membrane’, ‘L-type voltage-gated calcium channel complex’, ‘cell 
adhesion’ and ‘integral component of synaptic vesicle membrane’ (Table S2). Next, we tested 
the proximity of the proteins within each cellular component term in the entire network by 
measuring the fraction of cross-linked protein pairs of which the proteins were annotated with 
the same GO term, in comparison to a randomized rewired control (Fig. 3B). We found that 
the proteins in the network were significantly more connected to other proteins from the same 
cellular component (two−sample Kolmogorov−Smirnov test, p−value 2.2x10-16). Similarly, the 
path distance between the annotated proteins for each GO term was shorter compared to the 
non-annotated proteins for the same term (Fig. S8C). For each individual network, proteins 
were also found highly connected to proteins from the same cluster (two−sample 
Kolmogorov−Smirnov test, p−value<10-15, Fig. S3-6B). Thus, these network topology 
analyses argue for the capability of XL-MS in capturing authentic protein connectivity.
To compare the XL-based PPIs to previously reported protein-protein interactions, 
we overlaid the cross-linked protein pairs to the experimentally defined interactions retrieved 
from the public PPI databases STRING (211), InWEB (212) and BioGRID (213), which 
together represent a curated collection from 11 original sources (e.g., IntAct and BIND). As a 
result, 51% of the total protein pairs identified (531 protein pairs) were present in the public 
databases, suggesting that a large part of the cross-links potentially represent novel protein 
interactions (Fig. S8D). To retrieve the most reliable PPIs from the databases, we classified 
each PPI in different confidence levels (low, medium and high) depending on the data 
curation method applied in the database. We found that 39% of the cross-linked protein pairs 
represented PPIs with high confidence from at least one database. Interestingly, we 
observed that these 39% of cross-linked protein pairs contained a higher number of cross-
links compared to the cross-linked protein pairs not present in the databases (Fig. 3C). 
Furthermore, high confidence protein interactions present in both XL-MS and PPI databases 
were represented by proteins with more than six times higher median abundance than those 
absent in the databases (Fig. 3D). Similar results were obtained for the individual networks 
(Fig. S3-6). These observations imply that proteins with higher abundances are more likely to 
be detected by both XL-MS and other experimental approaches included in public PPI 
databases.
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Fig. 3. Characterization of XL-based protein interaction network. (A) Core component and separate 
modules of the combined network (dataset 1). Nodes represent proteins and edges show the interactions 
identified by XL-MS. Nodes are color-coded based on functional clusters generated by unsupervised 
edge-betweenness clustering and annotated by GO enrichment analysis. Disconnected modules were 
grouped using DAVID Gene Functional Classification and each group was subsequently annotated. 
Edges in red indicate protein-protein interactions (PPIs) reported in literature (high confidence in at least 
one database of STRING, InWEB and BioGRID). Sizes of the nodes are proportional to the protein 
abundances (Log2 scale). Widths of the edges are proportional to the number of unique Lys-Lys cross-
links. Insert represents the enlarged cluster annotated as ‘intrinsic component of postsynaptic density 
membrane’, with the edges labeled according to the number of samples in which the PPI was identified. 
Network representations of individual experiments are provided in Fig. S3-6. (B) Distribution of the 
number of cross-linked proteins pairs annotated within the same GO group in the XL-based network 
(labelled in orange) and a randomly rewired network (100 iterations, labelled in light blue). (C)
Distribution of the number of cross-links found between protein pairs present in at least one database 
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Validating protein-protein interaction sites of SNARE proteins
XL-MS provides information at the sequence level that can be utilized to reveal protein-
protein binding interfaces. To explore this, we first investigated the distribution of cross-linked 
lysines regarding human protein interaction interfaces as predicted by InteractomeINSIDER 
(214). We mapped the cross-linked lysines derived from our mouse data to the human 
proteome, generating 1,512 lysine positions with a confident mouse-human mapping (Table 
S3). A significant enrichment of interprotein cross-linked lysines located within the protein 
interaction interfaces was found (47%, Fisher’s exact test <0.00001), while intraprotein cross-
linked lysines were not enriched (26%, Fisher’s exact test 0.79, Fig. S9A). Thus, interprotein 
cross-linked sites seem to frequently occur within protein-protein interactions regions.
Second, we performed peptide array interaction assays to independently assess 
whether cross-linked lysine pairs are involved in experimentally verifiable interaction sites 
(Fig. 4A). Five presynaptic SNARE and associated proteins, namely Stxbp1, Snap25, Stx1a, 
Stxbp5 and Stxbp5l, were expressed in HEK293 cells, extracted and incubated with a peptide 
array presenting peptides with tile-wise overlapping amino acid sequence of the entire Stx1b 
(Table S4). The interaction between protein and peptide was detected by immunoblotting in 
two independent replicates and two technical replicates (Fig. 4B, Fig. S9B). Fluorescent 
signals were quantified, normalized and the non-specific binding was subtracted (Fig. S9B). 
The binding sites of Stxbp5 and Stxbp5l with Stx1b could not be validated due to the low 
signals observed. Only proteins binding to at least two peptides with overlapping sequence 
were considered true interactions and shown in interaction maps (Fig. 4C). Notably, the 
majority of the binding regions detected by peptide array was found close to the cross-linking 
sites (Fig. 4C). Using XL-MS and peptide array, we confirmed previously reported protein 
interactions and their binding sites, including Stx1 with Stxbp1 and Snap25 (Fig. 4C). 
The cross-inked lysine residues connecting Stxbp1, Stx1a, Stx1b and Snap25 were 
mapped onto the three-dimensional structure of the Stxbp1-Stx1 interaction in closed 
conformation (PDB 3C98). The missing loops from the crystal structures of Stxbp1 (residues 
506-531) and Stx1 (residues 10-26) were modeled with I-TASSER (Fig. 4D). The majority of 
cross-links detected between Stxbp1 and Stx1 were located at the proximity between the two 
proteins and were within the maximal Cα-Cα distance restraint (15 cross-links were below 27 
__________________________________________________________________________
(DB) with high confidence (labelled in red) or do not present in any of the three databases (i.e. STRING, 
InWEB and BioGRID, labelled in black). (D) Boxplot showing the distribution of protein abundances in 
different categories: xlink, cross-linked proteins identified in this study; public DB, protein interactions 
present in at least one public database with high confidence (i.e. STRING, InWEB and BioGRID). The 
number of proteins and median abundance are indicated in each box. Protein abundance data was 
obtained from (41).
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Å). Two long-distance cross-links were found between Stxbp1 and Stx1: one within the
Stxbp1 loop region modeled by I-TASSER and the other within the Habc domain of Stx1. The 
first cross-link is likely due to the extremely high flexibility of the Stxbp1 loop while the second 
may correspond to an alternative conformation of Stx1 (e.g. open conformation as previously 
proposed (215)) as opposed to the closed conformation used herein. 
Fig. 4. Peptide array analysis of selected cross-linked proteins. (A) Cross-link maps of selected 
SNARE proteins (dataset 1). Protein domains are depicted based on UniProt database and previous 
publications (*, from (216)). Identified cross-links located in unique and shared peptides of Stx1a and 
Stx1b are represented as solid and dotted lines, respectively. (B) Results of Stxbp1 and control peptide 
array experiments. Examples of specific, non-specific and no binding signals are depicted. Arrowheads 
indicate antibody positive controls. Quantification and peptides sequences (two independent and two 
technical replicates) are described in Fig. S9B and Table S4. (C) Comparison of binding regions 
determined by peptide array (boxes colored in red) and XL-MS (edges). The number of samples in which 
the cross-links were identified is indicated on the edges (dataset 1). For peptide array assays, full-length 
proteins are shown as circles and the protein used to generate peptide sequences in the arrays (Stx1b) 
is represented as sequence bars. Yellow edges match arrows with the same color in panel D. (D) Cross-
link mapping of Stxbp1 interactions. Stxbp1 (green) and Stx1 (blue) cross-linked sites were mapped onto 
the Stxbp1-Stx1 complex structure (PDB 3C98, Stx1 in closed conformation). Cross-links are indicated in 
red (if below DSSO maximal distance restraint) or in magenta (if exceeding DSSO maximal distance 
restraint). Yellow sticks show the two lysine residues of Stx1 (Lys45 and Lys55) found outside of the 
binding region with Stxbp1 as defined by peptide array. Black edge indicates cross-linked site of Snap25.
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In addition, two cross-linked sites of Stx1b (Lys45 and Lys55) were found approximately 20 
amino acids away from the binding site between Stxbp1 and Stx1b as defined by the peptide 
array (Fig. 4D, yellow edges). In the three-dimensional structure these lysines are facing to 
the opposite side of the binding interface of the Stx1-Stxbp1 interaction (Fig. 4D), suggesting 
that they may not directly contribute to this interaction but still can be cross-linked due to their 
close vicinity to the binding site. Taken together, using XL-MS and independent approaches 
we were able to validate the binding sites of several protein-protein interactions.
Modeling the AMPAR-auxiliary protein complex
From the cross-linked proteins identified we investigated the AMPA receptor (AMPAR) in 
more detail. The AMPAR is a key ligand-gated ion channel that mediates the fast 
neurotransmission and plasticity in the postsynapse. Its activity, function and properties are 
tightly regulated by the interaction with several auxiliary proteins. Here, we combined 
structural modeling and interaction site investigation on the GO cluster ‘intrinsic component of 
the postsynaptic density’ to provide novel insights in protein interaction and assembly of the 
AMPAR (Fig. 5A). This cluster consists of 10 proteins, including the AMPAR complex (Gria1-
4) as well as the previously established AMPAR interactors Frrs1l, Cacng2, Cacng8, and 
Olfm1 (20). The use of synaptosomes and microsomes fractions from hippocampus and 
cerebellum showed combinations of AMPAR subunits and auxiliary proteins known to be 
enriched in these specific brain regions and sub-compartments, such as Cacng8 in 
hippocampus, Cacng2 (217) and Gria4 (218) in cerebellum, and Frrs1l (21) in endoplasmic 
reticulum. Based on the identified cross-links, we performed interaction space analysis using 
the DisVis Webserver and generated docking models using HADDOCK2.2 for the 
interactions between the AMPAR (PDB 5IDE, showing the physiologically relevant Gria2/3 
composition) and its known binding partners Olfm1 (PDB 5AMO), Frrs1l, Cacng2 and 
Cacng8 (Fig. 5A). The dopamine beta-monooxygenase N-terminal (DOMON) domain 
structure of Frss1l was modeled based on sequence homology using the available structure 
with highest sequence coverage (PDB 4ZEL) and the cross-links involved in both Cacng2 
and Cacng8 were mapped onto the structure of Cacng2 (PDB 5VOT). Interestingly, we 
observed that the interaction spaces of Frss1l and Cacng2 which comprise the center of 
mass of all positions satisfying the cross-link distance restraint, partially overlap at the region 
close to the ligand-binding domain (LBD) of the AMPAR. In contrast, the interaction space of 
Olfm1 occupies the area close to the N-terminal domain (NTD) of the AMPAR. Similarly, we 
also found that the Frssl1 DOMON domain structure and the Cacng2 structure partially 
overlap in the docking models. Together, these results show it is unlikely that Frss1l and 
Cacng2/8 interact simultaneously with the same AMPAR subunit, especially considering that 
the transmembrane domain of Frrs1l is not included in our interaction analysis (structure not
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determined). While this prediction is not experimentally confirmed, it is consistent with 
previous studies showing the spatial segregation of the Frrs1l- and Cacng2/8-containing 
AMPAR in ER and synaptic membrane, respectively (21). We also provided an estimated 
binding location of AMPAR and Frrs1l, for which the binding site within the AMPAR interactor 
complex is currently unknown.
Replication of cross-linking data and resource
A typical MS analysis with data dependent acquisition usually achieves 70-80% 
reproducibility at protein level in technical replicates and 60-70% at peptide level (219),
mainly due to the stochastic selection for sequencing of low abundant proteins. To further 
discuss this issue and expand our cross-link repository, we performed cross-linking 
experiments of three additional biologically independent replicates of hippocampal 
synaptosomes. We obtained 7,183 unique Lys-Lys cross-links comprising 1,746 different 
proteins (dataset 2 in Table S1A), of which 60% intraprotein cross-links and 63% cross-linked 
protein pairs (intra- and interprotein) were identified in at least two independent replicates 
(Fig. S10A). We detected a low percentage of potentially false cross-links between 
cytoplasmic and extra-cellular regions (0.46%), similar to the first dataset (0.87%) (Fig. 
S10B). 
Fig. 5. Analysis of previously established and novel 
interactors of the AMPAR. Interaction space models 
(semi-transparent volume, left) and docking models (right) 
of the interactions between AMPAR (PDB 5IDE) and its 
known interactors Olfm1 (PDB 5AMO), Frrs1l DOMON 
domain (modeled based on PDB 4ZEL) and Cacng2/8 
(PDB 5VOT) were generated based on the XL-MS data. 
Interaction space models were calculated using the 
DisVis Webserver and docking models were generated 
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Fig. 6. Evaluation of XL-MS approach on 3 biologically independent replicates for hippocampal 
synaptosomes. (A) Venn diagram showing the number of identified cross-linked protein pairs (from 
interprotein cross-links) in different replicates (dataset 2). (B) Boxplot showing the distribution of protein 
abundances for cross-linked protein pairs identified in one, two and all three replicates. The number of 
proteins and median abundance are indicated in each box. Protein abundance data was obtained from 
(41). (C) Percentage of cross-linked protein pairs present in any PPI databases (i.e. STRING, InWEB 
and BioGRID) identified in one, two and all three replicates. The total number of cross-linked protein 
pairs identified is indicated above each bar. (D) Distribution of the fraction of direct neighbors (cross-
linked proteins pairs) from the triplicate dataset that are in the same cluster in the initial network (Fig. 3A, 
labelled in red) and a randomly rewired network (100 iterations, labelled in grey). (E) Pie chart showing 
the percentage of protein pairs from the initial hippocampal synaptosome dataset identified in the 
triplicate network. Only proteins containing interprotein cross-links in both datasets were considered.
To gain insight in the reproducibility of the XL-MS method within the same dataset, 
we inspected the overlap in interprotein cross-linked protein pairs of the individual replicates. 
Of the 934 protein pairs present in the dataset, 516 were found in only one, 162 in two, and 
252 in three replicates (Fig. 6A). This is expected given the stochastic nature of the cross-
linking events and low abundance of cross-linked peptide pairs. In accordance with our 
previous observations, the number of times a protein interaction was identified correlated to 
their abundances, with proteins present in all experimental replicates having more than five 
times higher median abundance than those found in only one sample (Fig. 6B).
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Furthermore, we examined the existence of the cross-links in public PPI databases. Of the 
516 protein pairs that were identified in only one replicate, 32% corresponded to previously 
reported PPIs, while 78% of the 252 proteins pairs identified in all three replicates were 
reported PPIs (Fig. 6C). To assess reproducibility of the network topology between datasets, 
we compared the triplicate XL-MS dataset with the initial network (Fig. 3A). We observed that 
a large fraction of proteins pairs in the replicated dataset belongs to the same clusters in the 
initial protein interaction network, showing a high similarity between the two datasets 
(two−sample Kolmogorov−Smirnov test, p−value 2.2x10-16, Fig. 6D). Next, we compared the 
protein pairs from the initial hippocampal synaptosome preparation with the triplicate dataset 
considering only proteins present in both networks. We found 77% of the cross-linked protein 
pairs associated in the triplicate dataset, 67% directly and 10% indirectly (i.e. connected by 
one neighbor in common), showing a high reproducibility for proteins detected in both 
datasets (Fig. 6E). Taken together, these observations illustrate the reproducibility of XL-MS 
within and between datasets and indicate that cross-link identifications largely depend on the 
protein abundance, with proteins found in all experimental replicates being of highest 
abundance and mostly participating in previously reported PPIs. 
Taken together, from the seven XL-MS experiments performed in this study, we 
obtained 11,999 unique cross-links comprising connections within and between 2,362 
proteins, representing one of the largest cross-linking datasets. All the cross-links identified 
are available for inspection in our interactive web tool (http://xlink.cncr.nl). The interaction 
network from all seven XL-MS experiments is also presented in Fig. S11, including detailed 
information of each cross-link (e.g., the number of samples in which each PPI was found, 
identification FDR and previously reported protein interactions) This data resource and online 
tools can assist the exploration and selection of cross-links of interest for further biochemical 
and/or biological follow-up experiments.
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Discussion
In this study, we generated an extensive XL-MS dataset of synaptosomes and microsomes 
from mouse brains, yielding one of the largest cross-link collections to date (11,999 unique 
Lys-Lys connections). The complete dataset is available as a user-friendly resource for 
interrogation (http://xlink.cncr.nl). We employed this new type of data to investigate three 
different protein features, such as protein structure, protein interaction and interaction sites, 
opening new avenues in revealing the architecture and assembly of protein complexes. For 
each of these features we validated the reliability of the data by several approaches in key 
synaptic proteins, such as the structural dynamics of Camk2 and protein interaction sites of 
SNARE proteins. Finally, we combined structural modeling and protein interaction site 
investigation based on XL-MS to extend our knowledge on the architecture of the AMPAR 
complex.
High-resolution protein structures provide a means to validate cross-link assignment 
and enable probing alternative conformational states of proteins/complexes. In line with our 
previous studies (207, 208), we observed that the agreement between observed Lys-Lys 
distances and those predicted by high-resolution structures follows a highly distinctive 
bimodal distribution: some proteins/complexes show at least 98% of matched cross-links 
whereas others give a much lower value. In the presented data, >99% of the Lys-Lys 
distances in 8 out of 9 protein complexes complied with the respective high-resolution 
structures, with the exception of Camk2, in which only c.a. 65% of the cross-links were within 
the 23.4 + 10 Å distance restraint (in extended state). Whereas the organization of the rigid 
central hub of the holoenzyme has been elucidated, the relative positioning of the kinase 
domains remains challenging due to their high flexibility, especially in the extended and 
activation-competent conformation (220, 221). Examination of the Camk2 structures of the 
extended, compact and auto-inhibited conformational states, confirmed the existence of large 
movements (221) between the kinase and the hub domains via the extremely flexible linker 
region. Furthermore, alternative contacts between adjacent kinase domains were proposed 
based on 11 long-distance cross-links centered at K258, a cross-linking hotspot at the kinase 
domain (Fig. 2C). In addition to other already reported inter-kinase domain interactions (222),
these potential contacts show the dynamics of the kinase-domains and extend our 
knowledge about their organization in-solution. Taken together, the exploration of three-
dimensional protein structures allowed us to validate the reliability of our cross-linking 
approach and to probe the dynamic structure and the contacting possibilities for the kinase 
domains of Camk2.
98
4      Chapter 4
 
In terms of protein-protein interactions, we generated a XL-based protein interaction 
network that revealed a highly modular organization and a scale-free topology, which has 
been shown to characterize many biological phenomena (210). Comparing our cross-linking 
data with the accumulated experimental evidences in STRING, InWEB and BioGRID 
databases showed that 39% of detected cross-links were previously reported high confidence 
interactions, suggesting the presence of a large number novel candidate protein interactions 
in our dataset. Most proteins in each module participated in a shared cellular component and 
related protein complexes, such as the postsynaptic density, synaptic vesicles, G-protein 
signaling, voltage-gated calcium channels, or the mitochondrial respiratory chain. The 
reverse was also found, i.e., proteins from a common cellular compartment or 
macromolecular machinery were found significantly more inter-connected in our network. 
Similar results were observed for each brain area and subcellular fraction individually. The 
presence of diverse functional groups is in line with current models of the synapse arguing for 
high molecular and functional complexity (55), including protein synthesis, proteasomal 
degradation, mitochondrial function and metabolic cascades. With further exploration, our 
cross-linking data may also provide novel insights into protein complexes involved in these 
biological processes.
Cross-linking technology has been previously employed to assist the 
characterization of protein interaction surfaces (64, 223), as was also suggested by the 
significant enrichment of interprotein cross-links within predicted interaction interfaces. To 
further validate interaction interfaces provided by our XL-MS, we used peptide array assays 
to resolve the binding sites for a selection of proteins of interest centered at the SNARE 
complex, as has been extensively used previously (224). The SNARE complex plays an 
essential role in presynaptic vesicle fusion leading to neurotransmitter release (reviewed in 
(225)). We detected cross-links predominantly located in the Habc domain of Stx1a/b 
connected to other members of this molecular machinery, such as Stx1a, Stx1b, Stxbp1 and 
Snap25, well in agreement with the known protein complex topology (216). Whereas the 
majority of the XL-MS data is in good agreement with the binding sites determined by peptide 
array, we also found several cross-linking sites located at the proximity of the interaction 
interfaces but do not directly contribute to the binding, such as the two lysines residues of 
Stx1 (Lys45 and Lys55) detected between the Stxbp1-Stx1 interaction (226). These results 
confirmed that XL-MS provides a valuable exploratory platform for binding site prediction, 
however, this type of data ideally needs to be validated by orthogonal approaches (223).
Lastly, we used our XL-MS data to reveal novel insights in protein interaction and 
assembly of the AMPAR complex. By modeling the interaction of Olfm1, Cacng2, Cacng8 
and Frss1l with AMPAR we found that the interaction space occupied by Olfm1 is mostly 
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located at the NTD of AMPAR, whereas the interaction space of Cacng2 and the DOMON 
domain of Frss1l partly overlap at the AMPAR LBD. These analyses are in agreement with 
previous data obtained for the interaction of Olfm1 in the extracellular space (26) and the 
described binding sites of Cacng2/8 (227). In particular, the shared interaction space 
between Cacng2/8 and Frrs1l on the AMPAR suggests that their interactions with the 
AMPAR are exclusive and may occur as part of different protein complexes, in agreement 
with the mutually exclusive populations of AMPAR assemblies suggested by Brechet et al.
(21). To our knowledge, these results present the first model on Frrs1l-AMPAR interaction, of 
which the loss has been shown to be critical for the development of epileptic-dyskinetic 
encephalopathy (21, 228).
Several aspects of this relatively new XL-MS methodology were evaluated in this 
study. Regarding reliability, the statistical assessment of our data analysis software (207)
estimated a 2% false-discovery rate (FDR). This value was supported by the topological 
validation, based on the cross-links found between cytoplasmic and extra-cellular regions, as 
well as the structural validation by measuring the distances of linked lysine pairs based on 
existing high-resolution structures. Regarding detection bias and coverage, we found that the 
main factor driving the detection of cross-links seems to be protein abundance. High 
abundance proteins contained a higher number of cross-links and were present in a larger 
number of samples and replicates. This is likely due to the bias in MS2 selection during 
intensity-triggered data-dependent acquisitions (DDA), i.e., low abundance cross-links are 
less likely to be selected for sequencing in the mass spectrometer. No major bias was 
observed for the number of lysines of the protein or the subcellular distribution of the cross-
linker, as a wide spectrum of synaptic proteins were cross-linked across the pre- and post-
synaptic compartments, both in the cytoplasmic and extra-cellular regions. Regarding 
reproducibility, 60% of the intraprotein cross-links and 63% cross-linked protein pairs (intra-
and interprotein) were identified in at least two independent replicates. These values are 
slightly lower than the typical reproducibility of 70-80% at protein level and similar to the 60-
70% reproducibility at peptide level in LC-MS/MS experiments (219), consistently with the low 
abundance of cross-linked peptides. The similarity in protein-protein connectivity between 
datasets also argues in favor for the validity of the results obtained by XL-MS. In addition, a 
high reproducibility was observed for the proteins identified in both datasets, which indicates 
that cross-links not replicated are predominantly due to missing detections rather than to a 
different connectivity. Altogether, each cross-linking experiment provided data that 
corresponded to a partially stochastic sub-sample of the original protein interactions.
XL-MS provides valuable and complementary information in comparison to other 
techniques in protein interaction studies, such as proximity labeling and antibody-based 
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proteomic approaches. The recently developed proximity labeling approaches rely on the 
identification of labeled proteins located in the vicinity of the protein of interest, which is 
engineered to contain an enzyme responsible for the labeling reaction (229). In these 
approaches, the labeling radius is based on the diffusion of the reactive molecule, which is 
difficult to control. Multiple filtering steps are required to improve the spatial resolution, which 
generally lead to the removal of more than 90% of the identified proteins. In contrast, XL-MS 
is a high throughput methodology that defines the spatial resolution based on the length of 
the spacer arm of the cross-linker, thus providing a higher fidelity even in large-scale 
analysis. Antibody-based proteomics is a low throughput approach usually focused on a few 
individual proteins and often presents a high background where typically 90% of proteins 
identified are unspecific interactors. Moreover, the success of the experiments critically 
depends on the availability of high affinity and specificity antibodies, the strength of the 
protein interactions and the efficiency of solubilization of the proteins. These limitations can 
be bypassed with XL-MS, which is capable of capturing weak and/or transient protein 
contacts from intact cells or organelles, as exemplified by the contacts between Camk2 
kinase domains. Importantly, proximity labeling and antibody-based proteomic approaches 
only yield a list of protein identifications, while XL-MS provides maximum distance limits 
between residues. These residue-to-residue connections enable to distinguish direct and 
indirect protein interactions, and provide a more detailed picture of the structural organization 
of protein complexes, as exemplified by the interaction space models of the AMPAR 
interactions. Conversely, XL-MS has a lower sensitivity compared to the other approaches 
since cross-linked peptides are much less abundant than linear peptides, which may underlie 
the previous identification of a higher number of AMPAR interactors than the present study 
(20, 230, 231). Also, XL-MS relies on the presence of amino acids susceptible to cross-link, 
which may allow interactions to be undetected. Future advances in mass spectrometer, in 
conjunction with the affinity isolation of the cross-linked peptides, hold the promise for 
increasing the sensitivity of the XL-MS approach. 
Taken together, we applied XL-MS directly at subcellular fractions from mouse brain 
to open up new avenues in probing protein structures, assemblies and interactions close to 
their native subcellular context. We extended the current knowledge on essential elements of 
the synapse, including Camk2 and the AMPAR, by a combination of structural modeling and 
protein interaction investigation. The reliability of the data was validated by several 
approaches as we deemed necessary for this recent methodology. Given the molecular 
complexity of the synapse and the large amount and depth of the cross-linking data 
generated, additional hypotheses should emerge for other proteins and functional groups. To 
enable this exploration, we provided the complete dataset in table format (Table S1) and as 
user-friendly web-based platform (http://xlink.cncr.nl).
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The aim of our study was to reveal the architecture and assembly of synaptic protein 
complexes. We used XL-MS as basis to investigate protein structure, protein-protein 
interaction and binding surfaces in their physiological subcellular context. We selected two 
subcellular fractions (synaptosomes and microsomes) from two different mouse brain regions 
(hippocampus and cerebellum) to extensively cover the synaptic proteome. Due to the 
discovery purpose of this experiments, each of the four preparations for mass spectrometry 
analysis were performed as a single dataset (dataset 1). In addition, we performed cross-
linking experiments of three biologically independent replicates of hippocampal 
synaptosomes to gain insight in the reproducibility of XL-MS and provide further data to be 
used as a resource (dataset 2). The fidelity of the results was extensively investigated by 
comparing the XL-MS data with previously reported high-resolution structures, protein-protein 
interaction and binding sites. For peptide array interaction assays, two independent and two 
technical replicates were performed.
Sample preparation
10 mouse hippocampi and cerebellum were dissected from 8-10 weeks old C57BL6 mice 
and stored at -80ºC. The subcellular fractions were prepared as described previously (41). In 
brief, the brain regions were pooled and homogenized in a dounce homogenizer on ice (12 
strokes, 900 rpm) in homogenization buffer (0.32 M sucrose, 5 mM HEPES pH 7.4, protease 
inhibitor cocktail (Roche)). The homogenate was centrifuged at 1,000g for 10min at 4ºC and 
the supernatant (S1) was divided for the different preparations. For the synaptosomal 
preparation, the supernatant (S1) was centrifuged at 100,000g for 2h at 4ºC in a 0.85/1.2M 
sucrose gradient. The synaptosomes were collected from the interface, diluted and 
centrifuged at 18,000g for 20 min at 4ºC. The pellet containing enriched synaptosomes was 
resuspended in homogenization buffer and kept for cross-linking. For the microsomal 
fraction, the supernatant (S1) was centrifuged at 20,000g for 20min at 4ºC and the 
supernatant (S2) was ultra-centrifuged at 100,000g for 2h at 4ºC. The pellet containing 
enriched microsomes was resuspended in homogenization buffer and kept for the cross-
linking procedure. All experiments were approved by the Vrije Universiteit Amsterdam Animal 
Users Care Committee, and were performed in accordance with the relevant guidelines and 
regulations.
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Cross-linking and strong cation exchange (SCX) fractionation
Cross-linking was performed by adding 1 mM DSSO (Thermo Fisher Scientific, resuspended 
freshly in anhydrous DMSO to 50 mM), and incubated at room temperature for 1 h. The 
reaction was quenched adding 50 mM Tris pH 8.0 at room temperature for 30 min. The 
cross-linked samples were denatured with lysis buffer (8 M urea in 50 mM ammonium 
bicarbonate), reduced with 5 mM DTT at 56°C for 30 min, and alkylated with 15 mM 
iodoacteamide for 30 min in the dark at room temperature. Cross-linked proteins are digested 
with Lys-C for 4 hours at 37°C and subsequently digested by trypsin overnight. The resulting 
peptide mixture was desalted using Sep-Pak C18 cartridges (Waters), dried under vacuum, 
and fractionated by strong cation exchange (SCX) chromatography as previously described 
(65) to enrich higher charged cross-linked peptides.
Liquid chromatography and mass spectrometry (LC-MS) analysis
For each preparation, 20-40 SCX fractions, containing predominantly higher charged 
peptides (z ≥ 3) were analyzed by LC-MS using an ultra HPLC Agilent 1200 system (Agilent 
Technologies), equipped with an in-house packed C18 column for reversed phase separation 
(column material: Poroshell 120 EC-C18, 2.7 µm (Agilent Technologies)) and coupled online 
to an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific). Mass analysis was 
performed using a previously described CID-MS2-MS3-ETD-MS2 acquisition strategy (208).
Both MS1 and MS2 spectra were acquired in the Orbitrap mass analyzer and MS3 spectra 
were acquired in the ion trap mass analyzer. Notably, MS3 acquisitions were only triggered 
when peak doublets with a specific mass difference (Δ=31.9721 Da) were detected in the 
CID MS2 spectra. The following MS parameters were used: MS1 resolution 60,000; MS2 
resolution, 30,000; MS2 isolation window, 1.6 m/z; MS3 isolation window: 3 m/z; MS2 CID 
normalized collision energy 25%; MS3 CID normalized collision energy 35%; calibrated 
charge dependent ETD parameters were enabled.
XL-MS data analysis
Peak lists (.mgf files) were generated in Proteome Discoverer (version 2.1) to convert each 
RAW file into three MGF files containing CID-MS2, ETD-MS2 and CID-MS3 data. During 
MGF conversion, the CID- and ETD-MS2 spectra were deconvoluted to charge state 1 using 
the MS2 Spectrum Processor add-on module in Proteome discoverer v2.1. The MGF files 
were used as input to identify cross-linked peptides with standalone XlinkX v2.0 (208). The
following settings of XlinkX were used: MS ion mass tolerance: 10 ppm; MS2 ion mass 
tolerance: 20 ppm; MS3 ion mass tolerance, 0.6 Da; fixed modification: Cys 
carbamidomethylation; variable modification: Met oxidation; enzymatic digestion: trypsin; 
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allowed number of missed cleavages: 3. All MS2 and MS3 spectra were searched against 
concatenated target-decoy databases generated based on the synapse proteome 
determined by bottom-up proteomics, containing 5,133 target sequence entries. Cross-links 
were reported at 2% false-discovery rate (FDR) based on a target-decoy calculation strategy 
(208). Cross-linked proteins identified in dataset 1 were annotated and evaluated using 
SynGO, with “brain expressed” gene set as background and 1% FDR (Table S1B). Raw data 
are deposited in the PRIDE repository with the identifier PXD010317 and PXD015160. All 
identified cross-links can be accessed in Table S1 and via our web-based tool 
(http://xlink.cncr.nl) for further investigations.
Structural modeling
The following structures were used for the spatial distance measurements: the AMPA-type 
glutamate receptor (homomeric Gria2; only cross-links unique to Gria2 were used; PDB 
3KG2), the voltage-dependent calcium channel (PDB 5GJV), the vesicular ATPase (PDB 
3J9V), the mitochondrial electron transport chain (ETC) complexes I-IV (PDB 5LNK, 1ZOY, 
1NTM and 1V54), and the 80S ribosome (PDB 4UG0). The Gria2 homomeric structure was 
used since this subunit contained the highest number of cross-links compared to the other 
Gria proteins (i.e., Gria1, Gria3 and Gria4).
The different conformational states of Camk2 were modeled based on the structures 
of the extended Camk2 structure of rat (PDB 5U6Y), the auto-inhibited kinase domain of C. 
elegans (PDB 2BDW) and the compact conformation of human (PDB 3SOA). Homology 
modelling was performed with Maestro 11.4 (Schrödinger, LLC, New York, NY, USA). All 
manual docking, manipulation, optimization and loop generation (G315-V345 for auto-
inhibited and T305-V345 for compact conformation) were created utilizing the Loop Search 
tool implemented in Sybyl X2.1.1 (Certara USA Inc., St. Louis, MO, USA). Energy 
minimization was performed using AMBER7 FF99 force field. Structure images and morphs 
between the different conformations were generated with PyMOL 1.8.4.1.
The following available structures were used in the structural analysis of the 
AMPAR-auxiliary protein complex: PDB 5IDE for AMPAR, PDB 5VOT for Cacng2/8, PDB 
5AMO for Olfm1. The structure of the DOMON domain of Frss1l was modeled based on 
sequence homology using the available structure with highest sequence coverage (PDB 
4ZEL). The side chains of AMPAR were modeled with Scwrl4 and the missing loop of 
Cacng2 (residues 39-56) was modeled with I-TASSER. Interaction space models were 
calculated using the DisVis Webserver, using a maximal Cα-Cα distance of 23.4 Å. Docking 
models were generated using HADDOCK2.2 for Frrs1l DOMON domain and Olfm1. Cacng2 
was structurally aligned in Pymol from PDB 5VOT.
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Protein network analysis
The XL-based protein-protein interaction (PPI) network was generated based on interprotein 
cross-links and visualized using Cytoscape v3.4.0 for each subcellular fraction and brain 
area, as well as for the different conditions combined. Myelin basic protein (MBP), which 
presented a high number of cross-links, was removed from the network to improve the 
readability of the figures and its cross-links can be found in the Table S1, our web-based 
platform and Fig. S13. Unsupervised edge-betweenness clustering was applied to the core 
component of the network and each cluster was annotated according to the Cellular 
Component of Gene Ontology enrichment analysis, with all proteins identified as background 
(complete analysis and exceptions shown in Table S2B). Disconnected modules were 
grouped using DAVID Gene Functional Classification using medium and low stringency, and 
each group was subsequently annotated. The connectivity between annotated proteins was 
tested by measuring the network path distances and the number of protein pairs directly 
connected with the same GO annotation (for cellular component terms with >50 proteins in 
the core component of the network). For the latter measurement, we performed graph 
rewiring while preserving the degree distribution (repeated in 100 permutations) as a control
using the igraph R package. For each individual network and the replication experiment, this 
analysis was performed using the clusters from the combined network. The same package 
was used to calculate the modularity score of the network. Protein abundances were 
obtained from our previous proteomic study of synaptosomes and microsomes (41). Protein 
domain information of all cross-linked proteins in our dataset was retrieved from UniProt 
(Table S1A,C). Protein interactions known from literature were obtained from three 
databases, STRING (211), BioGRID (213) and InWEB (212). Only experimentally determined 
interactions and physical interactions were considered from STRING and BioGRID, 
respectively. For classification of confidence levels, a combined score of < 400 was 
considered as low, 400-700 as medium and ≥ 700 as high for STRING; a final score of < 0.2 
or no score provided was considered as low, 0.2-0.7 as medium, ≥ 0.7 as high for InWEB; 
interactions evidenced by low throughput experiments were considered as high and the rest 
as low confidence for BioGRID. Only interactions with high confidence level in at least one 
database were considered for downstream analysis (i.e. comparisons shown in Fig. 3C-D).
Expression plasmids
Mouse Stx1a (NM_016801) was cloned into the pCMV6-Entry vector, yielding Stx1a‐pCMV6-
Entry including a C‐terminal Myc-Flag tag (Origene MR203927). Snap25 (NM_030991.3) was 
Gateway-cloned into pDEST-EGFP vector, yielding Snap25-pDEST-EGFP including three N-
terminal Flag-tags. Stxbp1 (NM_013038.3) was Gateway-cloned into pDEST vector, yielding 
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Stxbp1-pDEST including three N-terminal Flag-tags. Mouse Stxbp5 and Stxbp5l were fused 
to EYFP-tag and cloned into a p156RRL vector, as described previously (232).
Cell culture and transfection
HEK293 cells (ATCC) were cultured in 10 cm dishes as described previously (165). Cells 
were transfected at 60% confluency with 5 μg plasmid using polyethylenimine (25 kDa linear, 
Polysciences) and incubated for 48h. Cells were washed twice with ice-cold PBS and 
collected in extraction buffer (0.5% DDM, 25 mM HEPES (pH 7.4), 150 mM NaCl, and EDTA‐
free complete protease inhibitor (Roche)). Proteins were extracted by gently mixing at 10 rpm 
for 1 h at 4ºC, and separated from the insoluble debris by two centrifugation steps for 20 min 
at 20,000g.
Protein interaction interfaces analysis
The position of the mouse cross-linked lysines were mapped onto the human proteome as 
retrieved from UniProt. Only lysines with high confidence mapping were considered for 
further analysis, i.e. lysine located at the same protein position with identical amino acid 
sequence up to the lysine position. The corresponding cross-linked lysines in human were 
compared to human protein interaction interfaces based on interactomeINSIDER (214).
Enrichment analysis was performed by Fisher exact test.
Peptide array interaction assays
CelluSpots Peptide Arrays (Intavis Bioanalytical Instruments AG) were blocked with 3% BSA 
(Sigma-Aldrich) in TBS-T (25mM Tris, 150mM NaCl, 0.005% Tween, pH 7.4) for 1h. After 
three washes with TBS-T, the arrays were incubated with protein extracts from expressing 
cells overnight at 4ºC (one 10 cm culture dish for each array). Next, arrays were washed 3 
times and incubated with primary antibodies (Flag or GFP tag for different proteins) for 2h at 
4 ºC. IRDye 800 secondary antibody was employed for the detection using an Odyssey Fc 
imaging system (LI-COR Bioscience). Images were obtained with Image Studio software 
(version 2.0.38) and analyzed with Protein Array Analyzer for ImageJ. The background was 
subtracted and signals were normalized to the positive control spot of each array (antibody 
antigen). The arithmetic mean of the three spots with protein tags not present in the proteins 
probed (Myc, His and HA) was used as negative control. The two technical replicates 
performed for each protein were averaged, followed by the subtraction of the signals of non-
transfected (for Flag-tagged proteins) or GFP (for GFP-fused proteins) non-specific binding 
controls. For low signal spots, only the overlapping protein sequence of at least two different 
peptides with signals after the filtering were considered as positive hits. The following 
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antibodies were used for the assay: Flag-tag (1:1000, Sigma-Aldrich, F1804), GFP (1:2000, 
Neuromab, 75-131), IRDye 800 CW Goat anti Mouse (1:10,000, LI-COR Biotechnology, 925-
32210).
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Supplementary figures
Fig. S1. General evaluation of XL-MS approach. (A) Sunburst plot showing the annotation in synaptic 
functions of the cross-linked proteins identified (cellular component SynGO terms (11)). Inner rings are 
parent terms of more specific child terms in outer rings, color-coded according to enrichment Q-value. 
Notably, a wide and significant coverage of synapse-specific proteins is found distributed across both 
pre- and post-synapse locations. (B) Correlation between the number of cross-linked lysines of each 
protein and the protein abundance corrected for the total number of lysines, (C) the protein abundance, 
and (D) the total number of lysines. (E-G) Correlation between the protein abundance of each protein 
and the total number of lysines or sequence length. 
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Fig. S2. Mapping of cross-linking data onto high-resolution structure of several protein 
complexes. (A) Cross-link mapping of the mitochondrial electron transport chain (ETC) complexes I-IV 
(PDB 5LNK, 1ZOY, 1NTM and 1V54). (B) Cross-link mapping of three selected synaptic protein 
complexes: the AMPA receptor (PDB 3KG2), voltage-dependent calcium channel (VDCC, PDB 5GJV), 
and vacuolar-type ATPase (V-ATPase, PDB 3J9V). (C) Cross-link mapping of the 80S ribosome (PDB 
4UG0). For clarity, nucleic acids are not shown. (D) Full length model of an auto-inhibited state of Camk2 
with high-resolution structure of the auto-inhibited kinase dimer (dotted rectangle, PDB 2BDW). Cross-
links are represented as the Euclidean distance between the C of the cross-linked residues, and 
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Fig. S3. Characterization of XL-based protein interaction network from hippocampus 
synaptosomes. (A) Nodes represent proteins and edges show the interactions identified by a single XL-
MS experiment in hippocampal synaptosomes (dataset 1). Protein names are included and disconnected 
protein modules with at least 3 proteins connected are shown. Each node represents a protein and the 
edge the PPI identified by cross-linking. Nodes are color-coded based on functional clusters shown in the 
combined network (Fig. 3A). Edges in red indicate protein-protein interactions (PPIs) found in both XL-
MS data and in literature (high confidence in at least one database of STRING, InWEB and BioGRID). 
Sizes of the nodes are proportional to the protein abundances (Log2 scale). Widths of the edges are 
proportional to the number of unique Lys-Lys cross-links. The confidence of each cross-link is indicated 
as dotted and solid lines for 2% FDR and 1% FDR, respectively. All information regarding individual PPIs 
can be retrieved at http://xlink.cncr.nl. (B) Distribution of the fraction of direct neighbors (cross-linked 
proteins pairs) that are in the same cluster in the combined network (labelled in orange) and a randomly 
rewired network (100 iterations, labelled in light blue). (C) Distribution of the number of cross-links found 
between protein pairs present in at least one database (DB) with high confidence (labelled in red) or do 
not present in any of the three databases (i.e. STRING, InWEB and BioGRID, labelled in black). (D)
Boxplot showing the distribution of protein abundances in different categories: xlink, cross-linked proteins 
identified in this study; public DB, protein interactions present in at least one public database with high 
confidence (i.e. STRING, InWEB and BioGRID). The number of proteins and median abundance are 
indicated in each box. Protein abundance data was obtained from (41).
4
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Fig. S4. Characterization of XL-based protein interaction network from hippocampus 
microsomes. (A) Nodes represent proteins and edges show the interactions identified by a single XL-
MS experiment in hippocampal microsomes (dataset 1). Protein names are included and disconnected 
protein modules with at least 3 proteins connected are shown. Each node represents a protein and the 
edge the PPI identified by cross-linking. Nodes are color-coded based on functional clusters shown in the 
combined network (Fig. 3A). Edges in red indicate protein-protein interactions (PPIs) found in both XL-
MS data and in literature (high confidence in at least one database of STRING, InWEB and BioGRID). 
Sizes of the nodes are proportional to the protein abundances (Log2 scale). Widths of the edges are 
proportional to the number of unique Lys-Lys cross-links. The confidence of each cross-link is indicated 
as dotted and solid lines for 2% FDR and 1% FDR, respectively. All information regarding individual PPIs 
can be retrieved at http://xlink.cncr.nl. (B) Distribution of the fraction of direct neighbors (cross-linked 
proteins pairs) that are in the same cluster in the combined network (labelled in orange) and a randomly 
rewired network (100 iterations, labelled in light blue). (C) Distribution of the number of cross-links found 
between protein pairs present in at least one database (DB) with high confidence (labelled in red) or do 
not present in any of the three databases (i.e. STRING, InWEB and BioGRID, labelled in black). (D)
Boxplot showing the distribution of protein abundances in different categories: xlink, cross-linked proteins 
identified in this study; public DB, protein interactions present in at least one public database with high 
confidence (i.e. STRING, InWEB and BioGRID). The number of proteins and median abundance are 
indicated in each box. Protein abundance data was obtained from (41).
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Fig. S5. Characterization of XL-based protein interaction network from cerebellum synaptosomes.
(A) Nodes represent proteins and edges show the interactions identified by a single XL-MS experiment in
cerebellar synaptosomes (dataset 1). Protein names are included and disconnected protein modules with 
at least 3 proteins connected are shown. Each node represents a protein and the edge the PPI identified 
by cross-linking. Nodes are color-coded based on functional clusters shown in the combined network 
(Fig. 3A). Edges in red indicate protein-protein interactions (PPIs) found in both XL-MS data and in 
literature (high confidence in at least one database of STRING, InWEB and BioGRID). Sizes of the 
nodes are proportional to the protein abundances (Log2 scale). Widths of the edges are proportional to 
the number of unique Lys-Lys cross-links. The confidence of each cross-link is indicated as dotted and 
solid lines for 2% FDR and 1% FDR, respectively. All information regarding individual PPIs can be 
retrieved at http://xlink.cncr.nl. (B) Distribution of the fraction of direct neighbors (cross-linked proteins 
pairs) that are in the same cluster in the combined network (labelled in orange) and a randomly rewired 
network (100 iterations, labelled in light blue). (C) Distribution of the number of cross-links found between 
protein pairs present in at least one database (DB) with high confidence (labelled in red) or do not 
present in any of the three databases (i.e. STRING, InWEB and BioGRID, labelled in black). (D) Boxplot 
showing the distribution of protein abundances in different categories: xlink, cross-linked proteins 
identified in this study; public DB, protein interactions present in at least one public database with high 
confidence (i.e. STRING, InWEB and BioGRID). The number of proteins and median abundance are 
indicated in each box. Protein abundance data was obtained from (41).
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Fig. S6. Characterization of XL-based protein interaction network from cerebellum microsomes.
(A) Nodes represent proteins and edges show the interactions identified by a single XL-MS experiment in
cerebellar microsomes (dataset 1). Protein names are included and disconnected protein modules with 
at least 3 proteins connected are shown. Each node represents a protein and the edge the PPI identified 
by cross-linking. Nodes are color-coded based on functional clusters shown in the combined network 
(Fig. 3A). Edges in red indicate protein-protein interactions (PPIs) found in both XL-MS data and in 
literature (high confidence in at least one database of STRING, InWEB and BioGRID). Sizes of the 
nodes are proportional to the protein abundances (Log2 scale). Widths of the edges are proportional to 
the number of unique Lys-Lys cross-links. The confidence of each cross-link is indicated as dotted and 
solid lines for 2% FDR and 1% FDR, respectively. All information regarding individual PPIs can be 
retrieved at http://xlink.cncr.nl. (B) Distribution of the fraction of direct neighbors (cross-linked proteins 
pairs) that are in the same cluster in the combined network (labelled in orange) and a randomly rewired 
network (100 iterations, labelled in light blue). (C) Distribution of the number of cross-links found between 
protein pairs present in at least one database (DB) with high confidence (labelled in red) or do not 
present in any of the three databases (i.e. STRING, InWEB and BioGRID, labelled in black). (D) Boxplot 
showing the distribution of protein abundances in different categories: xlink, cross-linked proteins 
identified in this study; public DB, protein interactions present in at least one public database with high 
confidence (i.e. STRING, InWEB and BioGRID). The number of proteins and median abundance are 
indicated in each box. Protein abundance data was obtained from (41).
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Fig. S7. Extended and detailed XL-based protein interaction network (extended Fig. 3A). Nodes 
represent proteins and edges show the interactions identified by XL-MS (dataset 1). Protein names are 
included and disconnected protein modules with at least 3 proteins connected are shown. Each node 
represents a protein and the edge the PPI identified by cross-linking. Nodes are color-coded based on 
functional clusters generated by unsupervised edge-betweenness clustering for the core component or 
gene functional classification for the disconnected modules, and annotated by GO enrichment analysis. 
Disconnected modules were located next to the functionally closest cluster of the core component of the 
network. Edges in red indicate protein-protein interactions (PPIs) found in both XL-MS data and in 
literature (high confidence in at least one database of STRING, InWEB and BioGRID). Sizes of the 
nodes are proportional to the protein abundances (Log2 scale). Widths of the edges are proportional to 
the number of unique Lys-Lys cross-links. The confidence of each cross-link is indicated as dotted and 
solid lines for 2% FDR and 1% FDR, respectively. Edges are labeled according to the number of 
samples in which the PPI was identified. All information regarding individual PPIs can be retrieved at 
http://xlink.cncr.nl.
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Fig. S8. XL-based protein interaction network analysis. (A) Degree distribution of the XL-based 
protein interaction network (Fig. 3A). (B) Power law log-log plot of the network. X-axis represents the 
degree of a node (number of edges) and y-axis represents the probability that a node with a given 
degree exists in the network. (C) Density plot of the path lengths between the proteins annotated with the 
same GO term and between all non−annotated nodes in the core component of the network. (D) Number 
of cross-linked protein pairs found in at least one of the public PPI databases (i.e., StringDB, InWEB and 
BrioGRID) with any confidence level.
4
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Fig. S9. Protein interaction interfaces and peptide array analysis (extended Fig. 4). (A) Percentage 
and total number of cross-linked lysines within and beyond the protein-protein interaction interfaces 
predicted by InteractomeINSIDER for the human proteome (Table S3). Fisher exact test showed a 
significant enrichment for interprotein cross-links within the interaction interfaces (*** <0.00001), but not 
for intraprotein cross-links (ns, 0.79). (B) The signal intensity detected by immunoblotting for each 
peptide spot (red squares) was processed by Protein Array Analyzer of ImageJ. Two independent 
replicates and two technical replicates were performed for each protein tested. Peptide sequences are 
presented in Table S4. 
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Fig. S10. Evaluation of XL-MS approach on biologically independent replicates for hippocampal 
synaptosomes (extended Fig. 6). (A) Venn diagram showing the number of identified intraprotein 
cross-links over the different replicates. (B) Pie chart showing the number of cross-links identified 
between cytoplasmic and extra-cellular regions of proteins (dataset 2). 
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Fig. S11. Complete XL-based protein interaction network from all seven cross-linking MS 
experiments. Nodes represent proteins and edges show the interactions identified by XL-MS (dataset 1 
and 2). Disconnected protein modules with at least 3 proteins connected are shown. Nodes layout is 
based on unsupervised edge-betweenness clustering. Edges in red and orange indicate protein-protein 
interactions (PPIs) reported in literature (STRING, InWEB and BioGRID) classified with and without high 
confidence in at least one database, respectively. Labels and widths of the edges indicate the number of 
samples in which the PPI was identified. The confidence of each cross-link is indicated as dotted and 
solid lines for 2% FDR and 1% FDR, respectively. All information regarding individual PPIs can be 
retrieved at http://xlink.cncr.nl.
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Supplementary materials
Table S1. Complete list of cross-links identified, SynGO enrichment analysis and cross-linked 
protein list.
Table S2. Clustering and GO enrichment analysis of the proteins in the XL-based protein 
interaction network.
Table S3. Human protein mapping and overlap of cross-linked lysine positions with protein 
interaction interfaces.
Table S4. Sequences and signal intensities for the peptides included in the two independent 
replicates of peptide arrays.
Movie S1. Dynamic simulation of the three conformational states of Camk2.
4
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Chapter 5: General discussion
 
 
The complex molecular architecture of the synapse represents a huge challenge for 
understanding the mechanisms underlying synaptic transmission in physiological and 
pathological conditions. In this thesis, I made use of several proteomic methodologies based 
on mass spectrometry to extend our knowledge of the molecular composition of the synapse. 
Given that this work represents a middle ground between technology and biology, this 
discussion focusses on the application and future perspective of proteomics in synaptic 
biology.
In chapter 2, I investigated synapse formation and maturation by analyzing the 
synaptic proteome in the developing mouse brain. Previous studies have focused on the 
analysis of the synaptic proteome during critical periods of development. For instance, 
Dahlhaus et al (108) investigated the development and plasticity of mouse visual cortex at 
postnatal day 30 (P30, critical period) and P46 (young adult); and Moczulska et al (44)
analyzed the differences in the synapse proteome between mouse P30 and P53 cortex. By 
covering eight distinct time points, our study recapitulates and expands in a more cohesive 
and comprehensive analysis the synaptic proteome development from juvenile to adolescent 
and different adult ages. Among the 1978 proteins identified, changes in the expression 
levels of the main components of the synapse were quantified throughout development, 
which provides an indication for their functional roles at specific stages of synaptogenesis. 
Moreover, the highly coordinated expression changes of multiple proteins may suggest their 
involvement in common biological processes (54), which may serve as guide for the 
functional characterization of still uninvestigated proteins. For instance, we observed several 
non-canonical SNARE proteins, such as Snap29 and -47, following an expression pattern 
opposite to core presynaptic proteins, which suggest their implication in different biological 
functions during development. In addition, the low expression and restricted distribution of 
Cxadr in mature brain indicated that this protein might play a prominent role in immature 
synapses. A significantly reduced synapse densities was observed when knocking down the 
expression of Cxadr in cultured primary mouse neurons, consistent with the suggested role of 
Cxadr in synapse formation or maturation.
Recently, several studies have provided additional knowledge on the synapse 
proteome dynamics during development from brain extract and neuronal cultures. Bruderer et 
al (233) examined the developmental changes of about 6,000 proteins in mouse 
somatosensory cortex 1-barrel field at P9, P15, P30, and P54. Similar to our data, synaptic 
transmission-related proteins displayed a strong increase in expression during early 
development which leveled off thereafter. Non-synaptic proteins could also be evaluated 
since the whole tissue was analyzed. For instance, a decrease in expression levels was 





processes. Another study investigated the proteome dynamics during neuronal differentiation 
by analyzing hippocampal neuron cultures at day in vitro (DIV) 1, 5 and 14 (54). Again, the 
expression levels of synaptic proteins was shown to increase throughout neuronal 
development, including presynaptic (e.g. Syp, Pclo, Vamp2 and Snap25) and postsynaptic 
proteins (e.g. Shank2, PSD95 and glutamate receptors). Interestingly, the increase in 
expression of synaptic proteins was observed even before the peak of synaptogenesis, 
supporting a model of pre- and postsynaptic scaffolding proteins being expressed prior to 
synapse formation. In the same line, a very recent study quantified the dynamics of a 
thousand surface N-glycoproteins in primary cortical neurons at DIV 4, 6, 8, 16, 18, and 20 
(234). Most surface protein abundance changes, including synaptic proteins, occurred within 
the first week prior to the time window for synapse formation. Taken together, many synaptic 
proteins seem to be produced and trafficked to the membrane surface before synapses are 
formed, followed by their later organization into synaptic domains by surface diffusion. 
Characterizing in depth the dynamic reorganization of the synaptic proteome, independent of 
global protein abundance changes, is an exciting future direction that holds the promise to 
shed light on the molecular events leading to synapse formation and function.
In chapter 3, I interrogated the molecular mechanisms underlying the synaptic 
function of the postsynaptic receptor mGluR5. Biological processes associated with a protein, 
like mGluR5, can be inferred from the adaptation of the proteome to the genetic and/or 
pharmacological manipulation of the protein of interest. The most prominent response of the
synaptic proteome to the reduction of mGluR5 activity found was the change in protein levels 
of specific pathways in the mitochondria. Together with the indications obtained from 
biochemical assays and electron microscopy, we proposed mGluR5 as a regulator of the link 
between mitochondrial function and synaptic activity. This study exemplifies the application of 
proteomic profiling as a versatile resource for evaluating the molecular mechanisms behind 
the function of particular proteins.
Proteomic studies of mGluR5 have focused on the characterization of the receptor 
interactome (235, 236). In particular, recently a growing interest was raised for the presence 
of mGluR5 heteroreceptors in the brain (237). For instance, a physical and functional 
interaction has been found between mGluR1 and mGluR5, both members of the group 1 
metabotropic glutamate receptors (165, 238). In the same line, we observed a reduced 
mGluR1 expression in synaptosomes from mGluR5 KO mice, suggesting a mGluR1-mGluR5 
co-regulation rather than a functional compensation between receptor family members. The 
assembly of mGluR5 with additional metabotropic glutamate receptors, as well as their single 
cell co-expression in the brain has been described very recently (239). While the functional 
and pharmacological implication of the different heteroreceptors remain to be investigated 
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(240), these studies highlight the progress of the field towards a more specific dissection of 
mGluR5 containing receptors.
In a different research direction, proteomic studies aimed to analyze the mGluR5-
mediated protein synthesis, given the implication of the receptor in long-term depression 
(LTD) (134, 135). The most recent study (241) investigated the phosphorylation and protein
translation induced by mGluR1/5 activation. Proteins involved in translation (e.g. ribosomal 
proteins), folding (chaperones) and degradation (proteasome) were found among the newly 
synthesized proteins. These findings suggest that mGluR1/5 regulates the balance between 
protein synthesis and degradation (242). ATP production and protein translation are also 
regulated by mitochondria located in axons and dendrites (175, 176) and thus, our 
observations of a connection between mGluR5 and mitochondria might be underlying the 
same process. Further research would be required to clarify the relation between mGluR5, 
mitochondria and protein synthesis, as well as between mGluR5 activation and inhibition, for 
which the development of more specific mGluR5 activators would be essential.
In chapter 4, I investigated the synaptic proteome architecture by evaluating protein 
structures, assemblies and protein-protein interactions using cross-linking mass spectrometry 
(XL-MS). The identification of thousands of specific protein positions in close spatial proximity 
allowed the inspection of protein three-dimensional conformations and interactions between 
proteins in their physiological subcellular context. We focused on the analysis of the 
structural dynamics of Camk2 and the assembly of the AMPA receptor complex with three 
auxiliary subunits, illustrating the potential of the data to reveal protein complexes 
architecture. The reliability of the cross-link collection generated was technically evaluated 
and validated, as we considered required for a recent methodology. This chapter 
corresponds to one of the largest cross-linking datasets to date and the first of this magnitude 
in the brain. Thus, this study provided a new entry into exploration of additional proteins and 
functional groups.
Regarding protein structure, XL-MS has been previously used at small scale in 
order to investigate protein structure and interactions (64, 243, 244). Accordingly, we have 
shown good agreement between the spatial distances of the cross-linked pairs and those 
predicted by high-resolution structures, such as AMPAR, V-ATPase, ribosomal and 
mitochondrial complexes. XL-MS provides structural data complementary to X-ray 
crystallography, electron microscopy and nuclear magnetic resonance (NMR) spectroscopy. 
In contrast with these methods, cross-linking allows the analysis under near-physiological 
conditions of even large complexes difficult to purify or crystalize. The integration of multiple 





structure and function of the transcription-coupled pre-mRNA capping complex was 
elucidated by combining cryo-EM, native MS and cross-linking MS (245).
While our dataset exemplifies the advances in cross-linking to generate large 
amounts of structural data, other methodologies are also quickly expanding. In recent years, 
the number of structures resolved by cryo-EM have increased exponentially and it is 
expected to surpass soon the number of structures determined by X-ray crystallography 
(246). Structural biology is also becoming more accessible to scientists from other fields, 
partly due to the creation of international initiatives providing structural biology research 
infrastructures to non-experts (iNEXT-Discovery, https://inext inext-discovery.eu). Moreover, 
great advances have recently been made in protein structure prediction by using artificial 
intelligence (247, 248). Given the current increase in data generation rate of XL-MS, cryo-EM 
and in-silico prediction, the cross-validation and integration of these complementary data will 
be fundamental in the near future for structural biology at a system level.
Regarding protein interaction, we have shown the capability of XL-MS in capturing 
authentic protein connectivity in an unbiased and high-throughput manner. Comparing the 
XL-based interactome to previously reported protein interactions, our data recapitulated 
known synaptic protein complexes such as the AMPAR (20), presynaptic release machinery 
(225) and V-ATPase (249). Previous efforts to unravel the synaptic interactome have taken 
advantage of targeted approaches, such as affinity purification and yeast-two hybrid (206,
250). These approaches have provided a static picture of the interactome of multiple synaptic 
proteins (20, 251, 252). However, protein interactions are highly dynamic and adjust 
according to the biological context, such as developmental stage, cellular location and 
(synaptic) activity (21, 252, 253). Addressing the dynamics of the synaptic interactome is now 
becoming feasible by using XL-MS and other recent MS-based methodologies, such as 
proximity labelling (229, 254). These methods offer a more direct, high-throughput approach 
for analyzing protein interactions with higher time resolution in their physiological context. 
These technological advances represent a promising new entry into the synaptic interactome 
and its adaptation to diverse physiological and pathological conditions.
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Proteomics data to understand the synapse
The proteomic perspective adopted in this thesis allowed me to investigate several aspects of 
the molecular profile of the synapse, including protein composition, function, structure and 
interactions. For each of these features, we pointed out specific proteins of interest for 
validation and/or follow up, such as Cxadr, mGluR5 and the AMPAR. The candidates 
analyzed here illustrate the use and value of each dataset on individual proteins and 
complexes, i.e. to explore their role in synapse formation and maturation following their 
expression pattern across brain development, as shown with Cxadr in chapter 2; to evaluate 
the molecular mechanisms behind the function of particular proteins, as shown with mGluR5 
in chapter 3; to examine the interaction and assembly of protein complexes, as shown with 
AMPA receptor and its auxiliary subunits in chapter 4. Beyond the new insights uncovered for 
these proteins, most of the data generated in this thesis can be further utilized as a resource 
for probing additional proteins.
In addition, the combination and integration of multiple types of data from different 
sources holds the potential for revealing a broader picture (255). For instance, the correlation 
of proteins based on their expression profile can provide an indication of shared biological 
functions. When analyzing the protein correlation within the individual datasets obtained in 
this thesis (e.g. developmental series and mGluR5 KO proteomics in chapter 2 and 3,
respectively), we can observe a low-resolution clustering between proteins (Fig. 1). However, 
more specific protein clusters emerge by combining the information contained in both these 
datasets, showing that subsets of proteins under different experimental conditions respond 
similar in adjusting their expression level. This naive example hints towards the synergetic 
use of datasets, and the possibility to extract additional information from the combination of 





Figure 1. Correlation of protein expression profiles from separate and integrated datasets of this thesis. 
A) Heatmaps show the correlation between 1281 proteins using the expression data obtained in the 
synaptic development study (Chapter 2) and the mGluR5 KO mice study (Chapter 3). B) Heatmap 
showing the correlation between the same proteins when combining the data from both datasets. Each 
row corresponds to a protein, which were grouped by hierarchical clustering analysis. Proteins are 
represented in the same order in all three heatmaps. The color-code indicate Spearman correlation 
values.
The combination of proteomics with other cell biological levels of study has been 
previously explored with multidisciplinary approaches (256), including genomics, 
transcriptomics, post-transcriptional modification, morphological and phenotypic data. For 
instance, the implication of oligodendrocytes in Alzheimer’s disease has been studied by the 
combination of transcriptomics, proteomics and GWAS data, providing further insights into 
the molecular networks and key component associated with the disease (257, 258). In 
addition, two recent studies have reported protein changes in primary neuronal culture after 
knockdown of candidate genes of interest (259) or overexpression of a microRNA (191)
related to schizophrenia. Currently, there are >100 known independent genetic risk loci 
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associated with schizophrenia (121), but their contribution to the disease is unclear. Rosato 
et al (259) examined the neuronal phenotypes by knocking down 41 risk genes each by 
shRNA, and showed that three of them, Tcf4, Tbr1, and Top3b, caused similar changes in 
synaptic development. Proteomic analysis of the neuronal cultures with the individual 
knockdown of these three genes revealed limited overlap in protein changes. Interestingly, 
when the effect of Tcf4, Tbr1, and Top3b knockdown of all 210 regulated proteins was taken 
together, protein-protein interaction enrichment analysis identified a set of proteins involved 
in neurotransmitter release, including the core proteins SNAP25, SNAP29, NAPB, STX7, and 
STXBP5. This strongly suggests that polygenic risk in schizophrenia may converge onto 
common cellular pathways. The mir-137 locus is another genetic risk factor for schizophrenia. 
He et al (191) overexpressed mir-137 in primary neuronal culture, and showed by DIA that 
the proteins that changed significantly were enriched for cell adhesion and cell development, 
including NFASC, NLGN, NRXN, and HAPLN. Together with the electrophysiological and 
morphological data, it was concluded that mir-137 regulates synaptic function by regulating 
synaptogenesis, synaptic ultrastructure and synapse function.
The integration and consolidation of data from different sources, as well as the 
development of computational modelling and integrative system analysis, are important for 
untangling and modeling the complex relationships between proteins and, in our case, the 
molecular machinery of the synapse (260). The data resources generated here are 
contributing to modeling the molecular architecture of the synapse with the prospect of 
improving the future understanding of the brain, psychiatric and neurodegenerative disorders, 
and the potential of therapeutic approaches.
Future perspective
Protein isoforms and post-translational modification (PTM)
Protein features beyond the scope of my thesis, such as protein isoforms and post-
translational modifications (PTMs), can shape the protein architecture underlying synaptic 
function. A single gene can originate multiple variants of the same protein, or isoforms, that 
occasionally possess unique properties, functions and/or different expression patterns. For 
instance, the activity-dependent regulation of the synaptic GTPase-activating protein 
(SynGAP) isoforms has been shown to modulate the function of the protein at the synapse 
(261). In pathological conditions, the imbalance between the different Mapt isoforms has 
been associated with several tauopathies, such as Alzheimer’s disease and frontotemporal 
dementia (262). Furthermore, the protein localization, function and interactions can be further 
modulated by posttranslational modifications, such as phosphorylation. The postsynaptic 





of protein phosphorylation and consequent changes in protein-protein interactions (253). Also 
in Alzheimer’s disease, the phosphorylation state of Mapt is a critical hallmark for the disease 
pathogenesis and has been associated with the course of the clinical outcome (263). The 
further investigation and integration of these elements might assist the comprehensive 
characterization of the synaptic proteome diversity and the synaptic function in health and 
disease.
Towards cell-type and synapse-type specific proteomics
Neuronal cell-types and their synapses possess very diverse molecular, morphological and 
functional properties (264). Regarding cell-types, the development of single-cell 
transcriptomics technology has exposed the varied molecular composition of neurons with 
more than 100 different neuronal cell-types, including excitatory and inhibitory neurons (163).
Although single-cell RNA data is predictive for cell-type specific synapse composition, it is 
unclear whether these predictions hold at the synapse level. Regarding synapse-types, a 
map of the synaptic diversity across the whole brain and life-span has been generated from 
the combination of two postsynaptic markers (265, 266). These studies exposed the vast 
synaptic variety across the brain and their distinct electrophysiological properties and 
response patterns to behavioral activity.
A noteworthy consideration for the correct interpretation of our results is that the 
synaptic data presented in this study was generated from the analysis of bulk tissue samples. 
Consequently, no distinction was made between the different neuronal cell-types and their 
synapses. The results shown here correspond to the average synapse derived from the 
combination of all different cell-types, which might have caused the dilution of certain traits 
from the most sparse neuron and synapse types. To overcome this molecular “averaging” 
and gain specificity, different strategies have been explored (267). First, the analysis of brain 
cell-types has been performed by isolating and collecting the cells of interest, typically using 
cell-sorting methods and laser microdissection (49, 268). Similarly, synapse-types can also 
be analyzed using Fluorescence Activated Synaptosome Sorting (FASS) which allows the 
exploration of specific synapse subpopulations previously tagged with a fluorescent protein 
marker (50). Second, computational methodologies have emerged for in-silico deconvolution 
of the cellular component contained in mixture samples (269, 270), while their application has 
been so far restricted to transcriptomics data. Third, other technologies such as proximity 
ligation methods, are currently being used for the characterization of the molecular 
components of subcellular regions, including the synaptic cleft and the inhibitory postsynaptic 
density (51, 254). Only recently, the increase in mass spectrometry sensitivity, improvement 
in sample preparation and data analysis have allowed for the first time the quantification of 
thousands of proteins from single cells (271, 272). Despite still being under development, 
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further advances in these technologies hold the promise of reliable high-throughput single-
cell proteomics in the near future. Altogether, cell-type proteomics represent an emerging
area with multiple active fronts that open up new avenues towards the future dissection of 
neuron-type and even synapse-type specific proteomes.
Towards functional proteomics and understanding the synapse dynamics
Synaptic transmission is a highly dynamic process. Presynaptic vesicle trafficking and fusion, 
constant cytoskeletal rearrangement and postsynaptic receptor movements are some of the 
events governed by the coordinated adaptation of the synaptic proteome (273). These 
processes involve the precise spatial and temporal modulation of protein conformations, 
post-translational modifications and protein-protein interactions. For instance, extensive
changes were found in the phosphorylation state of presynaptic proteins during 
neurotransmitter release (274). Furthermore, the synapse composition, structure and 
biophysical properties can be further modulated by synaptic plasticity, which critically 
depends on protein interactions and expression changes (275). While most studies have 
focused on the dynamic regulation of particular protein complexes (276), the analysis of 
synaptic protein networks during synaptic plasticity has become feasible (253, 277). The 
characterization of the protein network dynamics and its relationship with brain disorders 
might provide valuable insights into the molecular mechanism of synaptic function and 
alteration in neurological and psychiatric disorders (252).
The results presented in this thesis correspond to a snapshot of the average synaptic state in 
the particular conditions of each experiment. For instance, we examined in the cross-linking 
study the structure of Camk2 and observed a mixture of different conformational states 
together in the same samples. Camk2 undergoes conformational changes upon activation by 
NMDAR-dependent Ca2+ influx, an essential step for long term potentiation (LTP) and 
memory formation (278). Thus, the presence of Camk2 molecules in different conformations 
within the same experiment most likely reflects the combination of synapses in different 
activation and plasticity states in our samples. Currently, quantitative cross-linking mass 
spectrometry is emerging as a viable approach for analyzing structural and interactome 
dynamics (279). This strategy combines chemical cross-linking with protein or peptide 
labelling, including stable isotope labelling by amino acids in cell culture (SILAC) or tandem 
mass tag (TMT). In the latter, the labelled peptides of each sample are combined and 
analyzed together, which results in fewer missing identifications among samples and might 
increase the sensitivity for low-abundant species, such as the cross-link peptides. With 
further optimization of mass spectrometry acquisition strategies and compatible data analysis 
methods, quantitative cross-linking has the potential to become a powerful tool for describing 





technologies will allow in the future to step up from the current descriptive synaptic 
proteomics toward a more functional characterization of synaptic mechanism and dynamics.
Conclusion
Understanding the computational machinery of the synapse is essential for understanding 
how the brain processes the information that mediates our thoughts, behavior and feelings. In 
this thesis, I investigated distinct aspects of the complex protein architecture of the synapse 
while applying and developing the proteomic tools required for it. By analyzing the brain 
development using a quantitative proteomic workflow, we revealed the expression profile of 
synaptic proteome during synapse formation and maturation. We exposed the adaptation of 
the synaptic proteome to the genetic and pharmacological perturbation of the function of one 
protein, the metabotropic glutamate receptor 5. We generated an extensive cross-linking 
resource that provides a new perspective to explore of synaptic proteins structures and 
interactions; the generation of this molecular catalog of synaptic proteins provides new entry 
points for understanding the basis of synaptic transmission and synaptic dysfunction in brain 
disease. Further technological advances in mass spectrometry will come hand in hand with a 
deeper and more functional dissection of the molecular mechanisms behind synaptic 
function.
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Synaptic transmission constitutes the major mode of communication in the brain. In 
physiological conditions, trillions of synapses mediate neurotransmission and undergo 
activity-dependent plasticity involved in learning and memory. In pathological conditions, 
dysregulation of the synaptic composition, structure and/or function underlie multiple 
psychiatric and neurodegenerative disorders. The function and organization of the synapse 
require specialized molecular machineries composed by specific proteins engaged in 
transient or stable protein-protein interactions (PPIs). In the past decade, over 2,000 different 
proteins have been identified at the synapse, which corresponds to approximately 10% of 
protein-coding genes in mammalian genomes. This complex molecular architecture 
represents a major challenge for understanding the mechanisms underlying synaptic 
transmission in physiological and pathological conditions.
To dissect the complex synaptic proteome, unambiguous identification of hundreds 
of protein is required. Mass spectrometry-based proteomics is a powerful and versatile tool 
for molecular profiling in a broad spectrum of applications. Multiple advances in proteomic 
methodologies allow now reliable protein identification, quantification, and protein interaction 
determination in biological samples, including the nervous system. In this thesis, we applied 
several proteomic tools based on mass spectrometry to study the molecular composition of 
the synapse and provide new entry points for understanding the basis of synaptic 
transmission and synaptic dysfunction in brain disease
First, we investigated the synapse formation and maturation during brain 
development. This process requires prominent changes of the synaptic proteome and 
potentially involves thousands of different proteins at every synapse. While synaptic proteins 
have been studied in depth during critical periods of development, the adaptation of the 
synaptic proteome throughout various stages of postnatal development has not been 
described. Here, we analyzed the cortical synaptic membrane proteome at eight distinct time 
points of postnatal mouse brain development, including juvenile, adolescent and adult 
stages. Using iTRAQ-based quantitative proteomics, we quantified 1560 proteins of which 
696 showed statistically significant differences over time. Synaptic proteins generally showed 
increased expression levels during maturation, whereas specific proteins decreased in 
abundance. For instance, several non-canonical SNARE proteins, such as Snap 29/47 and 
Stx 7/8/12, showed higher expression in immature synapses, which suggest their implication 
in specific biological functions during development. In this line, we evaluated the function of 
Cxadr, a protein showing a fast decline in expression during neuronal development. Knock 
down of the expression of Cxadr in cultured primary mouse neurons revealed a significant 
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decrease in synapse density. Altogether, these results reveal the expression profile of 
synaptic proteome during development and provide new insights into the molecular 
processes underlying synaptogenesis and synapse maturation.
Next, we explored the mechanism behind the synaptic modulation mediated by a 
particular protein, the metabotropic glutamate receptor 5 (mGluR5). This receptor plays a 
major role in the modulation of synaptic function and plasticity, as well as in several brain 
disorders. Moreover, the pharmacological modulation of mGluR5, in particularly its inhibition, 
has been extensively targeted as a promising therapeutic intervention. However, the negative 
outcome of mGluR5 antagonists in clinical trials reveals the need for a better understanding 
of the complex processes underlying mGluR5 function and inhibition at the synapse. Using a 
data independent acquisition (DIA) proteomic approach, we determined the molecular 
response of the synapse to a reduction of mGluR5 activity by pharmacological inhibition and 
gene deletion in mice. In both cases, we found that next to dysregulation of synaptic proteins, 
the major regulation in protein expression in both models concerned specific processes in 
mitochondria, such as oxidative phosphorylation. Electron microscopy analysis revealed the 
alteration in shape and area of specifically postsynaptic mitochondria in mGluR5 KO 
synapses. Computational and biochemical assays suggested an increase of mitochondrial 
function in neurons, with increased level of NADP/H and oxidative damage in mGluR5 KO. 
Together, the mGluR5-dependent adaptation of the synaptic proteome allowed us to provide 
diverse lines of evidence of the modulation of synaptic mitochondrial function by mGluR5, 
which might be relevant for improving the clinical potential of mGluR5.
Third, we studied the organization of protein complexes in the synapse. Synaptic 
function goes beyond the action of individual proteins and requires functionally specialized 
molecular machineries composed by multiple proteins. In recent years, chemical cross-linking 
combined with mass spectrometry (XL-MS) has emerged as a powerful approach to 
investigate both protein structure and interactions. In this study, we made use of this state-of-
the-art technology in combination with biochemical and computational approaches to reveal 
the architecture and assembly of synaptic protein complexes from mouse hippocampus and 
cerebellum. We obtained 11,999 unique lysine-lysine cross-links, comprising connections 
within and between 2362 proteins, which represents one of the largest cross-linking datasets 
to date. We employed this new type of data to investigate three different protein features: 
protein structure, protein interaction and binding interfaces. For each of these features, we 
validated the reliability of the data by several approaches as we deemed necessary for a 
recent methodology. This extensive collection was the basis to analyze the structural 
dynamics of Camk2 and the assembly of the AMPA receptor complex with three auxiliary 





providing an extensive resource that opens up new avenues in probing protein structures and 
interactions close to their native subcellular context.
Collectively, the application and development of multiple proteomic methodologies 
allowed us to reveal several aspects of the molecular architecture of the synapse, including 
protein composition, function, structure and interaction. Beyond the new insights uncovered 
for specific proteins in this thesis, the data resources generated can be further used for 
probing additional proteins and contributes to improve our understanding of synapse function 
and brain disease.
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